PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11078493-1	2000	PURPOSE: To examine the feasibility of using fenretinide (4-HPR) for the prevention and treatment of prostate cancer.	Fenretinide	45-56	haptoglobin-related protein	Homo sapiens	60-63
11122886-1	2000	Retinoids are derivatives of vitamin A that include all- trans-retinoic acid (ATRA), 13-cis-retinoic acid, (13-cis-RA), and fenretinide (4-HPR).	Fenretinide	124-135	haptoglobin-related protein	Homo sapiens	139-142
11054663-5	2000	In this report, we provide evidence that DPH2L is down-regulated during differentiation or apoptosis in several cancer cell lines after treatment with all-trans RA or N-(4-hydroxyphenyl)retinamide and during cell-cycle arrest.	Fenretinide	167-196	diphthamide biosynthesis 1	Homo sapiens	41-46
11027625-1	2000	Fenretinide (4-HPR) is a synthetic retinoid with cancer chemopreventative potential and clinically manageable side effects, compared to the prototype retinoid, all-trans retinoic acid (RA).	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
11010810-3	2000	Fenretinide induced high levels of caspase-dependent apoptosis accompanied by an increase in free radicals and the release of cytochrome c in the absence of mitochondrial permeability transition.	Fenretinide	0-11	cytochrome c, somatic	Homo sapiens	126-138
11010810-7	2000	These results suggest that the effector pathway of fenretinide-induced apoptosis of neuroblastoma is caspase dependent, involving mitochondrial release of cytochrome c independently of permeability changes, and mediated by specific RARs.	Fenretinide	51-62	cytochrome c, somatic	Homo sapiens	155-167
11027625-0	2000	Apoptosis and restriction of G(1)/S cell cycle by fenretinide in Burkitt"s lymphoma mutu I cell line accessed with bcl-6 down-regulation.	Fenretinide	50-61	BCL6 transcription repressor	Homo sapiens	115-120
10999486-2	2000	A satisfactory correlation was found between the HINT scores and the experimental dissociation constants of three of the ligands, fenretinide, N-ethylretinamide and all-trans retinol, despite their hydrophobic nature.	Fenretinide	130-141	histidine triad nucleotide binding protein 1	Homo sapiens	49-53
10824459-0	2000	Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.	Fenretinide	11-41	serpin family E member 1	Homo sapiens	86-119
10962560-0	2000	pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.	Fenretinide	26-55	RB transcriptional corepressor 1	Homo sapiens	0-3
10969771-0	2000	Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation.	Fenretinide	0-11	caspase 3	Homo sapiens	20-29
10969771-1	2000	Fenretinide (4-HPR) is a synthetic retinoid that displays a broad range of biological effects and has also demonstrated clinical efficacy as a chemopreventative agent.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
10917548-1	2000	The effect of the chemopreventive synthetic retinoid N-(4-hydroxyphenyl)-retinamide (4-HPR) on aromatase activity and expression was examined.	Fenretinide	53-83	haptoglobin-related protein	Homo sapiens	87-90
10918204-0	2000	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.	Fenretinide	15-26	insulin like growth factor 1	Homo sapiens	61-95
10918204-0	2000	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.	Fenretinide	15-26	insulin like growth factor 2	Homo sapiens	97-103
10918204-0	2000	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.	Fenretinide	15-26	insulin like growth factor binding protein 3	Homo sapiens	108-115
10918204-4	2000	We have previously shown that the synthetic retinoid fenretinide (4-HPR) lowers plasma IGF-I in pre-menopausal breast cancer patients.	Fenretinide	53-64	haptoglobin-related protein	Homo sapiens	68-71
10918204-4	2000	We have previously shown that the synthetic retinoid fenretinide (4-HPR) lowers plasma IGF-I in pre-menopausal breast cancer patients.	Fenretinide	53-64	insulin like growth factor 1	Homo sapiens	87-92
10918204-6	2000	Repeated measures analysis, after adjustment for age, body mass index (BMI) and year of study, showed a significant effect of fenretinide on IGF-I levels, which were further lowered after the second year of treatment and only partially recovered after drug discontinuation.	Fenretinide	126-137	insulin like growth factor 1	Homo sapiens	141-146
10955773-3	2000	One such strategy is to use retinoids like N-(4-hydroxyphenyl)retinamide (4-HPR), which has been found to possess chemopreventive activities in preclinical studies.	Fenretinide	43-72	haptoglobin-related protein	Homo sapiens	76-79
10772821-0	2000	BAG-1 promotes apoptosis induced by N-(4-hydroxyphenyl)retinamide in human cervical carcinoma cells.	Fenretinide	36-65	BAG cochaperone 1	Homo sapiens	0-5
10772821-1	2000	N-(4-hydroxyphenyl)retinamide (4-HPR) is a synthetic apoptosis-inducing retinoid with cancer chemopreventive properties and lower toxicity than all-trans retinoic acid.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
10824459-1	2000	Previous investigations have demonstrated that a synthetic retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR), inhibits the invasion of prostate adenocarcinoma in vitro.	Fenretinide	69-99	haptoglobin-related protein	Homo sapiens	103-106
10448131-3	1999	All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid.	Fenretinide	0-39	haptoglobin-related protein	Homo sapiens	42-45
10706389-1	2000	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	46-49
10706389-1	2000	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	46-49
10637240-1	2000	PURPOSE: N-(4-hydroxyphenyl) retinamide (?4-HPR, Fenretinide; R.W.	Fenretinide	9-39	haptoglobin-related protein	Homo sapiens	44-47
10597238-0	1999	Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.	Fenretinide	91-120	cytochrome c, somatic	Homo sapiens	61-73
10597238-0	1999	Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.	Fenretinide	91-120	caspase 3	Homo sapiens	78-87
10523855-0	1999	4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway.	Fenretinide	0-4	retinoic acid receptor gamma	Homo sapiens	127-135
10523855-8	1999	In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RARgamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	45-48
10523855-8	1999	In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RARgamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells.	Fenretinide	13-42	retinoic acid receptor gamma	Homo sapiens	91-99
10762020-5	2000	Both tamoxifen and the synthetic retinoid fenretinide (4-HPR) have been shown to decrease plasma IGF-I levels.	Fenretinide	42-53	haptoglobin-related protein	Homo sapiens	57-60
10762020-5	2000	Both tamoxifen and the synthetic retinoid fenretinide (4-HPR) have been shown to decrease plasma IGF-I levels.	Fenretinide	42-53	insulin like growth factor 1	Homo sapiens	97-102
10570055-0	1999	c-Jun N-terminal kinase mediates apoptotic signaling induced by N-(4-hydroxyphenyl)retinamide.	Fenretinide	64-93	mitogen-activated protein kinase 8	Homo sapiens	0-23
10570055-1	1999	N-(4-Hydroxyphenyl)retinamide (4-HPR), a retinoic acid analog, induces apoptosis in several cell types.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
10572559-17	1999	Based on experimental studies, the vitamin A analogue 4-hydroxyphenyl retinamide (4-HPR) was shown to delay and reduce carcinogen-induced breast cancer.	Fenretinide	54-80	haptoglobin-related protein	Homo sapiens	84-87
10427131-3	1999	Four glioma cell lines (C6, 9L, Med3 and U87) were treated with fenretinide.	Fenretinide	64-75	small nucleolar RNA, C/D box 87	Homo sapiens	41-44
10448131-3	1999	All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid.	Fenretinide	49-60	haptoglobin-related protein	Homo sapiens	42-45
10432011-0	1999	Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).	Fenretinide	72-101	haptoglobin-related protein	Homo sapiens	105-108
10357800-0	1999	Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells).	Fenretinide	18-43	transglutaminase 2, C polypeptide	Mus musculus	73-96
10357800-1	1999	4-Hydroxyphenylretinamide (4-HPR) is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials.	Fenretinide	0-25	haptoglobin-related protein	Homo sapiens	29-32
10328240-0	1999	Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells.	Fenretinide	64-75	retinoic acid receptor alpha	Homo sapiens	8-30
10328240-1	1999	The role of retinoic acid receptor (RAR) expression in sensitivity to N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) as well as on the tumorigenicity of human ovarian carcinoma cells was examined.	Fenretinide	70-99	retinoic acid receptor alpha	Homo sapiens	36-39
10328240-1	1999	The role of retinoic acid receptor (RAR) expression in sensitivity to N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) as well as on the tumorigenicity of human ovarian carcinoma cells was examined.	Fenretinide	101-105	retinoic acid receptor alpha	Homo sapiens	12-34
10328240-1	1999	The role of retinoic acid receptor (RAR) expression in sensitivity to N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) as well as on the tumorigenicity of human ovarian carcinoma cells was examined.	Fenretinide	101-105	retinoic acid receptor alpha	Homo sapiens	36-39
10328240-1	1999	The role of retinoic acid receptor (RAR) expression in sensitivity to N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) as well as on the tumorigenicity of human ovarian carcinoma cells was examined.	Fenretinide	109-120	retinoic acid receptor alpha	Homo sapiens	12-34
10328240-1	1999	The role of retinoic acid receptor (RAR) expression in sensitivity to N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) as well as on the tumorigenicity of human ovarian carcinoma cells was examined.	Fenretinide	109-120	retinoic acid receptor alpha	Homo sapiens	36-39
10473110-10	1999	Fenretinide treatment resulted in cleavage of poly ADP-ribose polymerase, indicating an activation of the caspase 3.	Fenretinide	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	46-72
10473110-10	1999	Fenretinide treatment resulted in cleavage of poly ADP-ribose polymerase, indicating an activation of the caspase 3.	Fenretinide	0-11	caspase 3	Homo sapiens	106-115
10393722-1	1999	BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) is toxic to myeloid leukemia and cervical carcinoma cell lines, probably in part due to its ability to increase levels of reactive oxygen species (ROS).	Fenretinide	35-64	haptoglobin-related protein	Homo sapiens	68-71
10393722-1	1999	BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) is toxic to myeloid leukemia and cervical carcinoma cell lines, probably in part due to its ability to increase levels of reactive oxygen species (ROS).	Fenretinide	75-86	haptoglobin-related protein	Homo sapiens	68-71
10334206-2	1999	In this study, we used cell proliferation and telomerase in MNU (N-methyl-N-nitrosourea)-induced mammary carcinomas as targets for assessing the response of tumor cells to 4-(hydroxyphenyl)retinamide (4-HPR), a known inhibitor of mammary carcinogenesis in animal models and premenopausal women.	Fenretinide	172-199	haptoglobin-related protein	Homo sapiens	203-206
10432011-4	1999	This study focuses on the ability of N-(4-hydroxyphenyl)-retinamide (4-HPR), a synthetic retinoid, to reverse malignant characteristics towards a normal phenotype, using the human prostate carcinoma cell line DU-145.	Fenretinide	37-67	haptoglobin-related protein	Homo sapiens	71-74
10188730-4	1999	Previously, we reported that the synthetic retinoid fenretinide (HPR) is an inducer of apoptosis in neuroblastoma (NB) cells, sharing the neuroectodermal origin with melanoma cells.	Fenretinide	52-63	haptoglobin-related protein	Homo sapiens	65-68
10325501-1	1999	An NCI-sponsored, phase II trial of N-(4-hydroxyphenyl)- retinamide (4-HPR) in patients with organ-confined prostate cancer in the period prior to radical prostatectomy was carried out.	Fenretinide	36-67	haptoglobin-related protein	Homo sapiens	71-74
10069458-0	1999	Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide.	Fenretinide	132-161	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-76
9920792-0	1999	Carcinoma cell lines resistant for growth inhibition and apoptosis to retinoic acid are responsive to 4-hydroxy-phenyl-retinamide: correlation with tissue transglutaminase.	Fenretinide	102-129	transglutaminase 2	Homo sapiens	148-171
10709674-3	1999	As discussed above, all six potential chemopreventive agents, aspirin, 2-CPR, DFMO, 4-HPR, piroxicam, and 9-cis-retinoic acid, decreased the level of AOM-induced ACF.	Fenretinide	84-89	ACF	Homo sapiens	162-165
9923820-1	1999	PURPOSE: Fenretinide [N-(4-hydroxyphenyl)retinamide, 4HPR], a synthetic retinoid, is a potent inducer of apoptosis in small-cell lung cancer (SCLC) cell lines that may act through the generation of reactive oxygen species, suggesting that it may enhance the activity of other cytotoxic agents.	Fenretinide	9-20	haptoglobin-related protein	Homo sapiens	54-57
9923820-1	1999	PURPOSE: Fenretinide [N-(4-hydroxyphenyl)retinamide, 4HPR], a synthetic retinoid, is a potent inducer of apoptosis in small-cell lung cancer (SCLC) cell lines that may act through the generation of reactive oxygen species, suggesting that it may enhance the activity of other cytotoxic agents.	Fenretinide	22-51	haptoglobin-related protein	Homo sapiens	54-57
9395213-0	1997	Inhibition by N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid of exogenous and endogenous development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in the livers of rats.	Fenretinide	14-43	hematopoietic prostaglandin D synthase	Rattus norvegicus	139-164
10578478-0	1999	N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.	Fenretinide	0-29	transforming growth factor beta 1	Homo sapiens	44-75
10578478-1	1999	N-(4 hydroxyphenyl)retinamide (4-HPR), a synthetic derivative of all-trans-retinoic acid, induces DNA synthesis arrest and apoptosis in human breast cancer cells in a dose- and time-dependent manner.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
9724094-4	1998	Cyclin D1 and cdk4 expression and Rb phosphorylation were significantly reduced, by 40-75%, after 24 hr of treatment with RA or 4HPR; these decreases were either transient, e.g., only at 24 hr for cdk4, or sustained for 72 hr.	Fenretinide	128-132	cyclin D1	Homo sapiens	0-9
9724094-4	1998	Cyclin D1 and cdk4 expression and Rb phosphorylation were significantly reduced, by 40-75%, after 24 hr of treatment with RA or 4HPR; these decreases were either transient, e.g., only at 24 hr for cdk4, or sustained for 72 hr.	Fenretinide	128-132	cyclin dependent kinase 4	Homo sapiens	14-18
9724094-4	1998	Cyclin D1 and cdk4 expression and Rb phosphorylation were significantly reduced, by 40-75%, after 24 hr of treatment with RA or 4HPR; these decreases were either transient, e.g., only at 24 hr for cdk4, or sustained for 72 hr.	Fenretinide	128-132	cyclin dependent kinase 4	Homo sapiens	197-201
9724094-10	1998	Simultaneous treatment of cells with 4HPR and 25-100 microM fumonisin B1 resulted in a dose-dependent reduction in the elevation in ceramide, the extent of PARP cleavage, and induction of apoptosis.	Fenretinide	37-41	poly(ADP-ribose) polymerase 1	Homo sapiens	156-160
9662255-0	1998	Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.	Fenretinide	29-40	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-56
9662255-1	1998	We investigated the effects of all-trans retinoic acid (ATRA) and fenretinide (4-HPR) on c-erbB-2 expression in SK-BR-3, BT-474 and MCF-7 breast cancer cells and on the growth, differentiation, apoptosis and cisplatin (CDDP) sensitivity of SK-BR-3 cells.	Fenretinide	66-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	89-97
9626341-0	1998	Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.	Fenretinide	10-21	insulin like growth factor 1	Homo sapiens	32-37
9626341-0	1998	Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.	Fenretinide	10-21	insulin like growth factor binding protein 3	Homo sapiens	42-49
9797705-0	1998	Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.	Fenretinide	14-43	haptoglobin-related protein	Homo sapiens	47-50
9797705-0	1998	Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.	Fenretinide	14-43	progesterone receptor membrane component 1	Homo sapiens	88-91
9797705-1	1998	A clinical trial of N-[4-hydroxyphenyl]retinamide (4-HPR) has been in progress for the past 4 years to evaluate its role in chemoprevention of breast cancer.	Fenretinide	20-49	haptoglobin-related protein	Homo sapiens	53-56
9554442-0	1998	Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.	Fenretinide	115-145	retinoic acid receptor beta	Homo sapiens	0-27
9554442-1	1998	BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4HPR) can inhibit the growth of tumor cells.	Fenretinide	35-65	haptoglobin-related protein	Homo sapiens	68-71
9560096-3	1998	The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide) (HPR) has significant antiproliferative activity against a number of animal and human malignancies and has been used in clinical trials as a chemopreventive agent in patients with breast and prostate cancer and oral leukoplakia.	Fenretinide	23-34	haptoglobin-related protein	Homo sapiens	68-71
9560096-3	1998	The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide) (HPR) has significant antiproliferative activity against a number of animal and human malignancies and has been used in clinical trials as a chemopreventive agent in patients with breast and prostate cancer and oral leukoplakia.	Fenretinide	36-65	haptoglobin-related protein	Homo sapiens	68-71
9639444-0	1998	Effects of fenretinide (4-HPR) on dark adaptation.	Fenretinide	11-22	haptoglobin-related protein	Homo sapiens	26-29
9639444-1	1998	OBJECTIVES: To assess the alterations in dark adaptation induced by low (200 mg/d) doses of fenretinide (4-HPR), to assess whether these effects were cumulative and whether they were reversible, and to attempt to elucidate the mechanism underlying the changes in night vision.	Fenretinide	92-103	haptoglobin-related protein	Homo sapiens	107-110
9649125-0	1998	Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.	Fenretinide	57-87	insulin like growth factor 1	Homo sapiens	18-46
9649125-2	1998	We studied and compared the effects of N-(4-hydroxyphenyl)-retinamide (4-HPR) in terms of growth inhibition and modulation of the IGF-I system in ER+ (MCF-7) and oestrogen receptor-negative (ER-) (MDA-MB231) breast cancer cell lines.	Fenretinide	39-69	insulin like growth factor 1	Homo sapiens	130-135
9649125-6	1998	Immunoreactive IGF-I-like protein concentration in conditioned medium was reduced by 38% in MCF-7 and by 90% in MDA-MB231 cell lines following treatment for 48 h with 5 microM 4-HPR.	Fenretinide	176-181	insulin like growth factor 1	Homo sapiens	15-20
9649125-8	1998	Exposure to 5 microM 4-HPR for 48 h inhibited [125I]IGF-I binding and Scatchard analysis revealed a decrease of more than 50% in maximum binding capacity (Bmax) and a reduced receptor number/cell in both cancer cell lines.	Fenretinide	21-26	insulin like growth factor 1	Homo sapiens	52-57
9649125-10	1998	We conclude that 4-HPR induces a significant down-regulation of the IGF-I system in both ER+ (MCF-7) and ER- (MDA-MB231) breast cancer cell lines.	Fenretinide	17-22	insulin like growth factor 1	Homo sapiens	68-73
8857507-0	1996	N-(4-hydroxyphenyl)-retinamide increases lecithin:retinol acyltransferase activity in rat liver.	Fenretinide	0-30	lecithin retinol acyltransferase	Rattus norvegicus	41-73
9316650-1	1997	BACKGROUND: Although fenretinide (4-HPR) is currently being evaluated in a phase II clinical study for the chemoprevention of prostate cancer [Greenwald et al.	Fenretinide	21-32	haptoglobin-related protein	Homo sapiens	36-39
9125196-7	1997	We found that 4-hydroxyphenylretinamide (4-HPR) inhibited the catabolism of RA.	Fenretinide	14-39	haptoglobin-related protein	Homo sapiens	43-46
9526578-2	1997	The Fenretinide (4-HPR) Breast Cancer Study is a randomized multicenter clinical trial originally designed and conducted by the investigators of the Istituto Nazionale Tumori of Milan.	Fenretinide	4-15	haptoglobin-related protein	Homo sapiens	19-22
9388681-0	1997	Fenretinide inhibits phorbol ester-induced cyclooxygenase-2 expression in human colon adenocarcinoma cells.	Fenretinide	0-11	prostaglandin-endoperoxide synthase 2	Homo sapiens	43-59
9168437-1	1997	We demonstrate that N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR), a synthetic retinoic acid (RA) derivative, is a potent and selective inducer of apoptosis in malignant T lymphoid cells, but has little effect on normal lymphoid cells of the thymus or spleen.	Fenretinide	20-60	haptoglobin-related protein	Homo sapiens	64-67
8993839-0	1997	Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.	Fenretinide	0-11	transforming growth factor beta 1	Homo sapiens	51-82
8993839-1	1997	N-(4-Hydroxyphenyl)retinamide (4-HPR, Fenretinide) is a retinoid derivative with antineoplastic activity in various tumor types including prostate carcinoma.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
8993839-1	1997	N-(4-Hydroxyphenyl)retinamide (4-HPR, Fenretinide) is a retinoid derivative with antineoplastic activity in various tumor types including prostate carcinoma.	Fenretinide	38-49	haptoglobin-related protein	Homo sapiens	33-36
9018085-0	1996	Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses.	Fenretinide	34-45	haptoglobin-related protein	Homo sapiens	49-52
9018085-1	1996	Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months.	Fenretinide	79-90	haptoglobin-related protein	Homo sapiens	94-97
8948605-1	1996	Both retinoic acid (RA) and the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) have shown efficacy in head and neck cancer chemoprevention trials.	Fenretinide	51-80	haptoglobin-related protein	Homo sapiens	83-86
8857507-3	1996	We have conducted studies to examine the effects of 4-HPR on the activity of the enzyme lecithin:retinol acyltransferase (LRAT).	Fenretinide	52-57	lecithin retinol acyltransferase	Rattus norvegicus	88-120
8857507-3	1996	We have conducted studies to examine the effects of 4-HPR on the activity of the enzyme lecithin:retinol acyltransferase (LRAT).	Fenretinide	52-57	lecithin retinol acyltransferase	Rattus norvegicus	122-126
8857507-5	1996	To determine whether 4-HPR, like retinoic acid, is able to induce liver LRAT activity, vitamin A-deficient rats having negligible liver LRAT activity were treated with single doses of 4-HPR (0.02-2.5 mg) and liver homogenates were assayed for LRAT activity using 3H-retinol bound to the cellular-retinol binding protein, CRBP, as substrate.	Fenretinide	21-26	lecithin retinol acyltransferase	Rattus norvegicus	72-76
8857507-6	1996	Treatment with 4-HPR resulted in a dose- and time-dependent increase in liver LRAT activity which reached a maximum at 24 h. The activity of LRAT assayed in vitro and of hepatic 3H-retinyl ester content determined after an in vivo pulse of 3H-retinol were highly correlated (r = 0.802, P < 0.0002).	Fenretinide	15-20	lecithin retinol acyltransferase	Rattus norvegicus	78-82
8857507-6	1996	Treatment with 4-HPR resulted in a dose- and time-dependent increase in liver LRAT activity which reached a maximum at 24 h. The activity of LRAT assayed in vitro and of hepatic 3H-retinyl ester content determined after an in vivo pulse of 3H-retinol were highly correlated (r = 0.802, P < 0.0002).	Fenretinide	15-20	lecithin retinol acyltransferase	Rattus norvegicus	141-145
8640761-1	1996	The activities of N-(4-hydroxyphenyl)retinamide [(4-HPR), Fenretinide] and all-trans-retinoic acid (RA) were determined for (a) the inhibition of cell proliferation; (b) the activation of human retinoid receptor-mediated target gene expression; (c) the inhibition of estradiol- and progesterone-induced gene activation in breast cancer cell lines; and (d) the regulation of the expression of tumor suppressor retinoblastoma protein.	Fenretinide	18-47	haptoglobin-related protein	Homo sapiens	52-55
9063520-0	1996	Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability.	Fenretinide	38-49	haptoglobin-related protein	Homo sapiens	53-56
9063520-1	1996	BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid being clinically tested in the chemoprevention of different tumors and precancerous lesions.	Fenretinide	12-23	haptoglobin-related protein	Homo sapiens	27-30
8645719-0	1996	Retinol-binding protein secretion from the liver of N-(4-hydroxyphenyl) retinamide-treated rats.	Fenretinide	52-82	retinol binding protein 4	Rattus norvegicus	0-23
8645719-1	1996	N-(4-Hydroxyphenyl)retinamide (HPR; Fenretinide), a synthetic retinoid possessing antitumor activity, depresses plasma retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	0-29	retinol binding protein 4	Rattus norvegicus	131-154
8645719-1	1996	N-(4-Hydroxyphenyl)retinamide (HPR; Fenretinide), a synthetic retinoid possessing antitumor activity, depresses plasma retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	0-29	retinol binding protein 4	Rattus norvegicus	156-159
8645719-1	1996	N-(4-Hydroxyphenyl)retinamide (HPR; Fenretinide), a synthetic retinoid possessing antitumor activity, depresses plasma retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	36-47	retinol binding protein 4	Rattus norvegicus	131-154
8645719-1	1996	N-(4-Hydroxyphenyl)retinamide (HPR; Fenretinide), a synthetic retinoid possessing antitumor activity, depresses plasma retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	36-47	retinol binding protein 4	Rattus norvegicus	156-159
8687125-1	1996	The O-glucuronide analog of N-(4-hydroxyphenyl)retinamide (4-HPROG) has shown a greater chemopreventive activity than the parent N-(4-hydroxyphenyl)retinamide (4-HPR).	Fenretinide	28-57	haptoglobin-related protein	Homo sapiens	61-64
8713132-0	1996	Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells.	Fenretinide	47-77	haptoglobin-related protein	Homo sapiens	81-84
8651965-1	1996	OBJECTIVE: To evaluate the efficacy and tolerability of N-[4 hydroxyphenyl] retinamide (4-HPR), a synthetic retinoid, in the treatment of rheumatoid arthritis (RA).	Fenretinide	56-86	haptoglobin-related protein	Homo sapiens	90-93
21552953-0	1995	N-(4-hydroxyphenyl)retinamide induces apoptosis in human leukemia hl-60 cells and mediates vimentin down-regulation.	Fenretinide	0-29	vimentin	Homo sapiens	91-99
8621233-0	1996	Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression.	Fenretinide	26-37	haptoglobin-related protein	Homo sapiens	40-43
7473815-3	1995	Fenretinide [N-(4-hydroxyphenyl)retinamide; HPR] is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	44-47
7473815-3	1995	Fenretinide [N-(4-hydroxyphenyl)retinamide; HPR] is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	44-47
9816026-1	1995	The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR; Fenretinide), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown.	Fenretinide	24-53	haptoglobin-related protein	Homo sapiens	57-60
7586155-0	1995	N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
7586155-2	1995	N-(4-hydroxyphenyl) retinamide (4-HPR), a derivative of all-trans-retinoic acid (RA) is currently in clinical trials as a chemopreventive agent for breast cancer.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
7586162-8	1995	Although retinol and 4HPR cross-competed for RBP binding, N-phenylretinamide, in which the 4-hydroxyl group is absent, and N-(4-methoxyphenyl)retinamide, a major cellular metabolite of 4HPR, in which the hydroxyl group is blocked, did not show affinity for the binding protein.	Fenretinide	21-25	retinol binding protein 4	Homo sapiens	45-48
8595390-0	1995	The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells.	Fenretinide	23-53	haptoglobin-related protein	Homo sapiens	57-60
21552857-2	1995	All-trans retinoic acid (ATRA) and N-(4-hydroxyphenyl)retinamide (4HPR) are currently being evaluated in clinical trials for their potential use in cancer chemoprevention and therapy.	Fenretinide	35-64	haptoglobin-related protein	Homo sapiens	67-70
7654032-2	1995	In this study, a series of experiments were performed to examine the effects of N-(4-hydroxyphenyl) retinamide (4-HPR, Fenretinide) on cellular adhesion, motility and proteolytic activity of established prostate cancer cell lines, TSU-PR 1 and PC-3.	Fenretinide	112-117	proprotein convertase subtilisin/kexin type 1	Homo sapiens	231-248
7654032-4	1995	Radiomigration assay also demonstrated that 4-HPR concentration of 10(-6) M reduced the cellular motility by 29% in TSU-PR1 and 28% in PC-3 cells (p < 0.05).	Fenretinide	44-49	transmembrane protein 37	Homo sapiens	120-123
9816026-1	1995	The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR; Fenretinide), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown.	Fenretinide	62-73	haptoglobin-related protein	Homo sapiens	57-60
7744071-12	1995	Additionally, the bulky end groups of fenretinide and N-ethyl retinamide replacing the retinol hydroxyl group have been found to prevent retinoid binding to CRBP.	Fenretinide	38-49	retinol binding protein 1	Bos taurus	157-161
7538673-7	1995	We found that mac25 accumulates in senescent cells and is up-regulated in normal, growing mammary epithelial cells by all-trans-retinoic acid or the synthetic retinoid fenretinide.	Fenretinide	168-179	insulin like growth factor binding protein 7	Homo sapiens	14-19
21607448-1	1994	Fenretinide (4-HPR), a synthetic amide derivative of retinoic acid, has proven effective in preventing chemically induced mammary carcinoma in rodents.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
7961949-1	1994	The three-dimensional structures of complexes between bovine plasma retinol-binding protein (RBP) and three retinol analogs with different end groups (fenretinide, all-trans retinoic acid, and axerophthene) have been determined to 1.8-1.9-A resolution.	Fenretinide	151-162	retinol binding protein 4	Bos taurus	93-96
8033144-1	1994	The efficacy of the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been demonstrated in the inhibition of cancers in a variety of tissues.	Fenretinide	29-58	haptoglobin-related protein	Homo sapiens	62-65
8149338-0	1994	Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR).	Fenretinide	73-84	haptoglobin-related protein	Homo sapiens	88-91
8208624-1	1994	The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) has been demonstrated to inhibit the development of primary and metastatic neoplasms in several animal models.	Fenretinide	23-53	haptoglobin-related protein	Homo sapiens	57-60
8180126-6	1994	RAR-beta gene expression is induced both by retinoic acid and by fenretinide in normal cells, but tumor cells fail to respond to either.	Fenretinide	65-76	retinoic acid receptor beta	Homo sapiens	0-8
8217599-1	1993	N-(4-hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid which reduces the incidence of experimental tumours in animals and has been chosen for its weak toxicity to be tested as a chemopreventive agent in humans.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
7808027-6	1994	Autocrine stimulation of human breast cancer cell lines by tgf-alpha, insulin-like growth factors I and II is significantly abrogated by fenretinide.	Fenretinide	137-148	transforming growth factor alpha	Homo sapiens	59-68
7808027-6	1994	Autocrine stimulation of human breast cancer cell lines by tgf-alpha, insulin-like growth factors I and II is significantly abrogated by fenretinide.	Fenretinide	137-148	insulin like growth factor 1	Homo sapiens	70-106
8221674-1	1993	Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	48-51
8221674-1	1993	Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents.	Fenretinide	15-45	haptoglobin-related protein	Homo sapiens	48-51
8319203-1	1993	Fenretinide (HPR), 13-cis-retinoic acid, and all-trans-retinoic acid are vitamin A derivatives used in the treatment of cancer and severe acne.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	13-16
8402658-0	1993	The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.	Fenretinide	23-34	insulin like growth factor 1	Homo sapiens	49-77
8402658-1	1993	We studied the effect of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)], a synthetic analogue of retinoic acid, on plasma insulin-like growth factor I (IGF-I) levels in a consecutive cohort of stage I breast cancer patients belonging to a randomized phase III trial of breast cancer chemoprevention.	Fenretinide	25-36	insulin like growth factor 1	Homo sapiens	127-155
8402658-1	1993	We studied the effect of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)], a synthetic analogue of retinoic acid, on plasma insulin-like growth factor I (IGF-I) levels in a consecutive cohort of stage I breast cancer patients belonging to a randomized phase III trial of breast cancer chemoprevention.	Fenretinide	25-36	insulin like growth factor 1	Homo sapiens	157-162
8402658-1	1993	We studied the effect of fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)], a synthetic analogue of retinoic acid, on plasma insulin-like growth factor I (IGF-I) levels in a consecutive cohort of stage I breast cancer patients belonging to a randomized phase III trial of breast cancer chemoprevention.	Fenretinide	38-67	insulin like growth factor 1	Homo sapiens	127-155
8360775-0	1993	N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.	Fenretinide	0-29	retinol binding protein 4	Rattus norvegicus	52-75
8360775-0	1993	N-(4-hydroxyphenyl)retinamide (fenretinide) induces retinol-binding protein secretion from liver and accumulation in the kidneys in rats.	Fenretinide	31-42	retinol binding protein 4	Rattus norvegicus	52-75
8360775-1	1993	The chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (HPR) depresses serum retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	29-58	retinol binding protein 4	Rattus norvegicus	93-116
8360775-1	1993	The chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (HPR) depresses serum retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	29-58	retinol binding protein 4	Rattus norvegicus	118-121
8360775-1	1993	The chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (HPR) depresses serum retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	60-63	retinol binding protein 4	Rattus norvegicus	93-116
8360775-1	1993	The chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (HPR) depresses serum retinol and retinol-binding protein (RBP) concentrations.	Fenretinide	60-63	retinol binding protein 4	Rattus norvegicus	118-121
8297658-0	1993	Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR).	Fenretinide	60-71	haptoglobin-related protein	Homo sapiens	75-78
7685988-1	1993	The in vitro anticlastogenic effects of a new synthetic retinoid derivative, N-(4-hydroxyphenyl)-retinamide (4-HPR), were studied in two human lymphoblastid cell lines (3640P and 4087P).	Fenretinide	77-107	haptoglobin-related protein	Homo sapiens	111-114
8007703-1	1993	Fenretinide (4-HPR), a synthetic derivative of retinoic acid, has proven effective at inhibiting in vitro breast cancer cell growth and preventing the progression of chemically induced mammary carcinoma in rodents.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
8412202-0	1993	Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
8412202-2	1993	The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias.	Fenretinide	58-69	haptoglobin-related protein	Homo sapiens	73-76
8382073-3	1993	Attention is presently focused on two compounds, the synthetic retinoid fenretinide (4-HPR) and the antioestrogen tamoxifen, and their possible synergism.	Fenretinide	72-83	haptoglobin-related protein	Homo sapiens	87-90
1624219-4	1992	In similar experiments, two closely related retinamides, all-trans-(phenyl)retinamide (PR) and N-(4-hydroxyphenyl)retinamide (4-HPR), also potentiated murine splenocyte rIL-2 responses.	Fenretinide	95-124	interleukin 2	Rattus norvegicus	169-174
1386578-3	1992	The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.	Fenretinide	66-77	retinol binding protein 4	Homo sapiens	162-165
1386578-3	1992	The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.	Fenretinide	66-77	retinol binding protein 4	Homo sapiens	199-202
1386578-3	1992	The remarkable early reduction in plasma retinol level induced by fenretinide administration may be associated with the high binding affinity of this retinoid to RBP and to its interference with the RBP-TTR complex formation.	Fenretinide	66-77	transthyretin	Homo sapiens	203-206
1306735-0	1992	Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR).	Fenretinide	100-111	haptoglobin-related protein	Homo sapiens	115-118
1388202-0	1992	Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).	Fenretinide	87-116	retinol binding protein 4	Rattus norvegicus	27-50
1388202-0	1992	Secretion of vitamin A and retinol-binding protein into plasma is depressed in rats by N-(4-hydroxyphenyl)retinamide (fenretinide).	Fenretinide	118-129	retinol binding protein 4	Rattus norvegicus	27-50
1388202-1	1992	In clinical trials the cancer preventive drug N-(4-hydroxyphenyl)retinamide (HPR) markedly lowers plasma concentrations of retinol and retinol-binding protein (RBP).	Fenretinide	46-75	retinol binding protein 4	Rattus norvegicus	135-158
1388202-1	1992	In clinical trials the cancer preventive drug N-(4-hydroxyphenyl)retinamide (HPR) markedly lowers plasma concentrations of retinol and retinol-binding protein (RBP).	Fenretinide	46-75	retinol binding protein 4	Rattus norvegicus	160-163
1624219-4	1992	In similar experiments, two closely related retinamides, all-trans-(phenyl)retinamide (PR) and N-(4-hydroxyphenyl)retinamide (4-HPR), also potentiated murine splenocyte rIL-2 responses.	Fenretinide	126-131	interleukin 2	Rattus norvegicus	169-174
1835622-0	1991	Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.	Fenretinide	26-37	haptoglobin-related protein	Homo sapiens	41-44
1305675-4	1992	In vitro assays indicate that fenretinide (4-HPR), alpha-interferon, and 5-fluorouracil possess significant antitumoral activity in human transitional cell carcinoma (TCC) lines.	Fenretinide	30-41	haptoglobin-related protein	Homo sapiens	45-48
1305678-1	1992	The ability of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) to affect the outcome of previously resected superficial bladder cancer was investigated in a pilot study using DNA content flow cytometry and conventional cytology as intermediate endpoints.	Fenretinide	38-67	haptoglobin-related protein	Homo sapiens	71-74
1535505-1	1992	Fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] is an effective agent for the inhibition of N-nitroso-N-methylurea-induced breast cancer in rats.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	46-49
34742949-2	2022	However, fenretinide reduces plasma vitamin A levels by interacting with retinol-binding protein 4 (RBP4), which often results in reversible night blindness in patients.	Fenretinide	9-20	retinol binding protein 4	Homo sapiens	73-98
33815111-6	2021	In contrast, EtOH + Fen-treated mice were resistant to the effects of EtOH on promoting intestinal permeability and had higher intestinal protein levels of claudin one and occludin.	Fenretinide	20-23	occludin	Mus musculus	172-180
33815111-7	2021	Also, EtOH + Fen-treated mice had significantly lower plasma levels of endotoxin, and reductions in expression of TNF-alpha and TLR4 positive macrophages, Kupffer cells, and hepatocytes in the intestine and liver.	Fenretinide	13-16	tumor necrosis factor	Mus musculus	114-123
33815111-7	2021	Also, EtOH + Fen-treated mice had significantly lower plasma levels of endotoxin, and reductions in expression of TNF-alpha and TLR4 positive macrophages, Kupffer cells, and hepatocytes in the intestine and liver.	Fenretinide	13-16	toll-like receptor 4	Mus musculus	128-132
34742949-2	2022	However, fenretinide reduces plasma vitamin A levels by interacting with retinol-binding protein 4 (RBP4), which often results in reversible night blindness in patients.	Fenretinide	9-20	retinol binding protein 4	Homo sapiens	100-104
34742949-3	2022	Cell culture and in vitro studies show that fenretinide binds and inhibits the activity of beta-carotene oxygenase 1 (BCO1), the enzyme responsible for endogenous vitamin A formation.	Fenretinide	44-55	beta-carotene oxygenase 1	Mus musculus	91-116
34742949-3	2022	Cell culture and in vitro studies show that fenretinide binds and inhibits the activity of beta-carotene oxygenase 1 (BCO1), the enzyme responsible for endogenous vitamin A formation.	Fenretinide	44-55	beta-carotene oxygenase 1	Homo sapiens	118-122
34742949-5	2022	The goal of this study was to determine if the inhibition of BCO1 by fenretinide affects vitamin A formation in mice fed beta-carotene.	Fenretinide	69-80	beta-carotene oxygenase 1	Mus musculus	61-65
2527636-0	1989	Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor.	Fenretinide	49-78	haptoglobin-related protein	Homo sapiens	82-85
34106748-0	2021	N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide Delta4-desaturase 1-independent mechanism.	Fenretinide	0-30	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	53-58
34106748-0	2021	N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide Delta4-desaturase 1-independent mechanism.	Fenretinide	0-30	delta like canonical Notch ligand 4	Homo sapiens	114-133
34106748-3	2021	N-(4-hydroxyphenyl) retinamide (4-HPR), an inhibitor of dihydroceramide Delta4-desaturase 1 (DES1), suppressed cell-cell fusion, and viral infection.	Fenretinide	0-30	delta like canonical Notch ligand 4	Homo sapiens	72-91
34106748-3	2021	N-(4-hydroxyphenyl) retinamide (4-HPR), an inhibitor of dihydroceramide Delta4-desaturase 1 (DES1), suppressed cell-cell fusion, and viral infection.	Fenretinide	0-30	delta 4-desaturase, sphingolipid 1	Homo sapiens	93-97
34106748-3	2021	N-(4-hydroxyphenyl) retinamide (4-HPR), an inhibitor of dihydroceramide Delta4-desaturase 1 (DES1), suppressed cell-cell fusion, and viral infection.	Fenretinide	32-37	delta like canonical Notch ligand 4	Homo sapiens	72-91
34106748-3	2021	N-(4-hydroxyphenyl) retinamide (4-HPR), an inhibitor of dihydroceramide Delta4-desaturase 1 (DES1), suppressed cell-cell fusion, and viral infection.	Fenretinide	32-37	delta 4-desaturase, sphingolipid 1	Homo sapiens	93-97
33380244-4	2021	Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1beta, IL-6, and TNF-alpha in dextran sulfate sodium (DSS)-induced mice.	Fenretinide	31-36	interleukin 1 alpha	Mus musculus	150-158
33380244-4	2021	Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1beta, IL-6, and TNF-alpha in dextran sulfate sodium (DSS)-induced mice.	Fenretinide	31-36	interleukin 6	Mus musculus	160-164
33380244-4	2021	Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1beta, IL-6, and TNF-alpha in dextran sulfate sodium (DSS)-induced mice.	Fenretinide	31-36	tumor necrosis factor	Mus musculus	170-179
34363869-4	2021	We analyzed the effects of FEN on mutant SOD1 (mSOD1) toxicity in motoneuronal (NSC34) and a muscle (C2C12) cell lines and evaluated the impacts of chronic administration of a new nanomicellar fenretinide formulation (NanoMFen) on ALS disease progression in the SOD1G93A mouse model.	Fenretinide	27-30	superoxide dismutase 1, soluble	Mus musculus	47-52
34363869-5	2021	The results showed that FEN significantly prevents the toxicity of mSOD1 expression in NSC34 motor neuron; furthermore, FEN is able to partially overcome the toxic effect of mSOD1 on the myogenic program of C2C12 muscle cells.	Fenretinide	24-27	superoxide dismutase 1, soluble	Mus musculus	67-72
34363869-5	2021	The results showed that FEN significantly prevents the toxicity of mSOD1 expression in NSC34 motor neuron; furthermore, FEN is able to partially overcome the toxic effect of mSOD1 on the myogenic program of C2C12 muscle cells.	Fenretinide	120-123	superoxide dismutase 1, soluble	Mus musculus	67-72
34363869-5	2021	The results showed that FEN significantly prevents the toxicity of mSOD1 expression in NSC34 motor neuron; furthermore, FEN is able to partially overcome the toxic effect of mSOD1 on the myogenic program of C2C12 muscle cells.	Fenretinide	120-123	superoxide dismutase 1, soluble	Mus musculus	174-179
34106748-12	2021	4-HPR (also known as fenretinide) is an inhibitor of DES1 and it exhibits antitumor activity and suppresses cell-cell fusion and viral infection.	Fenretinide	0-5	delta 4-desaturase, sphingolipid 1	Homo sapiens	53-57
34106748-12	2021	4-HPR (also known as fenretinide) is an inhibitor of DES1 and it exhibits antitumor activity and suppresses cell-cell fusion and viral infection.	Fenretinide	21-32	delta 4-desaturase, sphingolipid 1	Homo sapiens	53-57
2527636-1	1989	A study was conducted to determine whether N-(4-hydroxyphenyl)retinamide (4-HPR) affects the development of new mammary tumors subsequent to the surgical removal of the first palpable tumor.	Fenretinide	43-72	haptoglobin-related protein	Homo sapiens	76-79
2694156-3	1989	N-(4-hydroxyphenyl)retinamide (4-HPR) currently appears to be the most efficacious retinoid against carcinogen-induced breast, urinary bladder, and lung cancer in rodents.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
3621188-1	1987	Retinyl acetate, 13-cis-retinoic acid (13cisRA), and N-(4-hydroxyphenyl)-retinamide (4HPR) were assayed for their in vivo effects on hepatic levels of cytochrome P450, cytosolic glutathione-S-transferase, and quinone reductase.	Fenretinide	53-83	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	151-203
2643696-3	1989	N-(4-hydroxyphenyl) retinamide (4-HPR) currently appears to be the most efficaceous retinoid against carcinogen-induced breast, urinary bladder, and lung cancer in rodents.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
33423090-0	2021	A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.	Fenretinide	31-42	haptoglobin-related protein	Homo sapiens	46-49
33123895-11	2020	4-HPR-induced reactive oxygen species (ROS) production and NF-kappaB inhibition might be the reason of 4-HPR selectivity on FLT3 mutated AML cells.	Fenretinide	103-108	fms related receptor tyrosine kinase 3	Homo sapiens	124-128
33439253-6	2021	Agents that target the viral component of the IMPalpha/beta1-virus interface include N-(4-hydroxyphenyl) retinamide (4-HPR), which specifically targets DENV/ZIKV/WNV non-structural protein 5 (NS5).	Fenretinide	85-115	inositol monophosphatase 1	Homo sapiens	46-60
33439253-6	2021	Agents that target the viral component of the IMPalpha/beta1-virus interface include N-(4-hydroxyphenyl) retinamide (4-HPR), which specifically targets DENV/ZIKV/WNV non-structural protein 5 (NS5).	Fenretinide	117-122	inositol monophosphatase 1	Homo sapiens	46-60
33079733-2	2021	The histone deacetylase (HDAC) inhibitors and the synthetic cytotoxic retinoid fenretinide have achieved durable clinical responses in T-cell lymphomas as single agents, and patients who failed prior HDAC inhibitor treatment have responded to fenretinide.	Fenretinide	79-90	histone deacetylase 9	Homo sapiens	200-204
33079733-2	2021	The histone deacetylase (HDAC) inhibitors and the synthetic cytotoxic retinoid fenretinide have achieved durable clinical responses in T-cell lymphomas as single agents, and patients who failed prior HDAC inhibitor treatment have responded to fenretinide.	Fenretinide	243-254	histone deacetylase 9	Homo sapiens	4-23
33079733-2	2021	The histone deacetylase (HDAC) inhibitors and the synthetic cytotoxic retinoid fenretinide have achieved durable clinical responses in T-cell lymphomas as single agents, and patients who failed prior HDAC inhibitor treatment have responded to fenretinide.	Fenretinide	243-254	histone deacetylase 9	Homo sapiens	25-29
31927141-10	2020	Several retinoids, notably anhydroretinol and fenretinide, capable of displacing retinol from binding sites on PKCdelta, can co-activate PKCdelta signaling but, owing to their extended system of conjugated double bonds, are unable to silence PKCdelta in a timely manner.	Fenretinide	46-57	protein kinase C delta	Homo sapiens	111-119
31927141-10	2020	Several retinoids, notably anhydroretinol and fenretinide, capable of displacing retinol from binding sites on PKCdelta, can co-activate PKCdelta signaling but, owing to their extended system of conjugated double bonds, are unable to silence PKCdelta in a timely manner.	Fenretinide	46-57	protein kinase C delta	Homo sapiens	137-145
31927141-10	2020	Several retinoids, notably anhydroretinol and fenretinide, capable of displacing retinol from binding sites on PKCdelta, can co-activate PKCdelta signaling but, owing to their extended system of conjugated double bonds, are unable to silence PKCdelta in a timely manner.	Fenretinide	46-57	protein kinase C delta	Homo sapiens	137-145
33123895-0	2020	4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-kappaB Inhibition.	Fenretinide	0-26	fms related receptor tyrosine kinase 3	Homo sapiens	50-54
33123895-7	2020	CD34+ AML stem/progenitor cells separated from 32 AML samples were treated with 4-HPR.	Fenretinide	80-85	CD34 molecule	Homo sapiens	0-4
33123895-8	2020	Correlation analysis showed that AML cells with FLT3-ITD genetic alteration were more sensitive to 4-HPR treatment than those without FLT3-ITD.	Fenretinide	99-104	fms related receptor tyrosine kinase 3	Homo sapiens	48-52
33123895-8	2020	Correlation analysis showed that AML cells with FLT3-ITD genetic alteration were more sensitive to 4-HPR treatment than those without FLT3-ITD.	Fenretinide	99-104	fms related receptor tyrosine kinase 3	Homo sapiens	134-138
32982239-0	2020	Nanomicellar Lenalidomide-Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor.	Fenretinide	26-37	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	80-84
33123895-11	2020	4-HPR-induced reactive oxygen species (ROS) production and NF-kappaB inhibition might be the reason of 4-HPR selectivity on FLT3 mutated AML cells.	Fenretinide	0-5	fms related receptor tyrosine kinase 3	Homo sapiens	124-128
32366203-1	2020	Fenretinide (4-HPR), a synthetic retinoid, has shown its antitumor activity in many tumor types with low cytotoxicity to normal cells and high clinical safety.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
32982239-1	2020	Purpose: In a previous study, we demonstrated that the combination of fenretinide with lenalidomide, administered by a novel nanomicellar formulation (FLM), provided a strong antitumor effect in a neuroblastoma TrkB-expressing tumor.	Fenretinide	70-81	neurotrophic receptor tyrosine kinase 2	Homo sapiens	211-215
32266855-1	2020	Fenretinide (4-HPR), as a semi-synthetic retinoid, has apoptosis-promoting effects as a single agent and chemotherapy synergist in vitro.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
32266855-3	2020	In this research, a new TPGS-Soluplus  mixed micelles were developed which encapsulation efficiencies of paclitaxel (PTX) and fenretinide (4-HPR) were as high as 98%, and the average diameter of the micelles was 66.26 nm.	Fenretinide	126-137	haptoglobin-related protein	Homo sapiens	141-144
32696214-0	2020	Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-kappaB inhibition in acute myeloid leukemia cells.	Fenretinide	22-48	nuclear factor kappa B subunit 1	Homo sapiens	57-66
32862802-0	2022	High-fat diet exacerbates cognitive and metabolic abnormalities in neuronal BACE1 knock-in mice - partial prevention by Fenretinide.	Fenretinide	120-131	beta-site APP cleaving enzyme 1	Mus musculus	76-81
32497314-1	2020	Fenretinide (4-HPR) is a synthetic derivative of All-Trans-Retinoic Acid (ATRA) characterised by improved therapeutic properties and toxicological profile relative to ATRA.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
32306138-2	2020	Our study aimed to investigate the age-dependent deterioration in lung function and the effects of treatment with Fenretinide formulation (LAU-7b) in Cftr knockout (KO) mice.	Fenretinide	114-125	cystic fibrosis transmembrane conductance regulator	Mus musculus	150-154
32144381-2	2020	Previously, we have identified fenretinide (retinoic acid p-hydroxyanilide) to affect PAX3-FOXO1 expression levels as well as FP-RMS cell viability.	Fenretinide	31-42	paired box 3	Homo sapiens	86-90
32144381-2	2020	Previously, we have identified fenretinide (retinoic acid p-hydroxyanilide) to affect PAX3-FOXO1 expression levels as well as FP-RMS cell viability.	Fenretinide	31-42	forkhead box O1	Homo sapiens	91-96
32144381-2	2020	Previously, we have identified fenretinide (retinoic acid p-hydroxyanilide) to affect PAX3-FOXO1 expression levels as well as FP-RMS cell viability.	Fenretinide	44-74	paired box 3	Homo sapiens	86-90
32144381-2	2020	Previously, we have identified fenretinide (retinoic acid p-hydroxyanilide) to affect PAX3-FOXO1 expression levels as well as FP-RMS cell viability.	Fenretinide	44-74	forkhead box O1	Homo sapiens	91-96
32273303-0	2020	Treatment of allergic asthma with Fenretinide formulation (LAU-7b) downregulates Ormdl3 expression and normalizes ceramides imbalance.	Fenretinide	34-45	ORM1-like 3 (S. cerevisiae)	Mus musculus	81-87
32273303-4	2020	We hypothesized that Fenretinide (FEN) can prevent the allergic asthma-induced augmentation of Ormdl3 gene expression, normalize aberrant levels of VLCCs and LCCs, and treat allergic asthma symptoms.	Fenretinide	21-32	ORM1-like 3 (S. cerevisiae)	Mus musculus	95-101
32273303-4	2020	We hypothesized that Fenretinide (FEN) can prevent the allergic asthma-induced augmentation of Ormdl3 gene expression, normalize aberrant levels of VLCCs and LCCs, and treat allergic asthma symptoms.	Fenretinide	34-37	ORM1-like 3 (S. cerevisiae)	Mus musculus	95-101
32238432-6	2020	The retinol-isomerase activities of Rpe65 and Des1 are inhibited by emixustat and fenretinide, respectively.	Fenretinide	82-93	delta(4)-desaturase, sphingolipid 1	Danio rerio	46-50
32273303-12	2020	- The novel oral clinical formulation of Fenretinide (LAU-7b) effectively lowers the AHR, protects against inflammatory cell infiltration and mucus accumulation induced by HDM in both Zpbp2 KO and WT A/J mice.	Fenretinide	41-52	zona pellucida binding protein 2	Mus musculus	184-189
31925643-0	2020	Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.	Fenretinide	0-11	cadherin 5	Homo sapiens	51-55
32106372-0	2020	Fenretinide attenuates lipopolysaccharide (LPS)-induced blood-brain barrier (BBB) and depressive-like behavior in mice by targeting Nrf-2 signaling.	Fenretinide	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	132-137
32106372-5	2020	Results here indicated that Fen treatment markedly improved Nrf2 expression and nuclear translocation in mouse brain endothelial cell line bEnd.3 cells, and promoted Nrf2-antioxidant responsive element (ARE) transcription activity, as well as its down-streaming signals, which was Nrf2-dependent.	Fenretinide	28-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	60-64
32106372-5	2020	Results here indicated that Fen treatment markedly improved Nrf2 expression and nuclear translocation in mouse brain endothelial cell line bEnd.3 cells, and promoted Nrf2-antioxidant responsive element (ARE) transcription activity, as well as its down-streaming signals, which was Nrf2-dependent.	Fenretinide	28-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	166-170
32106372-5	2020	Results here indicated that Fen treatment markedly improved Nrf2 expression and nuclear translocation in mouse brain endothelial cell line bEnd.3 cells, and promoted Nrf2-antioxidant responsive element (ARE) transcription activity, as well as its down-streaming signals, which was Nrf2-dependent.	Fenretinide	28-31	nuclear factor, erythroid derived 2, like 2	Mus musculus	166-170
31925643-0	2020	Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.	Fenretinide	0-11	forkhead box M1	Homo sapiens	57-62
31925643-0	2020	Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.	Fenretinide	0-11	nitric oxide synthase 3	Homo sapiens	67-71
31925643-0	2020	Fenretinide reduces angiogenesis by downregulating CDH5, FOXM1 and eNOS genes and suppressing microRNA-10b.	Fenretinide	0-11	microRNA 10b	Homo sapiens	94-106
31925643-6	2020	In this study, we aimed to investigate the effects of the fenretinide on some miRNAs involving in angiogenesis process and on the expression of CDH5, FOXM1 and eNOS genes upregulated in angiogenesis.	Fenretinide	58-69	forkhead box M1	Homo sapiens	150-155
31925643-6	2020	In this study, we aimed to investigate the effects of the fenretinide on some miRNAs involving in angiogenesis process and on the expression of CDH5, FOXM1 and eNOS genes upregulated in angiogenesis.	Fenretinide	58-69	nitric oxide synthase 3	Homo sapiens	160-164
31925643-13	2020	Our results have shown that fenretinide exhibited anti-angiogenic activity through the down-regulation of CDH5, FOXM1 and eNOS genes, and suppression of miR-10b.	Fenretinide	28-39	cadherin 5	Homo sapiens	106-110
31925643-13	2020	Our results have shown that fenretinide exhibited anti-angiogenic activity through the down-regulation of CDH5, FOXM1 and eNOS genes, and suppression of miR-10b.	Fenretinide	28-39	forkhead box M1	Homo sapiens	112-117
31925643-13	2020	Our results have shown that fenretinide exhibited anti-angiogenic activity through the down-regulation of CDH5, FOXM1 and eNOS genes, and suppression of miR-10b.	Fenretinide	28-39	nitric oxide synthase 3	Homo sapiens	122-126
31925643-13	2020	Our results have shown that fenretinide exhibited anti-angiogenic activity through the down-regulation of CDH5, FOXM1 and eNOS genes, and suppression of miR-10b.	Fenretinide	28-39	microRNA 10b	Homo sapiens	153-160
31484706-10	2019	Thus, fenretinide + venetoclax is a synergistic combination that warrants clinical testing in high BCL-2-expressing neuroblastoma.	Fenretinide	6-17	BCL2 apoptosis regulator	Homo sapiens	99-104
31988387-3	2020	The aim here was to examine the possibility of cross-talk between AnxA8 and Wnt signalling, as both are down-regulated upon fenretinide (FR)-mediated RPE transdifferentiation.	Fenretinide	124-135	annexin A8	Homo sapiens	66-71
31988387-3	2020	The aim here was to examine the possibility of cross-talk between AnxA8 and Wnt signalling, as both are down-regulated upon fenretinide (FR)-mediated RPE transdifferentiation.	Fenretinide	137-139	annexin A8	Homo sapiens	66-71
31621898-0	2020	Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects.	Fenretinide	0-11	apolipoprotein E	Mus musculus	65-69
31515297-11	2019	Notably, combination fenretinide-tocilizumab-reparixin treatment significantly suppressed IL-6 and IL-8 release, stem cell gene expression, and invasion in these diverse CSCE populations.	Fenretinide	21-32	interleukin 6	Homo sapiens	90-94
31515297-11	2019	Notably, combination fenretinide-tocilizumab-reparixin treatment significantly suppressed IL-6 and IL-8 release, stem cell gene expression, and invasion in these diverse CSCE populations.	Fenretinide	21-32	C-X-C motif chemokine ligand 8	Homo sapiens	99-103
31678518-0	2020	Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.	Fenretinide	0-11	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	38-44
31678518-0	2020	Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.	Fenretinide	0-11	mucin 5B, oligomeric mucus/gel-forming	Homo sapiens	45-50
31678518-0	2020	Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.	Fenretinide	0-11	CF transmembrane conductance regulator	Homo sapiens	99-103
31678518-6	2020	Fenretinide prevented the lipopolysaccharide-induced increase of MUC5AC gene expression, without affecting the level of MUC5B, in a lung goblet cell line.	Fenretinide	0-11	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	65-71
31880746-12	2020	The ALT and AST in 4-HPR group were significantly decreased compared with ACLF group.	Fenretinide	19-24	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	12-15
31484706-0	2019	Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.	Fenretinide	0-11	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	16-20
31484706-0	2019	Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2-Expressing Neuroblastoma Preclinical Models.	Fenretinide	0-11	BCL2 apoptosis regulator	Homo sapiens	57-62
31484706-2	2019	Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2).	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
31484706-2	2019	Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2).	Fenretinide	0-11	BCL2 apoptosis regulator	Homo sapiens	173-190
31484706-2	2019	Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2).	Fenretinide	0-11	BCL2 apoptosis regulator	Homo sapiens	192-197
31839811-0	2019	Fenretinide-induced Apoptosis of Acute Myeloid Leukemia Cells via NR4A1 Translocation into Mitochondria and Bcl-2 Transformation.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	66-71
31631013-4	2019	Inhibition of DEGS1 in hematopoietic stem and progenitor cells during the transition from quiescence to cellular activation with N-(4-hydroxyphenyl) retinamide activates coordinated stress pathways that coalesce on endoplasmic reticulum stress and autophagy programs to maintain immunophenotypic and functional HSCs.	Fenretinide	129-159	delta 4-desaturase, sphingolipid 1	Homo sapiens	14-19
31839811-0	2019	Fenretinide-induced Apoptosis of Acute Myeloid Leukemia Cells via NR4A1 Translocation into Mitochondria and Bcl-2 Transformation.	Fenretinide	0-11	BCL2 apoptosis regulator	Homo sapiens	108-113
31839811-1	2019	OBJECTIVE: Fenretinide is reported to induce NR4A1-associated apoptosis in several types of cancer cells.	Fenretinide	11-22	nuclear receptor subfamily 4 group A member 1	Homo sapiens	45-50
31839811-7	2019	In addition, the expression levels of NR4A1 in the nuclei and mitochondria of fenretinide-treated AML cells were also measured.	Fenretinide	78-89	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31839811-11	2019	Fenretinide induced the expression of NR4A1 and mitochondria-mediated apoptotic pathway-associated proteins in a time- and concentration-dependent manner.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	38-43
31839811-13	2019	Under the action of fenretinide, the NR4A1 protein expression was down-regulated in nuclear extracts whereas up-regulated in mitochondrial extracts.	Fenretinide	20-31	nuclear receptor subfamily 4 group A member 1	Homo sapiens	37-42
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	nuclear receptor subfamily 4 group A member 1	Homo sapiens	127-132
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	BCL2 apoptosis regulator	Homo sapiens	137-142
31839811-14	2019	At the same time, fenretinide promoted NR4A1 translocation from nuclei into mitochondria, and enhanced the interaction between NR4A1 and Bcl-2, thereby exposing the BH3 domain of Bcl-2 to exert the anti-apoptotic effect.	Fenretinide	18-29	BCL2 apoptosis regulator	Homo sapiens	179-184
31839811-15	2019	Moreover, fenretinide also exhibited an anti-leukemic effect and induced NR4A1 expression in the AML mouse model.	Fenretinide	10-21	nuclear receptor subfamily 4, group A, member 1	Mus musculus	73-78
31839811-17	2019	Besides, the NR4A1-mediated signaling pathway is highly involved in the fenretinide-induced apoptosis of AML cells.	Fenretinide	72-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	13-18
31276572-0	2019	Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.	Fenretinide	15-26	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	65-69
30939964-5	2019	By screening a library of nuclear-receptor-agonists for modifiers of the SQSTM1 aggregates, we identified 4-hydroxy(phenyl)retinamide (4HPR) as a potent modifier exerting detrimental effects on mutant-TBK1 motoneurons fitness exacerbating the autophagy overload.	Fenretinide	106-133	sequestosome 1	Homo sapiens	73-79
30939964-5	2019	By screening a library of nuclear-receptor-agonists for modifiers of the SQSTM1 aggregates, we identified 4-hydroxy(phenyl)retinamide (4HPR) as a potent modifier exerting detrimental effects on mutant-TBK1 motoneurons fitness exacerbating the autophagy overload.	Fenretinide	106-133	TANK binding kinase 1	Homo sapiens	201-205
30939964-5	2019	By screening a library of nuclear-receptor-agonists for modifiers of the SQSTM1 aggregates, we identified 4-hydroxy(phenyl)retinamide (4HPR) as a potent modifier exerting detrimental effects on mutant-TBK1 motoneurons fitness exacerbating the autophagy overload.	Fenretinide	135-139	sequestosome 1	Homo sapiens	73-79
30939964-5	2019	By screening a library of nuclear-receptor-agonists for modifiers of the SQSTM1 aggregates, we identified 4-hydroxy(phenyl)retinamide (4HPR) as a potent modifier exerting detrimental effects on mutant-TBK1 motoneurons fitness exacerbating the autophagy overload.	Fenretinide	135-139	TANK binding kinase 1	Homo sapiens	201-205
30939964-7	2019	4HPR-increased toxicity was associated with the upregulation of SQSTM1 in a context of strongly reduced ATG10, while rescue of ATG10 levels abolished 4HPR toxicity.	Fenretinide	0-4	sequestosome 1	Homo sapiens	64-70
30939964-7	2019	4HPR-increased toxicity was associated with the upregulation of SQSTM1 in a context of strongly reduced ATG10, while rescue of ATG10 levels abolished 4HPR toxicity.	Fenretinide	0-4	autophagy related 10	Homo sapiens	104-109
30939964-7	2019	4HPR-increased toxicity was associated with the upregulation of SQSTM1 in a context of strongly reduced ATG10, while rescue of ATG10 levels abolished 4HPR toxicity.	Fenretinide	0-4	autophagy related 10	Homo sapiens	127-132
30939964-7	2019	4HPR-increased toxicity was associated with the upregulation of SQSTM1 in a context of strongly reduced ATG10, while rescue of ATG10 levels abolished 4HPR toxicity.	Fenretinide	150-154	autophagy related 10	Homo sapiens	127-132
31103416-0	2019	Effects of Liraglutide and Fenretinide treatments on the diabetic phenotype of neuronal human BACE1 knock-in mice.	Fenretinide	27-38	beta-secretase 1	Homo sapiens	94-99
31103416-5	2019	Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice.	Fenretinide	16-27	leptin	Mus musculus	132-138
31103416-5	2019	Liraglutide and Fenretinide treatments inhibited adiposity gain and decreased circulating serum triglyceride (with Liraglutide) and leptin (with Fenretinide) levels in PLB4 mice.	Fenretinide	145-156	leptin	Mus musculus	132-138
31276572-7	2019	Furthermore, a retinoid derivative and an endoplasmic reticulum stress inducer, fenretinide, induced NOXA, and combination of fenretinide and ABT-263 strongly induced apoptosis in HNSCC cells regardless of the HPV or p53 statuses.	Fenretinide	80-91	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	101-105
31276572-7	2019	Furthermore, a retinoid derivative and an endoplasmic reticulum stress inducer, fenretinide, induced NOXA, and combination of fenretinide and ABT-263 strongly induced apoptosis in HNSCC cells regardless of the HPV or p53 statuses.	Fenretinide	80-91	tumor protein p53	Homo sapiens	217-220
31276572-7	2019	Furthermore, a retinoid derivative and an endoplasmic reticulum stress inducer, fenretinide, induced NOXA, and combination of fenretinide and ABT-263 strongly induced apoptosis in HNSCC cells regardless of the HPV or p53 statuses.	Fenretinide	126-137	tumor protein p53	Homo sapiens	217-220
30061204-1	2018	BACKGROUND/AIM: N-(4-hydroxyphenyl)retinamide (4-HPR) is a synthetic retinoid, less toxic than the parent all-trans retinoic acid (RA).	Fenretinide	16-45	haptoglobin-related protein	Homo sapiens	49-52
30836314-9	2019	The validated method was successfully applied to the analyses of pharmacokinetic samples from patients treated with safingol and all-trans-N-(4-hydroxyphenyl)retinamide; (fenretinide, 4-HPR) in a current phase I clinical trial (SPOC-2010-002, ClinicalTrials.gov Identifier: NCT01553071).	Fenretinide	129-168	haptoglobin-related protein	Homo sapiens	186-189
30251395-2	2018	The synthetic retinoid fenretinide (4-HPR) achieved multiple complete responses in relapse/refractory neuroblastoma in early-phase clinical trials, has low systemic toxicity, and has been considered for maintenance therapy clinical trials.	Fenretinide	23-34	haptoglobin-related protein	Homo sapiens	38-41
30129371-7	2018	Fenretinide and emixustat are VCMs for dry AMD and STGD1 that failed to halt geographic atrophy progression or improve vision in trials for AMD.	Fenretinide	0-11	ATP binding cassette subfamily A member 4	Homo sapiens	51-56
29767236-0	2018	Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38-MAPK signaling pathway.	Fenretinide	0-11	myosin light chain kinase	Homo sapiens	123-148
30086303-7	2018	Importantly, ATF6 containing a luminal achromatopsia eye disease mutation, unresponsive to proteotoxic stress, can be activated by fenretinide, a drug that upregulates DHC, suggesting a potential therapy for this and other ATF6-related diseases including heart disease and stroke.	Fenretinide	131-142	activating transcription factor 6	Homo sapiens	13-17
30086303-7	2018	Importantly, ATF6 containing a luminal achromatopsia eye disease mutation, unresponsive to proteotoxic stress, can be activated by fenretinide, a drug that upregulates DHC, suggesting a potential therapy for this and other ATF6-related diseases including heart disease and stroke.	Fenretinide	131-142	activating transcription factor 6	Homo sapiens	223-227
29767236-0	2018	Fenretinide inhibits the proliferation and migration of human liver cancer HepG2 cells by downregulating the activation of myosin light chain kinase through the p38-MAPK signaling pathway.	Fenretinide	0-11	mitogen-activated protein kinase 14	Homo sapiens	161-164
29767236-1	2018	N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide), which is a synthetic analog of all-trans retinoic acid (ATRA), effectively inhibits the growth of several types of tumor cells; however, its molecular mechanism remains unclear.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
29767236-1	2018	N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide), which is a synthetic analog of all-trans retinoic acid (ATRA), effectively inhibits the growth of several types of tumor cells; however, its molecular mechanism remains unclear.	Fenretinide	40-51	haptoglobin-related protein	Homo sapiens	33-36
28988109-3	2017	We show here for the first time that ZIKV NS5 is recognized with high nanomolar affinity by the host cell importin alpha/beta1 heterodimer, and that this interaction can be blocked by the novel DENV NS5 targeting inhibitor N-(4-hydroxyphenyl) retinamide (4-HPR).	Fenretinide	223-253	haptoglobin-related protein	Homo sapiens	257-260
29500274-8	2018	Complementary experiments in these animal models using the DES1 inhibitor fenretinide show more modest effects on cone recovery.	Fenretinide	74-85	delta 4-desaturase, sphingolipid 1	Homo sapiens	59-63
28692043-13	2017	Treatment of breast cancer xenografts in vivo with the retinoid fenretinide reduced the accumulation of CK5+ cells during estrogen depletion.	Fenretinide	64-75	keratin 5	Homo sapiens	104-107
28256636-0	2017	Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice.	Fenretinide	120-131	fibroblast growth factor 21	Mus musculus	9-36
28695226-0	2017	Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.	Fenretinide	0-11	ceramide synthase 5	Homo sapiens	105-110
28695226-13	2017	Fenretinide downregulates the levels of LCCs and upregulates the levels of VLCCs.	Fenretinide	0-11	GLE1 RNA export mediator	Homo sapiens	40-44
28695226-14	2017	Fenretinide changes the balance of LCCs and VLCCs by downregulating Cers5 enzyme.	Fenretinide	0-11	GLE1 RNA export mediator	Homo sapiens	35-39
28695226-14	2017	Fenretinide changes the balance of LCCs and VLCCs by downregulating Cers5 enzyme.	Fenretinide	0-11	ceramide synthase 5	Homo sapiens	68-73
28448568-0	2017	Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta4-desaturase 1.	Fenretinide	22-33	haptoglobin-related protein	Homo sapiens	130-133
28448568-0	2017	Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta4-desaturase 1.	Fenretinide	22-33	beta-carotene oxygenase 1	Homo sapiens	168-193
28448568-0	2017	Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta4-desaturase 1.	Fenretinide	22-33	stearoyl-CoA desaturase	Homo sapiens	195-220
28448568-0	2017	Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta4-desaturase 1.	Fenretinide	22-33	delta 4-desaturase, sphingolipid 1	Homo sapiens	247-260
28448568-1	2017	The therapeutic capacity of fenretinide (N-[4-hydroxyphenyl] retinamide; 4-HPR) has been demonstrated for several conditions, including cancer, obesity, diabetes, and ocular disease.	Fenretinide	28-39	haptoglobin-related protein	Homo sapiens	75-78
28448568-1	2017	The therapeutic capacity of fenretinide (N-[4-hydroxyphenyl] retinamide; 4-HPR) has been demonstrated for several conditions, including cancer, obesity, diabetes, and ocular disease.	Fenretinide	41-71	haptoglobin-related protein	Homo sapiens	75-78
28448568-3	2017	We hypothesized that investigation of two of the major physiological metabolites of fenretinide, N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR), might begin to resolve the multifaceted effects of this synthetic retinoid.	Fenretinide	84-95	haptoglobin-related protein	Homo sapiens	181-184
28448568-6	2017	The data demonstrate that while fenretinide is an inhibitor of the activities of these three enzymes, that 3-keto-HPR is a more potent inhibitor of all three enzymes, potentially mediating most of the in vivo beneficial effects of fenretinide.	Fenretinide	231-242	haptoglobin-related protein	Homo sapiens	114-117
28275870-1	2017	PURPOSE: By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from alpha, beta-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect.	Fenretinide	80-91	haptoglobin-related protein	Homo sapiens	95-98
28119491-6	2017	Fenretinide + romidepsin caused a reactive oxygen species (ROS)-dependent increase in proapoptotic proteins (Bim, tBid, Bax, and Bak), apoptosis, and inhibition of HDAC enzymatic activity, which achieved a synergistic increase in histone acetylation.	Fenretinide	0-11	BCL2 like 11	Homo sapiens	109-112
28119491-6	2017	Fenretinide + romidepsin caused a reactive oxygen species (ROS)-dependent increase in proapoptotic proteins (Bim, tBid, Bax, and Bak), apoptosis, and inhibition of HDAC enzymatic activity, which achieved a synergistic increase in histone acetylation.	Fenretinide	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
28119491-6	2017	Fenretinide + romidepsin caused a reactive oxygen species (ROS)-dependent increase in proapoptotic proteins (Bim, tBid, Bax, and Bak), apoptosis, and inhibition of HDAC enzymatic activity, which achieved a synergistic increase in histone acetylation.	Fenretinide	0-11	BCL2 antagonist/killer 1	Homo sapiens	129-132
28119491-8	2017	Romidepsin + fenretinide activated p38 and JNK via ROS, and knockdown of p38 and JNK1 significantly decreased the synergistic cytotoxicity.	Fenretinide	13-24	mitogen-activated protein kinase 14	Homo sapiens	35-38
28119491-8	2017	Romidepsin + fenretinide activated p38 and JNK via ROS, and knockdown of p38 and JNK1 significantly decreased the synergistic cytotoxicity.	Fenretinide	13-24	mitogen-activated protein kinase 8	Homo sapiens	43-46
28340497-0	2017	P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.	Fenretinide	91-102	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-4
28340497-1	2017	We previously reported that concurrent ketoconazole, an oral anti-fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid, fenretinide (4-HPR) in mice.	Fenretinide	157-168	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	83-87
28340497-1	2017	We previously reported that concurrent ketoconazole, an oral anti-fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid, fenretinide (4-HPR) in mice.	Fenretinide	157-168	haptoglobin-related protein	Homo sapiens	172-175
28429653-1	2017	Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
28256636-0	2017	Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice.	Fenretinide	120-131	fibroblast growth factor 21	Mus musculus	38-43
28256636-0	2017	Elevated Fibroblast growth factor 21 (FGF21) in obese, insulin resistant states is normalised by the synthetic retinoid Fenretinide in mice.	Fenretinide	120-131	insulin	Homo sapiens	55-62
28256636-5	2017	Fenretinide normalised elevated levels of FGF21 in both high-fat diet-induced obese mice and in genetically obese-diabetic Leprdbmice.	Fenretinide	0-11	fibroblast growth factor 21	Mus musculus	42-47
28256636-6	2017	Moreover, Fenretinide-mediated suppression of FGF21 was independent of body weight loss or improved hepatic insulin sensitivity and importantly does not induce unhealthy metabolic complications.	Fenretinide	10-21	fibroblast growth factor 21	Mus musculus	46-51
28256636-8	2017	The repression of FGF21 levels by Fenretinide occurs by reduced binding of RARalpha and Pol-II at the Fgf21 promoter.	Fenretinide	34-45	fibroblast growth factor 21	Mus musculus	18-23
28256636-8	2017	The repression of FGF21 levels by Fenretinide occurs by reduced binding of RARalpha and Pol-II at the Fgf21 promoter.	Fenretinide	34-45	retinoic acid receptor, alpha	Mus musculus	75-83
28256636-8	2017	The repression of FGF21 levels by Fenretinide occurs by reduced binding of RARalpha and Pol-II at the Fgf21 promoter.	Fenretinide	34-45	fibroblast growth factor 21	Mus musculus	102-107
28256636-9	2017	We therefore establish Fgf21 as a novel gene target of Fenretinide signalling via a retinoid-dependent mechanism.	Fenretinide	55-66	fibroblast growth factor 21	Mus musculus	23-28
28179290-1	2017	BACKGROUND/AIM: Combining an anticancer agent fenretinide (HPR) or C6-pyridinium ceramide (LCL29) with Foscan-mediated photodynamic therapy (FoscanPDT) is expected to augment anticancer benefits of each substance.	Fenretinide	46-57	haptoglobin-related protein	Homo sapiens	59-62
27843299-0	2016	Fenretinide inhibits macrophage inflammatory mediators and controls hypertension in spontaneously hypertensive rats via the peroxisome proliferator-activated receptor gamma pathway.	Fenretinide	0-11	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	124-172
27701038-1	2017	A simple and accurate high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the determination of N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and its metabolites, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR), in human plasma.	Fenretinide	143-172	haptoglobin-related protein	Homo sapiens	189-192
27701038-1	2017	A simple and accurate high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the determination of N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and its metabolites, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR), in human plasma.	Fenretinide	143-172	haptoglobin-related protein	Homo sapiens	260-263
27843299-6	2016	These effects were blocked by the pretreatment with PPARgamma antagonist in a dose-dependent manner, indicating fenretinide activated PPARgamma to exert anti-inflammation activity.	Fenretinide	112-123	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	52-61
27843299-6	2016	These effects were blocked by the pretreatment with PPARgamma antagonist in a dose-dependent manner, indicating fenretinide activated PPARgamma to exert anti-inflammation activity.	Fenretinide	112-123	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	134-143
27843299-8	2016	Taken together, these results indicate that fenretinide might be a potent antihypertensive agent that works by suppressing inflammation via activating PPARgamma.	Fenretinide	44-55	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	151-160
27843299-3	2016	In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARgamma expression.	Fenretinide	210-221	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	102-150
27843299-3	2016	In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARgamma expression.	Fenretinide	210-221	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	152-161
27843299-3	2016	In this study, we have shown that treatment with lipopolysaccharide (LPS) decreased the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in RAW264.7 macrophages, and pretreatment with fenretinide reversed the effect of LPS on PPARgamma expression.	Fenretinide	210-221	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	252-261
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	190-201	tumor necrosis factor	Rattus norvegicus	73-100
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	190-201	interleukin 6	Rattus norvegicus	102-115
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	190-201	C-C motif chemokine ligand 2	Rattus norvegicus	121-155
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	190-201	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	317-326
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	222-233	interleukin 6	Rattus norvegicus	102-115
27843299-4	2016	In addition, LPS-induced pro-inflammatory cytokine production, including tumor necrosis factor-alpha, interleukin 6, and monocyte chemoattractant protein 1 were dose-dependently reversed by fenretinide, and the effects of fenretinide on LPS-induced pro-inflammatory cytokine production were blocked by treatment with PPARgamma antagonist.	Fenretinide	222-233	C-C motif chemokine ligand 2	Rattus norvegicus	121-155
27628049-6	2016	Furthermore, we show that fenretinide or the ER stress inhibitor 4-PBA decreased curcumin-induced Glucose-regulated protein 78 (GRP78) upregulation, and produced a similar enhanced cytotoxic effect.	Fenretinide	26-37	heat shock protein family A (Hsp70) member 5	Homo sapiens	98-126
27530131-2	2016	Fenretinide (4-HPR) is a synthetic retinoid.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
27628049-6	2016	Furthermore, we show that fenretinide or the ER stress inhibitor 4-PBA decreased curcumin-induced Glucose-regulated protein 78 (GRP78) upregulation, and produced a similar enhanced cytotoxic effect.	Fenretinide	26-37	heat shock protein family A (Hsp70) member 5	Homo sapiens	128-133
27367907-0	2016	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
27367907-0	2016	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.	Fenretinide	0-11	mitogen-activated protein kinase 3	Homo sapiens	39-46
26919975-6	2016	Quantitative reverse transcription-polymerase chain reaction from endometriotic cells treated with fenretinide was used to examine expression of genes involved in RA signaling including stimulated by RA 6 (STRA6), cellular RA binding protein 2 (CRABP2), and fatty acid binding protein 5 (FABP5).	Fenretinide	99-110	fatty acid binding protein 5, epidermal	Mus musculus	258-286
26919975-6	2016	Quantitative reverse transcription-polymerase chain reaction from endometriotic cells treated with fenretinide was used to examine expression of genes involved in RA signaling including stimulated by RA 6 (STRA6), cellular RA binding protein 2 (CRABP2), and fatty acid binding protein 5 (FABP5).	Fenretinide	99-110	fatty acid binding protein 5, epidermal	Mus musculus	288-293
26919975-13	2016	CONCLUSIONS: Fenretinide increases STRA6 expression thereby potentially reversing the pathological loss of retinoid availability.	Fenretinide	13-24	stimulated by retinoic acid gene 6	Mus musculus	35-40
27367907-0	2016	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.	Fenretinide	0-11	Wnt family member 3A	Homo sapiens	55-60
27367907-0	2016	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.	Fenretinide	0-11	caspase 9	Homo sapiens	28-37
27367907-0	2016	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.	Fenretinide	0-11	catenin beta 1	Homo sapiens	61-73
27367907-3	2016	N-(4-Hydroxyphenyl) retinamide (4-HPR, fenretinide), a synthetic analogue of all-trans retinoic acid, has emerged as a promising and well-tolerated cancer chemopreventive and chemotherapeutic agent for various neoplasms, from breast cancer to neuroblastoma.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
27367907-3	2016	N-(4-Hydroxyphenyl) retinamide (4-HPR, fenretinide), a synthetic analogue of all-trans retinoic acid, has emerged as a promising and well-tolerated cancer chemopreventive and chemotherapeutic agent for various neoplasms, from breast cancer to neuroblastoma.	Fenretinide	39-50	haptoglobin-related protein	Homo sapiens	34-37
27045034-0	2016	Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.	Fenretinide	85-96	vascular endothelial growth factor A	Homo sapiens	27-31
26934645-5	2016	Furthermore, SKi or ABC294640 or fenretinide increase the expression of the senescence markers, p53 and p21 in LNCaP-AI prostate cancer cells.	Fenretinide	33-44	tumor protein p53	Homo sapiens	96-99
27085050-3	2016	In this study we tested the hypothesis that combining Foscan-mediated PDT with desaturase inhibitor fenretinide (HPR) enhances cancer cell killing.	Fenretinide	100-111	haptoglobin-related protein	Homo sapiens	113-116
26934645-3	2016	These effects are recapitulated by the dihydroceramide desaturase (Des1) inhibitor, fenretinide.	Fenretinide	84-95	delta 4-desaturase, sphingolipid 1	Homo sapiens	67-71
26934645-5	2016	Furthermore, SKi or ABC294640 or fenretinide increase the expression of the senescence markers, p53 and p21 in LNCaP-AI prostate cancer cells.	Fenretinide	33-44	H3 histone pseudogene 16	Homo sapiens	104-107
25739041-2	2015	The clinically-relevant fenretinide [N-(4-hydroxyphenyl) retinamide; 4HPR], was combined with the silicon phthalocyanine photosensitizer Pc4-mediated PDT to test for their potential to enhance killing of SCC17B cells, a clinically-relevant model of human head and neck squamous cell carcinoma.	Fenretinide	69-73	keratin 6B	Homo sapiens	137-140
26592777-11	2016	FEN and 4-OXO (but not RA) treatment additionally led to the activation of p38-MAPK, peIF2alpha and autophagy markers in adipocytes.	Fenretinide	0-3	mitogen-activated protein kinase 14	Mus musculus	75-78
26843908-3	2016	The p75 neurotrophin receptor (p75NTR) enhances the antineuroblastoma cell efficacy of fenretinide in vitro.	Fenretinide	87-98	nerve growth factor receptor	Homo sapiens	4-29
26843908-3	2016	The p75 neurotrophin receptor (p75NTR) enhances the antineuroblastoma cell efficacy of fenretinide in vitro.	Fenretinide	87-98	nerve growth factor receptor	Homo sapiens	31-37
26843908-4	2016	We examined the role of the retinoid binding protein, CRABP1, in p75NTR-mediated potentiation of the efficacy of fenretinide.	Fenretinide	113-124	cellular retinoic acid binding protein 1	Homo sapiens	54-60
26843908-4	2016	We examined the role of the retinoid binding protein, CRABP1, in p75NTR-mediated potentiation of the efficacy of fenretinide.	Fenretinide	113-124	nerve growth factor receptor	Homo sapiens	65-71
26843908-11	2016	Potentiation of the antineuroblastoma cell effects of fenretinide by p75NTR is not mediated solely through CRABP1.	Fenretinide	54-65	nerve growth factor receptor	Homo sapiens	69-75
26237500-0	2015	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IkappaBalpha kinase downregulation.	Fenretinide	15-26	NFKB inhibitor alpha	Homo sapiens	132-144
26220867-1	2015	Fenretinide, N-(4-hydroxyphenyl)retinamide, (4-HPR), a synthetic retinoid, owes its cancer-toxic effects in part to the generation of ceramide, a potent tumor-suppressing sphingolipid.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	47-50
26220867-1	2015	Fenretinide, N-(4-hydroxyphenyl)retinamide, (4-HPR), a synthetic retinoid, owes its cancer-toxic effects in part to the generation of ceramide, a potent tumor-suppressing sphingolipid.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	47-50
26389809-8	2016	CONCLUSIONS: The expression of AQP4 and AQP6 is downregulated during fenretinide-induced transdifferentiation.	Fenretinide	69-80	aquaporin 4	Homo sapiens	31-35
26389809-8	2016	CONCLUSIONS: The expression of AQP4 and AQP6 is downregulated during fenretinide-induced transdifferentiation.	Fenretinide	69-80	aquaporin 6	Homo sapiens	40-44
26640617-6	2016	We therefore hypothesized that the fenretinide-potentiating effects of p75NTR are the result of transcriptional enrichment of Complex II by p75ICD.	Fenretinide	35-46	nerve growth factor receptor	Homo sapiens	71-77
26640617-6	2016	We therefore hypothesized that the fenretinide-potentiating effects of p75NTR are the result of transcriptional enrichment of Complex II by p75ICD.	Fenretinide	35-46	nerve growth factor receptor	Homo sapiens	140-146
25963741-0	2015	Thymosin-beta4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.	Fenretinide	56-67	thymosin beta 4 X-linked	Homo sapiens	0-14
25963741-5	2015	The 4-HPR + SAHA combination induced caspase-dependent apoptosis through activation of caspase 3, reduced colony formation and cell migration in vitro, and tumorigenicity in vivo.	Fenretinide	4-9	caspase 3	Homo sapiens	87-96
25712051-0	2015	Fenretinide Perturbs Focal Adhesion Kinase in Premalignant and Malignant Human Oral Keratinocytes.	Fenretinide	0-11	protein tyrosine kinase 2	Homo sapiens	21-42
25712051-1	2015	Fenretinide"s Chemopreventive Mechanisms Include ECM Interactions.	Fenretinide	0-11	multimerin 1	Homo sapiens	49-52
25712051-5	2015	The cancer chemopreventive and synthetic vitamin A derivative, fenretinide, has demonstrated protein-binding capacities, for example, mTOR- and retinol-binding protein interactions.	Fenretinide	63-74	mechanistic target of rapamycin kinase	Homo sapiens	134-138
25712051-6	2015	These studies used a continuum of human oral keratinocytes (normal-HPV E6/E7-transduced-OSCC) to assess potential fenretinide-FAK drug protein interactions and functional consequences on cellular growth regulation and motility.	Fenretinide	114-125	protein tyrosine kinase 2	Homo sapiens	126-129
25712051-7	2015	Molecular modeling studies demonstrated that fenretinide has approximately 200-fold greater binding affinity relative to the natural ligand (ATP) at FAK"s kinase domain.	Fenretinide	45-56	protein tyrosine kinase 2	Homo sapiens	149-152
25712051-8	2015	Fenretinide also shows intermediate binding at FAK"s FERM domain and interacts at the ATP-binding site of the closest FAK analogue, PYK2.	Fenretinide	0-11	protein tyrosine kinase 2	Homo sapiens	47-50
25712051-8	2015	Fenretinide also shows intermediate binding at FAK"s FERM domain and interacts at the ATP-binding site of the closest FAK analogue, PYK2.	Fenretinide	0-11	protein tyrosine kinase 2	Homo sapiens	118-121
25712051-8	2015	Fenretinide also shows intermediate binding at FAK"s FERM domain and interacts at the ATP-binding site of the closest FAK analogue, PYK2.	Fenretinide	0-11	protein tyrosine kinase 2 beta	Homo sapiens	132-136
25712051-14	2015	Our data imply that fenretinide is uniquely capable of disrupting FAK"s and PYK2"s prosurvival and mobility-enhancing effects and further extend fenretinide"s chemopreventive contributions beyond induction of apoptosis and differentiation.	Fenretinide	20-31	protein tyrosine kinase 2	Homo sapiens	66-69
25712051-14	2015	Our data imply that fenretinide is uniquely capable of disrupting FAK"s and PYK2"s prosurvival and mobility-enhancing effects and further extend fenretinide"s chemopreventive contributions beyond induction of apoptosis and differentiation.	Fenretinide	20-31	protein tyrosine kinase 2 beta	Homo sapiens	76-80
25313218-4	2015	We screened a library of bioactive lipids and modulators of lipid metabolism and identified 4-hydroxyphenyl retinamide (4-HPR) (fenretinide) as an inhibitor of DENV in cell culture.	Fenretinide	92-118	haptoglobin-related protein	Homo sapiens	122-125
25576804-4	2015	In the current study, N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid, was used as a drug model of ROS induction to investigate its synergistic effect with AgNPs.	Fenretinide	22-51	haptoglobin-related protein	Homo sapiens	55-58
25461293-3	2015	The high expression of caveolin-1 on the A549 cell surface further enhanced the antitumor activity of the nanoencapsulated fenretinide.	Fenretinide	123-134	caveolin 1	Homo sapiens	23-33
25461293-4	2015	Caveolin-1 favored albumin uptake and improved the efficacy of the fenretinide-loaded albumin nanocapsules, especially in 3-D cultures where the densely packed 3-D structures impaired drug diffusibility and severely reduced the activity of the free drug.	Fenretinide	67-78	caveolin 1	Homo sapiens	0-10
25313218-4	2015	We screened a library of bioactive lipids and modulators of lipid metabolism and identified 4-hydroxyphenyl retinamide (4-HPR) (fenretinide) as an inhibitor of DENV in cell culture.	Fenretinide	128-139	haptoglobin-related protein	Homo sapiens	122-125
24885263-7	2014	Our data demonstrate that treatment of allergen-sensitized mice with fenretinide before allergen challenge prevents ovalbumin-induced changes in the AA/DHA ratio.	Fenretinide	69-80	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	116-125
24885263-8	2014	The levels of several metabolites, such as serotonin, and markers of cellular stress, which are increased after ovalbumin challenge, are also controlled by fenretinide treatment.	Fenretinide	156-167	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	112-121
24885263-9	2014	We observed the protective effect of fenretinide against ovalbumin-induced airway hyperresponsiveness and inflammation in the lungs, illustrated by a complete block in the infiltration of inflammatory cells to the airways and dramatically diminished goblet cell proliferation, even though IgE remained high.	Fenretinide	37-48	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	57-66
25414197-10	2014	CONCLUSIONS: These findings improve our understanding of the mechanism of cell death in Prominin-1-related disease and provide evidence that fenretinide may be worth studying in human disease.	Fenretinide	141-152	prominin 1	Homo sapiens	88-98
25340777-6	2014	Further, we have shown that this induction of apoptosis by fenretinide may be caused by increased retinol uptake via STRA6.	Fenretinide	59-70	signaling receptor and transporter of retinol STRA6	Homo sapiens	117-122
24392637-4	2014	RESULTS: Increasing concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR)-treatment pushed autophagy down to apoptosis in a dose-dependent manner, and 4-HPR-induced ROS contribute to this process.	Fenretinide	38-68	haptoglobin-related protein	Homo sapiens	72-75
24392637-4	2014	RESULTS: Increasing concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR)-treatment pushed autophagy down to apoptosis in a dose-dependent manner, and 4-HPR-induced ROS contribute to this process.	Fenretinide	38-68	haptoglobin-related protein	Homo sapiens	156-159
24357007-0	2014	Fenretinide induces ubiquitin-dependent proteasomal degradation of stearoyl-CoA desaturase in human retinal pigment epithelial cells.	Fenretinide	0-11	stearoyl-CoA desaturase	Homo sapiens	67-90
25069047-7	2014	This review covers the current knowledge about Fenretinide"s use as a therapy for cancer and potential to treat obesity, insulin resistance and glucose intolerance.	Fenretinide	47-58	insulin	Homo sapiens	121-128
24934240-5	2014	(N-(4-Hydroxyphenyl)  retinamide), a potent anti-angiogenic agent, could not only down-regulate the expression of vascular epithelial growth factor, but also decrease endocan transcription and expression in NB4 cells, a human acute promyelocytic leukemia cell line.	Fenretinide	1-32	endothelial cell specific molecule 1	Homo sapiens	167-174
25246272-3	2014	The antioxidant N-acetylcysteine decreased GSK3beta phosphorylation and poly(ADP-ribose) polymerase cleavage induced by 4HPR, As2O3, and PEITC, implicating oxidative stress in these effects.	Fenretinide	120-124	glycogen synthase kinase 3 beta	Homo sapiens	43-51
24357007-3	2014	We examined whether fenretinide, (N-(4-hydroxyphenyl)retinamide, 4HPR), which induces apoptosis in cancer cells and recently shown to improve insulin sensitivity, can modulate the expression of SCD.	Fenretinide	20-31	stearoyl-CoA desaturase	Homo sapiens	194-197
24357007-3	2014	We examined whether fenretinide, (N-(4-hydroxyphenyl)retinamide, 4HPR), which induces apoptosis in cancer cells and recently shown to improve insulin sensitivity, can modulate the expression of SCD.	Fenretinide	33-63	stearoyl-CoA desaturase	Homo sapiens	194-197
24357007-3	2014	We examined whether fenretinide, (N-(4-hydroxyphenyl)retinamide, 4HPR), which induces apoptosis in cancer cells and recently shown to improve insulin sensitivity, can modulate the expression of SCD.	Fenretinide	65-69	stearoyl-CoA desaturase	Homo sapiens	194-197
24357007-4	2014	We observed that fenretinide decreased SCD protein and enzymatic activity in the ARPE-19 human retinal pigment epithelial cell line.	Fenretinide	17-28	stearoyl-CoA desaturase	Homo sapiens	39-42
24357007-8	2014	In addition, PYR41, an inhibitor of ubiquitin activating enzyme E1, blocked the fenretinide-mediated decrease in SCD.	Fenretinide	80-91	stearoyl-CoA desaturase	Homo sapiens	113-116
24357007-9	2014	Immunoprecipitation analysis using anti-ubiquitin and anti-SCD antibodies and the blocking of SCD loss by PYR41 inhibition of ubiquitination further corroborate that fenretinide mediates the degradation of SCD in human RPE cells via the ubiquitin-proteasome dependent pathway.	Fenretinide	166-177	stearoyl-CoA desaturase	Homo sapiens	59-62
24357007-9	2014	Immunoprecipitation analysis using anti-ubiquitin and anti-SCD antibodies and the blocking of SCD loss by PYR41 inhibition of ubiquitination further corroborate that fenretinide mediates the degradation of SCD in human RPE cells via the ubiquitin-proteasome dependent pathway.	Fenretinide	166-177	stearoyl-CoA desaturase	Homo sapiens	94-97
24357007-10	2014	Therefore, the effect of fenretinide on SCD should be considered in its potential therapeutic role against cancer, type-2 diabetes, and retinal diseases.	Fenretinide	25-36	stearoyl-CoA desaturase	Homo sapiens	40-43
24835984-4	2014	Inhibitor co-crystal X-ray structures revealed unique disruptions of RBP4-TTR interactions by our compounds through induced loop conformational changes instead of steric hindrance exemplified by fenretinide.	Fenretinide	195-206	retinol binding protein 4, plasma	Mus musculus	69-73
25015569-0	2014	Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model.	Fenretinide	23-34	albumin	Mus musculus	62-69
24835984-4	2014	Inhibitor co-crystal X-ray structures revealed unique disruptions of RBP4-TTR interactions by our compounds through induced loop conformational changes instead of steric hindrance exemplified by fenretinide.	Fenretinide	195-206	transthyretin	Mus musculus	74-77
23764045-8	2013	Targeting these activated pro-proliferative genes by combined approaches of HDAC-inhibitors plus fenretinide, which inhibits cyclinD1, exhibit strong synergistic effects on induction of apoptosis.	Fenretinide	97-108	cyclin D1	Homo sapiens	125-133
24755119-2	2014	The combination of fenretinide (4-HPR), a synthetic retinoid inducing apoptosis by ROS generation, and TRAIL, a cell death ligand inducing caspase-dependent apoptosis, might result in more powerful cytotoxic activity.	Fenretinide	19-30	haptoglobin-related protein	Homo sapiens	34-37
24755119-8	2014	Confirming apoptosis, active caspase-3 and cleaved PARP were increased by fenretinide or TRAIL in both western blotting and ELISA.	Fenretinide	74-85	caspase 3	Homo sapiens	29-38
24755119-8	2014	Confirming apoptosis, active caspase-3 and cleaved PARP were increased by fenretinide or TRAIL in both western blotting and ELISA.	Fenretinide	74-85	poly(ADP-ribose) polymerase 1	Homo sapiens	51-55
24021153-1	2014	AIMS: We have recently shown that fenretinide preferentially targets CD34(+) cells of acute myeloid leukemia (AML), and here, we test whether this agent exerts the effect on CD34(+) cells of chronic myeloid leukemia (CML), which are refractory to imatinib.	Fenretinide	34-45	CD34 molecule	Homo sapiens	69-73
24021153-2	2014	RESULTS: As tested by colony-forming cell assays using clinical specimens, both number and size of total colonies derived from CD34(+) CML cells were significantly reduced by fenretinide, and by combining fenretinide with imatinib.	Fenretinide	175-186	CD34 molecule	Homo sapiens	127-131
24021153-2	2014	RESULTS: As tested by colony-forming cell assays using clinical specimens, both number and size of total colonies derived from CD34(+) CML cells were significantly reduced by fenretinide, and by combining fenretinide with imatinib.	Fenretinide	205-216	CD34 molecule	Homo sapiens	127-131
24021153-4	2014	Accordantly, fenretinide appeared to induce apoptosis in CD34(+) CML cells, particularly with regard to the cells in the subpopulation of CD34(+)CD38(-).	Fenretinide	13-24	CD34 molecule	Homo sapiens	57-61
24021153-4	2014	Accordantly, fenretinide appeared to induce apoptosis in CD34(+) CML cells, particularly with regard to the cells in the subpopulation of CD34(+)CD38(-).	Fenretinide	13-24	CD34 molecule	Homo sapiens	138-142
24021153-4	2014	Accordantly, fenretinide appeared to induce apoptosis in CD34(+) CML cells, particularly with regard to the cells in the subpopulation of CD34(+)CD38(-).	Fenretinide	13-24	CD38 molecule	Homo sapiens	145-149
24021153-5	2014	Through cell quiescent assays, including Ki-67 negativity test, we added evidence that nonproliferative CD34(+) CML cells were largely eliminated by fenretinide.	Fenretinide	149-160	CD34 molecule	Homo sapiens	104-108
24021153-7	2014	INNOVATION AND CONCLUSION: As compared with CD34(+) AML cells, the apoptotic effects of fenretinide on CD34(+) CML cells were more prominent whereas less varied among the samples of different patients, and also various stress-responsive events appeared to be more robust in fenretinide-treated CD34(+) CML cells.	Fenretinide	88-99	CD34 molecule	Homo sapiens	103-107
24021153-7	2014	INNOVATION AND CONCLUSION: As compared with CD34(+) AML cells, the apoptotic effects of fenretinide on CD34(+) CML cells were more prominent whereas less varied among the samples of different patients, and also various stress-responsive events appeared to be more robust in fenretinide-treated CD34(+) CML cells.	Fenretinide	88-99	CD34 molecule	Homo sapiens	103-107
24192821-3	2013	The caspase3/9-dependent pathway was triggered significantly in combination treatment, and moreover, the AMPK pathway also mediated the apoptosis induction in fenretinide and selenite combination.	Fenretinide	159-170	caspase 3	Homo sapiens	4-12
23813912-1	2013	BACKGROUND: A phase I study was conducted to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4-HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma.	Fenretinide	140-151	haptoglobin-related protein	Homo sapiens	155-158
23792118-5	2013	Among them, fenretinide (HPR) has been considered one of the most promising anti-tumor agent but it is partially efficacious due to both poor aqueous solubility and rapid metabolism.	Fenretinide	12-23	haptoglobin-related protein	Homo sapiens	25-28
24040340-1	2013	We previously reported that fenretinide (4-HPR) was cytotoxic to acute lymphoblastic leukemia (ALL) cell lines in vitro in association with increased levels of de novo synthesized dihydroceramides, the immediate precursors of ceramides.	Fenretinide	28-39	haptoglobin-related protein	Homo sapiens	43-46
23764045-0	2013	The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.	Fenretinide	62-73	histone deacetylase 9	Homo sapiens	4-23
24253178-2	2014	The retinoic acid analogue, fenretinide (4-hydroxyphenyl retinamide; 4-HPR), induces apoptosis in neuroblastoma cells in vitro and is currently in clinical trials for children with refractory neuroblastoma.	Fenretinide	28-39	haptoglobin-related protein	Homo sapiens	71-74
24253178-2	2014	The retinoic acid analogue, fenretinide (4-hydroxyphenyl retinamide; 4-HPR), induces apoptosis in neuroblastoma cells in vitro and is currently in clinical trials for children with refractory neuroblastoma.	Fenretinide	41-67	haptoglobin-related protein	Homo sapiens	71-74
24253178-6	2014	Specific inhibitors of JNK phosphorylation and scavengers of mitochondrial reactive oxygen species were used to demonstrate the roles of these phenomena in the enhancement of fenretinide efficacy.	Fenretinide	175-186	mitogen-activated protein kinase 8	Homo sapiens	23-26
24069363-0	2013	Fenretinide corrects the imbalance between omega-6 to omega-3 polyunsaturated fatty acids and inhibits macrophage inflammatory mediators via the ERK pathway.	Fenretinide	0-11	mitogen-activated protein kinase 1	Mus musculus	145-148
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	tumor necrosis factor	Mus musculus	114-117
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	interleukin 6	Mus musculus	119-123
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	chemokine (C-C motif) ligand 2	Mus musculus	125-129
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	chemokine (C-C motif) ligand 5	Mus musculus	134-139
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	FMR1 autosomal homolog 1	Mus musculus	158-162
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	mitogen-activated protein kinase 3	Mus musculus	224-230
24069363-5	2013	Indeed, our results demonstrate that 4HPR inhibited the excessive production of inflammatory mediators, including TNF, IL-6, CCL2 and CCL-5 in LPS-stimulated FXR1-KO macrophages, by selectively inhibiting phosphorylation of ERK1/2, which is naturally more phosphorylated in FXR1-KO cells.	Fenretinide	37-41	FMR1 autosomal homolog 1	Mus musculus	274-278
24069363-7	2013	Interestingly, treatment with 4HPR was associated with the normalization of arachidonic acid/docosahexaenoic acid ratio in macrophages, which we found to impact phosphorylation of ERK1/2.	Fenretinide	30-34	mitogen-activated protein kinase 3	Mus musculus	180-186
24069363-8	2013	Overall, this study shows for the first time that 4HPR modulates inflammatory cytokine expression in macrophages by correcting a phospholipid-bound fatty acid imbalance that impacts the phosphorylation of ERK1/2.	Fenretinide	50-54	mitogen-activated protein kinase 3	Mus musculus	205-211
23396089-8	2013	In addition, fenretinide inhibited the expression of the genes involved in RAS/RAF/ERK-mediated survival pathway.	Fenretinide	13-24	mitogen-activated protein kinase 1	Homo sapiens	83-86
23396089-3	2013	Fenretinide and ATRA-induced gene expressions and DNA bindings were profiled using microarray and chromatin immunoprecipitation with anti-RXRalpha antibody.	Fenretinide	0-11	retinoid X receptor alpha	Homo sapiens	138-146
23396089-10	2013	Most genes regulated by fenretinide and ATRA were bound by RXRalpha, suggesting a direct effect.	Fenretinide	24-35	retinoid X receptor alpha	Homo sapiens	59-67
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	tumor necrosis factor	Homo sapiens	46-54
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	death effector domain containing 2	Homo sapiens	132-137
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	caspase 8	Homo sapiens	139-144
23396089-12	2013	The data also suggested that fenretinide induces apoptosis via death receptor effector and by inhibiting the RAS/RAF/ERK pathway.	Fenretinide	29-40	zinc fingers and homeoboxes 2	Homo sapiens	113-116
23396089-12	2013	The data also suggested that fenretinide induces apoptosis via death receptor effector and by inhibiting the RAS/RAF/ERK pathway.	Fenretinide	29-40	mitogen-activated protein kinase 1	Homo sapiens	117-120
23314735-0	2013	p75NTR: an enhancer of fenretinide toxicity in neuroblastoma.	Fenretinide	23-34	nerve growth factor receptor	Homo sapiens	0-6
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	caspase 4	Homo sapiens	146-151
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	heat shock protein family A (Hsp70) member 1A	Homo sapiens	157-165
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	baculoviral IAP repeat containing 3	Homo sapiens	207-212
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	TNF alpha induced protein 3	Homo sapiens	217-224
23396089-7	2013	However, fenretinide specifically induced Fas/TNFalpha-mediated apoptosis by increasing the expression of pro-apoptotic genes i.e., DEDD2, CASP8, CASP4, and HSPA1A/B; whereas, ATRA induced the expression of BIRC3 and TNFAIP3, which inhibit apoptosis by interacting with TRAF2.	Fenretinide	9-20	TNF receptor associated factor 2	Homo sapiens	270-275
23396089-8	2013	In addition, fenretinide inhibited the expression of the genes involved in RAS/RAF/ERK-mediated survival pathway.	Fenretinide	13-24	zinc fingers and homeoboxes 2	Homo sapiens	79-82
23052481-3	2013	Fenretinide (4-HPR) is a synthetic retinoid that has shown clinical activity in recurrent NB and is cytotoxic to a variety of cancer cells, in part via the accumulation of dihydroceramides, which are precursors of GD2.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
23513221-4	2013	Fenretinide exerted a selective cytotoxic effect on primary AML CD34(+) cells, especially the LSC-enriched CD34(+)CD38(-) subpopulation, whereas no significant effect was observed on normal counterparts.	Fenretinide	0-11	CD34 molecule	Homo sapiens	64-68
23513221-4	2013	Fenretinide exerted a selective cytotoxic effect on primary AML CD34(+) cells, especially the LSC-enriched CD34(+)CD38(-) subpopulation, whereas no significant effect was observed on normal counterparts.	Fenretinide	0-11	CD34 molecule	Homo sapiens	107-111
23513221-4	2013	Fenretinide exerted a selective cytotoxic effect on primary AML CD34(+) cells, especially the LSC-enriched CD34(+)CD38(-) subpopulation, whereas no significant effect was observed on normal counterparts.	Fenretinide	0-11	CD38 molecule	Homo sapiens	114-118
23513221-5	2013	Methylcellulose colony formation assays further showed that fenretinide significantly suppressed the formation of colonies derived from AML CD34(+) cells but not those from normal CD34(+) cells.	Fenretinide	60-71	CD34 molecule	Homo sapiens	140-144
23052481-5	2013	Here, we demonstrate for the first time that pretreatment of fenretinide-resistant NB cells with 4-HPR significantly enhanced ch14.18/CHO-mediated CDC and ADCC and AICC by both human natural killer cells and peripheral blood mononuclear cells.	Fenretinide	61-72	haptoglobin-related protein	Homo sapiens	99-102
23314735-4	2013	We, therefore, hypothesized that p75NTR expression level would influence the effects of the redox-active chemotherapeutic drug fenretinide on neuroblastoma cells.	Fenretinide	127-138	nerve growth factor receptor	Homo sapiens	33-39
23314735-10	2013	RESULTS: Knockdown of p75NTR attenuates fenretinide-induced accumulation of mitochondrial superoxide and apoptosis.	Fenretinide	40-51	nerve growth factor receptor	Homo sapiens	22-28
23314735-12	2013	Pretreatment of cells with 2-thenoyltrifluoroacetone or dehydroascorbic acid uniquely prevents mitochondrial superoxide accumulation and cell death after fenretinide treatment, indicating that mitochondrial complex II is the likely site of fenretinide-induced superoxide generation and p75NTR-induced potentiation of these phenomena.	Fenretinide	154-165	nerve growth factor receptor	Homo sapiens	286-292
23314735-12	2013	Pretreatment of cells with 2-thenoyltrifluoroacetone or dehydroascorbic acid uniquely prevents mitochondrial superoxide accumulation and cell death after fenretinide treatment, indicating that mitochondrial complex II is the likely site of fenretinide-induced superoxide generation and p75NTR-induced potentiation of these phenomena.	Fenretinide	240-251	nerve growth factor receptor	Homo sapiens	286-292
23314735-13	2013	CONCLUSION: Modification of expression of p75NTR in a particular neuroblastoma cell line modifies its susceptibility to fenretinide.	Fenretinide	120-131	nerve growth factor receptor	Homo sapiens	42-48
23023528-2	2013	Fenretinide, an orally available drug that reduces retinol delivery to the eye through antagonism of serum retinol-binding protein (RBP), was used in a 2-year trial to determine whether retinol reduction would be effective in the management of geographic atrophy.	Fenretinide	0-11	retinol binding protein 4	Homo sapiens	132-135
23023528-4	2013	RESULTS: Fenretinide treatment produced dose-dependent reversible reductions in serum RBP-retinol that were associated with trends in reduced lesion growth rates.	Fenretinide	9-20	retinol binding protein 4	Homo sapiens	86-89
23372815-8	2013	Moreover, fenretinide induced reactive oxygen species and apoptosis as shown by caspase 9 and PARP cleavage and upregulated miR-9.	Fenretinide	10-21	caspase 9	Homo sapiens	80-89
23139430-4	2013	Moreover, fenretinide attenuated interleukin (IL)-1beta, IL-6, and cyclooxygenase-2 mRNA expression induced by A. actinomycetemcomitans.	Fenretinide	10-21	interleukin 6	Mus musculus	57-61
23139430-5	2013	Fenretinide also decreased IL-1beta, IL-6, and prostaglandin E2 proinflammatory cytokine levels in Raw 264.7 cells induced by A. actinomycetemcomitans.	Fenretinide	0-11	interleukin 1 beta	Mus musculus	27-35
23139430-5	2013	Fenretinide also decreased IL-1beta, IL-6, and prostaglandin E2 proinflammatory cytokine levels in Raw 264.7 cells induced by A. actinomycetemcomitans.	Fenretinide	0-11	interleukin 6	Mus musculus	37-41
23372815-8	2013	Moreover, fenretinide induced reactive oxygen species and apoptosis as shown by caspase 9 and PARP cleavage and upregulated miR-9.	Fenretinide	10-21	collagen type XI alpha 2 chain	Homo sapiens	94-98
22475870-2	2012	4HPR promoted the intrinsic apoptotic pathway by reactive oxygen species (ROS) generation and was accompanied by drop of Mcl-1 protein expression.	Fenretinide	0-4	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	121-126
23326540-8	2013	Chronic intraperitoneal injection of fenretinide increased the alveolar airspace surface area and increased the number of caspase-3 positive cells in rat lungs.	Fenretinide	37-48	caspase 3	Rattus norvegicus	122-131
23326540-9	2013	Fenretinide also suppressed HIF-1alpha and VEGF protein expression in rat lungs.	Fenretinide	0-11	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	28-38
23326540-9	2013	Fenretinide also suppressed HIF-1alpha and VEGF protein expression in rat lungs.	Fenretinide	0-11	vascular endothelial growth factor A	Rattus norvegicus	43-47
23326540-14	2013	Concomitant treatment with S1P normalizes the ceramide-S1P balance in the rat lungs and increases HIF-1alpha protein expression via activation of sphingosine kinase 1; as a consequence, S1P salvages fenretinide induced emphysema in rat lungs.	Fenretinide	199-210	sphingosine kinase 1	Rattus norvegicus	146-166
22498172-2	2012	We explored efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and (-)-epigallocatechin-3-gallate (EGCG) in altering expression of oncogenic microRNAs (OGmiRs) and tumor suppressor miRs (TSmiRs) for controlling growth of human malignant neuroblastoma SK-N-BE2 and IMR-32 cells.	Fenretinide	24-54	haptoglobin-related protein	Homo sapiens	58-61
22573912-7	2012	We observed that the synthetic retinoid fenretinide substituted for the retinol cofactor function but, on chronic use, distorted this signal balance, leading to predominance of PKCepsilon over PKCdelta.	Fenretinide	40-51	protein kinase C epsilon	Homo sapiens	177-187
22573912-7	2012	We observed that the synthetic retinoid fenretinide substituted for the retinol cofactor function but, on chronic use, distorted this signal balance, leading to predominance of PKCepsilon over PKCdelta.	Fenretinide	40-51	protein kinase C delta	Homo sapiens	193-201
22637576-7	2012	Finally, we show that the drug fenretinide, used clinically to presumably lower blood RBP levels and thus decrease circulating retinol, targets the functional coupling of STRA6 and LRAT to increase cellular vitamin A uptake in peripheral tissues.	Fenretinide	31-42	retinol binding protein 4, plasma	Mus musculus	86-89
22637576-7	2012	Finally, we show that the drug fenretinide, used clinically to presumably lower blood RBP levels and thus decrease circulating retinol, targets the functional coupling of STRA6 and LRAT to increase cellular vitamin A uptake in peripheral tissues.	Fenretinide	31-42	stimulated by retinoic acid gene 6	Mus musculus	171-176
22474281-2	2012	Recent in vitro data indicate that fenretinide inhibits dihydroceramide desaturase, an enzyme involved in the biosynthesis of lipotoxic ceramides that antagonize insulin action.	Fenretinide	35-46	delta(4)-desaturase, sphingolipid 1	Mus musculus	56-82
22474281-9	2012	These data suggest that fenretinide improves insulin sensitivity, at least in part, by inhibiting Des1 and suggest that therapeutics targeting this enzyme may be a viable therapeutic means for normalizing glucose homeostasis in the overweight and diabetic.	Fenretinide	24-35	delta(4)-desaturase, sphingolipid 1	Mus musculus	98-102
22798378-0	2012	Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo.	Fenretinide	70-81	mechanistic target of rapamycin kinase	Homo sapiens	18-47
22488409-0	2012	N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell invasion through suppressing NF-KB activation and inhibiting matrix metalloproteinase-9 expression.	Fenretinide	0-29	matrix metallopeptidase 9	Homo sapiens	119-145
22488409-1	2012	Synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been reported to exhibit anti-invasive and anti-metastatic activities by suppressing the enzymatic activity of matrix metalloproteinase (MMP)-9, but the underlying mechanism remains unclear.	Fenretinide	19-48	haptoglobin-related protein	Homo sapiens	52-55
22488409-1	2012	Synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been reported to exhibit anti-invasive and anti-metastatic activities by suppressing the enzymatic activity of matrix metalloproteinase (MMP)-9, but the underlying mechanism remains unclear.	Fenretinide	19-48	matrix metallopeptidase 9	Homo sapiens	172-204
22532987-1	2012	Fenretinide (4-HPR) cytotoxicity relative to glutathione levels in pediatric acute lymphoblastic leukemia cell lines cultured at bone marrow level hypoxia (5% O2) is evaluated.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
22427354-9	2012	Human oral mucosal correlative studies showed substantial interdonor variations in levels of the enzyme (cytochrome P450 3A4-CYP3A4) responsible for conversion of fenretinide to its highly active metabolite, 4-oxo-4-HPR.	Fenretinide	163-174	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	105-131
22427354-9	2012	Human oral mucosal correlative studies showed substantial interdonor variations in levels of the enzyme (cytochrome P450 3A4-CYP3A4) responsible for conversion of fenretinide to its highly active metabolite, 4-oxo-4-HPR.	Fenretinide	163-174	haptoglobin-related protein	Homo sapiens	216-219
22427354-6	2012	LC-MS/MS analyses of post-treatment samples revealed a delivery gradient with highest fenretinide levels achieved at the patch-mucosal interface (no metabolites), pharmacologically active levels in fenretinide-treated oral mucosa (mean: 5.65 muM; trace amounts of 4-oxo-4-HPR) and undetectable sera levels.	Fenretinide	198-209	haptoglobin-related protein	Homo sapiens	272-275
22428532-1	2012	4-(Hydroxyphenyl)retinamide (4-HPR) is a synthetic retinoid with a strong apoptotic effect towards different cancer cell lines in vitro, and it is currently tested in clinical trials.	Fenretinide	0-27	haptoglobin-related protein	Homo sapiens	31-34
22427354-7	2012	Epithelial markers for cell proliferation (Ki-67), terminal differentiation (transglutaminase 1-TGase1) and glucuronidation (UDP-glucuronosyltransferase1A1-UGT1A1) exhibited fenretinide concentration-specific relationships (elevated TGase1 and UGT1A1 levels <5 muM, reduced Ki-67 indices >5 muM) relative to blank-treated epithelium.	Fenretinide	174-185	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	125-155
22183330-0	2012	The mechanism of fenretinide (4-HPR) inhibition of beta-carotene monooxygenase 1.	Fenretinide	17-28	haptoglobin-related protein	Homo sapiens	32-35
22387538-0	2012	Combined treatment with fenretinide and indomethacin induces AIF-mediated, non-classical cell death in human acute T-cell leukemia Jurkat cells.	Fenretinide	24-35	apoptosis inducing factor mitochondria associated 1	Homo sapiens	61-64
22387538-8	2012	Taken together these results indicate, that Jurkat cells after treatment with a combination of fenretinide and indomethacin undergo AIF-mediated programmed cell death.	Fenretinide	95-106	apoptosis inducing factor mitochondria associated 1	Homo sapiens	132-135
22221098-2	2012	METHODS: We synthesised an amphiphilic dextrin derivative (DX-OL) able to host fenretinide (4-HPR) by complexation.	Fenretinide	79-90	haptoglobin-related protein	Homo sapiens	94-97
22162577-0	2012	Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.	Fenretinide	99-110	adiponectin, C1Q and collagen domain containing	Homo sapiens	33-44
22350416-4	2012	In this study, we developed a mathematical model that integrates temporal patterns of drug exposure, receptor occupancy, and signal transduction to predict the effects of the CD20 agonist rituximab in combination with rhApo2L/TNF-related apoptosis inducing ligand or fenretinide, a cytotoxic retinoid, upon growth kinetics in non-Hodgkin lymphoma xenografts.	Fenretinide	267-278	keratin 20	Homo sapiens	175-179
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	31-56
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	58-62
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	206-210
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	13-16	retinol binding protein 4, plasma	Mus musculus	31-56
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	13-16	retinol binding protein 4, plasma	Mus musculus	58-62
22382323-1	2012	Fenretinide (FEN), a ligand of retinol binding protein 4 (RBP4), has been suggested as a measure to reduce insulin resistance and its associated disorders such as obesity, and fatty liver by reducing serum RBP4.	Fenretinide	13-16	retinol binding protein 4, plasma	Mus musculus	206-210
22382323-9	2012	The mechanism by which fenretinide prevents fatty liver may be explained by an increased plasma adiponectin level, increased activation of hepatic AMP-activated protein kinase, and the expression of peroxisome proliferator-activated protein-alpha and peroxisomal acyl-CoA oxidase, which promote fat oxidation.	Fenretinide	23-34	adiponectin, C1Q and collagen domain containing	Mus musculus	96-107
22500077-0	2012	Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
22500077-4	2012	Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
22761939-1	2012	BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities against different malignancies, including ovarian tumors.	Fenretinide	12-23	haptoglobin-related protein	Homo sapiens	27-30
21964808-2	2012	A retinoid analogue, fenretinide [N-(4-hydroxyphenyl) retinamide;             4-HPR] can induce apoptosis in neuroblastoma cell lines and could have clinical             use after therapy with 13cisRA.	Fenretinide	21-32	haptoglobin-related protein	Homo sapiens	80-83
21964808-2	2012	A retinoid analogue, fenretinide [N-(4-hydroxyphenyl) retinamide;             4-HPR] can induce apoptosis in neuroblastoma cell lines and could have clinical             use after therapy with 13cisRA.	Fenretinide	34-64	haptoglobin-related protein	Homo sapiens	80-83
21908574-0	2011	Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children"s Oncology Group.	Fenretinide	32-57	haptoglobin-related protein	Homo sapiens	61-64
21933888-1	2011	PURPOSE: Fenretinide (4-HPR) is a cytotoxic retinoid with minimal systemic toxicity that has shown clinical activity against recurrent high-risk neuroblastoma.	Fenretinide	9-20	haptoglobin-related protein	Homo sapiens	24-27
22061047-1	2011	BACKGROUND: N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance.	Fenretinide	12-41	haptoglobin-related protein	Homo sapiens	45-48
22061047-1	2011	BACKGROUND: N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance.	Fenretinide	50-61	haptoglobin-related protein	Homo sapiens	45-48
21557271-0	2011	Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide.	Fenretinide	120-150	N-acylsphingosine amidohydrolase 1	Homo sapiens	14-29
21622882-1	2011	Apoptosis via the intrinsic caspase 9 pathway can be induced by oxidative stressors hydrogen peroxide (H2O2) and N-(4 hydroxyphenol) rentinamide (fenretinide), a synthetic retinoid.	Fenretinide	146-157	caspase-9	Ovis aries	28-37
21951911-2	2011	N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1.	Fenretinide	0-31	haptoglobin-related protein	Homo sapiens	35-38
21951911-2	2011	N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1.	Fenretinide	0-31	cyclin D1	Homo sapiens	152-161
21951911-2	2011	N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1.	Fenretinide	42-53	haptoglobin-related protein	Homo sapiens	35-38
21951911-2	2011	N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1.	Fenretinide	42-53	cyclin D1	Homo sapiens	152-161
21072519-1	2011	PURPOSE: Although fenretinide (4-HPR) has been studied in breast cancer and in neuroblastoma, little is known regarding its activity in pancreatic cancer, a neoplasm for which there are few therapeutic options.	Fenretinide	18-29	haptoglobin-related protein	Homo sapiens	33-36
21543327-2	2011	We previously demonstrated that fenretinide (4-HPR) inhibited DES activity in SMS-KCNR neuroblastoma cells.	Fenretinide	32-43	haptoglobin-related protein	Homo sapiens	47-50
21591606-0	2011	Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.	Fenretinide	0-11	sigma non-opioid intracellular receptor 1	Homo sapiens	61-90
21591606-0	2011	Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.	Fenretinide	0-11	sigma non-opioid intracellular receptor 1	Homo sapiens	92-96
21591606-0	2011	Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.	Fenretinide	0-11	transthyretin	Homo sapiens	103-116
21591606-0	2011	Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.	Fenretinide	0-11	sigma non-opioid intracellular receptor 1	Homo sapiens	125-129
21591606-5	2011	Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction lies in the polyene chain region.	Fenretinide	35-38	sigma non-opioid intracellular receptor 1	Homo sapiens	85-89
21391977-8	2011	4-HPR was oxidized to 4-oxo-4-HPR, at least in part via human CYP3A4.	Fenretinide	0-5	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	62-68
21723035-0	2011	TMEM14A inhibits N-(4-hydroxyphenyl)retinamide-induced apoptosis through the stabilization of mitochondrial membrane potential.	Fenretinide	17-46	transmembrane protein 14A	Homo sapiens	0-7
21723035-5	2011	Over-expression of TMEM14A in U87MG cells inhibited N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis.	Fenretinide	52-81	transmembrane protein 14A	Homo sapiens	19-26
21723035-5	2011	Over-expression of TMEM14A in U87MG cells inhibited N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis.	Fenretinide	52-81	haptoglobin-related protein	Homo sapiens	85-88
21557271-1	2011	BACKGROUND: The purpose of this study was to determine whether the therapeutic efficacy of fenretinide (4-HPR), a ceramide-generating anticancer agent, could be enhanced in prostate cancer cells by inclusion of a novel synthetic acid ceramidase (AC) inhibitor, DM102, a pivaloylamide of a 2-substituted aminoethanol.	Fenretinide	91-102	haptoglobin-related protein	Homo sapiens	106-109
21557271-1	2011	BACKGROUND: The purpose of this study was to determine whether the therapeutic efficacy of fenretinide (4-HPR), a ceramide-generating anticancer agent, could be enhanced in prostate cancer cells by inclusion of a novel synthetic acid ceramidase (AC) inhibitor, DM102, a pivaloylamide of a 2-substituted aminoethanol.	Fenretinide	91-102	N-acylsphingosine amidohydrolase 1	Homo sapiens	229-244
21557271-1	2011	BACKGROUND: The purpose of this study was to determine whether the therapeutic efficacy of fenretinide (4-HPR), a ceramide-generating anticancer agent, could be enhanced in prostate cancer cells by inclusion of a novel synthetic acid ceramidase (AC) inhibitor, DM102, a pivaloylamide of a 2-substituted aminoethanol.	Fenretinide	91-102	N-acylsphingosine amidohydrolase 1	Homo sapiens	1-3
22468231-4	2011	We evaluated synergistic efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and genistein (GST) for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells in culture and activation of multiple pathways for increasing apoptosis in ectopic and orthotopic neuroblastoma xenografts in nude mice.	Fenretinide	37-67	haptoglobin-related protein	Homo sapiens	71-74
21365528-5	2011	Administration of fenretinide in SHR to increase urinary RBP4 excretion significantly decreased plasma RBP4 levels and improved IR.	Fenretinide	18-29	retinol binding protein 4	Rattus norvegicus	57-61
21365528-5	2011	Administration of fenretinide in SHR to increase urinary RBP4 excretion significantly decreased plasma RBP4 levels and improved IR.	Fenretinide	18-29	retinol binding protein 4	Rattus norvegicus	103-107
21270111-4	2011	RESULTS: Autophagy was activated in response to fenretinide or bortezomib in B-RAF wild-type cells, shown by increased conversion of LC3 to the autophagic vesicle-associated form (LC3-II) and redistribution to autophagosomes and autolysosomes, increased acidic vesicular organelle formation and autophagic vacuolization.	Fenretinide	48-59	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	77-82
21270111-4	2011	RESULTS: Autophagy was activated in response to fenretinide or bortezomib in B-RAF wild-type cells, shown by increased conversion of LC3 to the autophagic vesicle-associated form (LC3-II) and redistribution to autophagosomes and autolysosomes, increased acidic vesicular organelle formation and autophagic vacuolization.	Fenretinide	48-59	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	133-136
21270111-4	2011	RESULTS: Autophagy was activated in response to fenretinide or bortezomib in B-RAF wild-type cells, shown by increased conversion of LC3 to the autophagic vesicle-associated form (LC3-II) and redistribution to autophagosomes and autolysosomes, increased acidic vesicular organelle formation and autophagic vacuolization.	Fenretinide	48-59	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	180-183
21270111-7	2011	Knockdown of Beclin-1 or ATG7 sensitized B-RAF wild-type cells to fenretinide- or bortezomib-induced cell death, demonstrating a pro-survival function of autophagy.	Fenretinide	66-77	beclin 1	Homo sapiens	13-21
21270111-7	2011	Knockdown of Beclin-1 or ATG7 sensitized B-RAF wild-type cells to fenretinide- or bortezomib-induced cell death, demonstrating a pro-survival function of autophagy.	Fenretinide	66-77	autophagy related 7	Homo sapiens	25-29
21270111-7	2011	Knockdown of Beclin-1 or ATG7 sensitized B-RAF wild-type cells to fenretinide- or bortezomib-induced cell death, demonstrating a pro-survival function of autophagy.	Fenretinide	66-77	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	41-46
21270111-8	2011	In addition, autophagy was partially reactivated in B-RAF-mutated cells treated with the BH3 mimetic ABT737 in combination with fenretinide or bortezomib, suggesting autophagy resistance is partly mediated by abrogated Beclin-1 function.	Fenretinide	128-139	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	52-57
21270111-8	2011	In addition, autophagy was partially reactivated in B-RAF-mutated cells treated with the BH3 mimetic ABT737 in combination with fenretinide or bortezomib, suggesting autophagy resistance is partly mediated by abrogated Beclin-1 function.	Fenretinide	128-139	beclin 1	Homo sapiens	219-227
21241664-0	2011	ERK1/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells.	Fenretinide	101-112	mitogen-activated protein kinase 3	Homo sapiens	0-6
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	64-69
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	31-42	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
21241664-3	2011	Previously, we have shown that fenretinide-induced apoptosis is Nur77 dependent, and the sensitivity of the cancer cells to fenretinide-induced apoptosis is positively associated with cytoplasmic enrichment of Nur77.	Fenretinide	124-135	nuclear receptor subfamily 4 group A member 1	Homo sapiens	210-215
21241664-4	2011	The goal of current study was to identify means to modulate nuclear export of Nur77 in order to improve the efficacy of fenretinide.	Fenretinide	120-131	nuclear receptor subfamily 4 group A member 1	Homo sapiens	78-83
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	3-14	epidermal growth factor	Homo sapiens	61-84
21241664-5	2011	Fenretinide treatment deactivated ERK1/2 in Huh7 cells, but activated ERK1/2 in HepG2 cells, which was positively associated with the sensitivity of cells to the apoptotic effect of fenretinide.	Fenretinide	0-11	mitogen-activated protein kinase 3	Homo sapiens	34-40
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	3-14	epidermal growth factor	Homo sapiens	86-89
21241664-5	2011	Fenretinide treatment deactivated ERK1/2 in Huh7 cells, but activated ERK1/2 in HepG2 cells, which was positively associated with the sensitivity of cells to the apoptotic effect of fenretinide.	Fenretinide	0-11	mitogen-activated protein kinase 3	Homo sapiens	70-76
21241664-5	2011	Fenretinide treatment deactivated ERK1/2 in Huh7 cells, but activated ERK1/2 in HepG2 cells, which was positively associated with the sensitivity of cells to the apoptotic effect of fenretinide.	Fenretinide	182-193	mitogen-activated protein kinase 3	Homo sapiens	70-76
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	3-14	caspase 3	Homo sapiens	136-145
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	101-112	mitogen-activated protein kinase 3	Homo sapiens	51-57
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	101-112	epidermal growth factor	Homo sapiens	61-84
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	101-112	epidermal growth factor	Homo sapiens	86-89
21241664-9	2011	Fenretinide/PD98059-induced cell death of HepG2 cell was positively associated with induction and cytoplasmic location as well as mitochondria enrichment of Nur77.	Fenretinide	0-11	nuclear receptor subfamily 4 group A member 1	Homo sapiens	157-162
21241664-7	2011	In fenretinide sensitive Huh7 cells, activation of ERK1/2 by epidermal growth factor (EGF) prevented fenretinide-induced cell death and caspase 3/7 induction.	Fenretinide	3-14	mitogen-activated protein kinase 3	Homo sapiens	51-57
21241664-11	2011	Taken together, the current study demonstrates that ERK1/2-modulated Nur77 intracellular location dictates the efficacy of fenretinide-induced apoptosis.	Fenretinide	123-134	mitogen-activated protein kinase 3	Homo sapiens	52-58
21498721-1	2011	BACKGROUND: The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment.	Fenretinide	35-46	haptoglobin-related protein	Homo sapiens	81-84
21241664-11	2011	Taken together, the current study demonstrates that ERK1/2-modulated Nur77 intracellular location dictates the efficacy of fenretinide-induced apoptosis.	Fenretinide	123-134	nuclear receptor subfamily 4 group A member 1	Homo sapiens	69-74
21822457-3	2011	We examined for the first time the efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and genistein (GST) alone and also in combination for controlling growth of human Ewing"s sarcoma SK-N-MC and RD-ES xenografts.	Fenretinide	47-77	haptoglobin-related protein	Homo sapiens	81-84
21498721-1	2011	BACKGROUND: The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment.	Fenretinide	48-77	haptoglobin-related protein	Homo sapiens	81-84
21738400-9	2011	Fenretinide induced the expression of the cone long wavelength sensitive opsin (OPN1lw) but not rhodopsin (RHO), while decreasing the expression of RPE cell markers.	Fenretinide	0-11	opsin 1, long wave sensitive	Homo sapiens	80-86
21319187-0	2011	Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.	Fenretinide	130-141	nuclear receptor subfamily 4 group A member 1	Homo sapiens	14-19
21319187-0	2011	Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.	Fenretinide	130-141	retinoic acid receptor beta	Homo sapiens	32-59
21319187-2	2011	Previously, we have shown that fenretinide induces apoptosis of Huh7 cells, but HepG2 cells are relatively resistant to fenretinide-induced apoptosis.	Fenretinide	31-42	MIR7-3 host gene	Homo sapiens	64-68
21319187-4	2011	Trichostatin A and scriptaid can either enhance fenretinide-induced apoptosis in the fenretinide sensitive HCC cells (Huh7 and Hep3B) or sensitize the fenretinide resistant cells (HepG2) to become sensitive to the apoptotic effect of fenretinide in a cancer cell-specific manner.	Fenretinide	48-59	MIR7-3 host gene	Homo sapiens	118-122
21319187-7	2011	Upon fenretinide and HDACi treatment, the expression of RARbeta and Nur77 were induced and colocalized in the cytosol.	Fenretinide	5-16	retinoic acid receptor beta	Homo sapiens	56-63
21319187-7	2011	Upon fenretinide and HDACi treatment, the expression of RARbeta and Nur77 were induced and colocalized in the cytosol.	Fenretinide	5-16	nuclear receptor subfamily 4 group A member 1	Homo sapiens	68-73
21319187-10	2011	Nur77 was essential for fenretinide-induced and HDACi-induced apoptosis of Huh7 cells.	Fenretinide	24-35	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
21319187-10	2011	Nur77 was essential for fenretinide-induced and HDACi-induced apoptosis of Huh7 cells.	Fenretinide	24-35	MIR7-3 host gene	Homo sapiens	75-79
21319187-11	2011	Induction of the expression, the interaction, and the nuclear export of RARbeta and Nur77 mediate fenretinide-induced and HDACi-induced apoptosis.	Fenretinide	98-109	retinoic acid receptor beta	Homo sapiens	72-79
21319187-11	2011	Induction of the expression, the interaction, and the nuclear export of RARbeta and Nur77 mediate fenretinide-induced and HDACi-induced apoptosis.	Fenretinide	98-109	nuclear receptor subfamily 4 group A member 1	Homo sapiens	84-89
21119025-3	2011	Infection of RCCs with a tropism-modified serotype 5/3 adenovirus expressing MDA-7/IL-24 (Ad.5/3-mda-7) caused plasma membrane clustering of CD95 and CD95 association with pro-caspase 8, effects that were enhanced by combined exposure to 17-N-allylamino-17-demethoxygeldanamycin (17AAG), As(2)O(3), or fenretinide and that correlated with enhanced cell killing.	Fenretinide	302-313	interleukin 24	Homo sapiens	77-82
21119025-3	2011	Infection of RCCs with a tropism-modified serotype 5/3 adenovirus expressing MDA-7/IL-24 (Ad.5/3-mda-7) caused plasma membrane clustering of CD95 and CD95 association with pro-caspase 8, effects that were enhanced by combined exposure to 17-N-allylamino-17-demethoxygeldanamycin (17AAG), As(2)O(3), or fenretinide and that correlated with enhanced cell killing.	Fenretinide	302-313	interleukin 24	Homo sapiens	83-88
21119025-3	2011	Infection of RCCs with a tropism-modified serotype 5/3 adenovirus expressing MDA-7/IL-24 (Ad.5/3-mda-7) caused plasma membrane clustering of CD95 and CD95 association with pro-caspase 8, effects that were enhanced by combined exposure to 17-N-allylamino-17-demethoxygeldanamycin (17AAG), As(2)O(3), or fenretinide and that correlated with enhanced cell killing.	Fenretinide	302-313	interleukin 24	Homo sapiens	97-102
21119025-3	2011	Infection of RCCs with a tropism-modified serotype 5/3 adenovirus expressing MDA-7/IL-24 (Ad.5/3-mda-7) caused plasma membrane clustering of CD95 and CD95 association with pro-caspase 8, effects that were enhanced by combined exposure to 17-N-allylamino-17-demethoxygeldanamycin (17AAG), As(2)O(3), or fenretinide and that correlated with enhanced cell killing.	Fenretinide	302-313	Fas cell surface death receptor	Homo sapiens	141-145
21054342-1	2011	BACKGROUND AND PURPOSE: Fenretinide (4-HPR) is a retinoic acid analogue, currently used in clinical trials in oncology.	Fenretinide	24-35	haptoglobin-related protein	Homo sapiens	39-42
20679253-2	2010	Treatment of cancer cells with N-(4-hydroxyphenyl) retinamide (4-HPR) induces apoptosis through destabilization of mitochondrial membrane and activation of caspase-mediated apoptotic pathways.	Fenretinide	31-61	haptoglobin-related protein	Homo sapiens	65-68
22174837-6	2011	RNAi-mediated knockdown of key GSH regulatory enzymes gamma-glutamylcysteine synthetase or glutathione disulfide reductase partially reversed the hypoxia-induced resistance to fenretinide, and increasing GSH levels using N-acetylcysteine augmented the hypoxia-induced resistance in a cell line-specific manner.	Fenretinide	176-187	glutamate-cysteine ligase catalytic subunit	Homo sapiens	54-87
20935456-2	2010	Many anticancer chemotherapeutics (anthracyclines, Vinca alkaloids, paclitaxel, and fenretinide), as well as physiological stimuli such as tumor necrosis factor alpha (TNFalpha), stimulate ceramide accumulation and increase oxidative stress in malignant cells.	Fenretinide	84-95	tumor necrosis factor	Homo sapiens	139-166
20532509-1	2010	PURPOSE: Fenretinide (4-HPR), a synthetic retinoid currently used in clinic for cancer therapy and prevention, markedly lowers plasma retinol levels, an effect associated with nyctalopia.	Fenretinide	9-20	haptoglobin-related protein	Homo sapiens	24-27
21117610-1	2010	Intravenous fenretinide (4-HPR), a cytotoxic retinoid, is being evaluated as part of a phase I clinical trial for patients with hematologic malignancies.	Fenretinide	12-23	haptoglobin-related protein	Homo sapiens	27-30
20976277-1	2010	BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug.	Fenretinide	100-111	haptoglobin-related protein	Homo sapiens	70-73
20976277-1	2010	BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug.	Fenretinide	100-111	haptoglobin-related protein	Homo sapiens	115-118
20976277-1	2010	BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug.	Fenretinide	100-111	haptoglobin-related protein	Homo sapiens	115-118
20637870-0	2010	HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia.	Fenretinide	56-67	hypoxia inducible factor 1 subunit alpha	Homo sapiens	0-10
20637870-0	2010	HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia.	Fenretinide	56-67	haptoglobin-related protein	Homo sapiens	71-74
20637870-2	2010	N-(4-Hydroxyphenyl)retinamide (4-HPR) exhibits potent anticancer and chemopreventive activities, but its inefficiency under hypoxia, through undetermined mechanisms, may contribute to its lack of activity in clinical trials.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
20877355-0	2010	Fenretinide-dependent upregulation of death receptors through ASK1 and p38alpha enhances death receptor ligand-induced cell death in Ewing"s sarcoma family of tumours.	Fenretinide	0-11	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	62-66
20877355-0	2010	Fenretinide-dependent upregulation of death receptors through ASK1 and p38alpha enhances death receptor ligand-induced cell death in Ewing"s sarcoma family of tumours.	Fenretinide	0-11	mitogen-activated protein kinase 14	Homo sapiens	71-79
20877355-2	2010	As fenretinide induces ESFT death through sustained p38(MAPK) phosphorylation, we hypothesised that this may be effected through upregulation of death receptors (DRs) and that treatment of fenretinide plus DR ligands may enhance apoptosis.	Fenretinide	3-14	mitogen-activated protein kinase 14	Homo sapiens	52-55
20877355-5	2010	RESULTS: Fenretinide upregulated cell surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, FAS and p75(NTR), in an ASK1- and p38alpha-dependent manner.	Fenretinide	9-20	TNF superfamily member 10	Homo sapiens	60-116
20877355-5	2010	RESULTS: Fenretinide upregulated cell surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, FAS and p75(NTR), in an ASK1- and p38alpha-dependent manner.	Fenretinide	9-20	TNF superfamily member 10	Homo sapiens	118-123
20877355-5	2010	RESULTS: Fenretinide upregulated cell surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, FAS and p75(NTR), in an ASK1- and p38alpha-dependent manner.	Fenretinide	9-20	neurotensin receptor 1	Homo sapiens	144-152
20877355-5	2010	RESULTS: Fenretinide upregulated cell surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, FAS and p75(NTR), in an ASK1- and p38alpha-dependent manner.	Fenretinide	9-20	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	160-164
20877355-5	2010	RESULTS: Fenretinide upregulated cell surface expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, FAS and p75(NTR), in an ASK1- and p38alpha-dependent manner.	Fenretinide	9-20	mitogen-activated protein kinase 14	Homo sapiens	170-178
20877355-6	2010	Cotreatment with fenretinide and DR ligands resulted in synergistic death compared with either agent alone; caspase-8 and Bid were cleaved in a time-dependent manner.	Fenretinide	17-28	caspase 8	Homo sapiens	108-117
20877355-6	2010	Cotreatment with fenretinide and DR ligands resulted in synergistic death compared with either agent alone; caspase-8 and Bid were cleaved in a time-dependent manner.	Fenretinide	17-28	BH3 interacting domain death agonist	Homo sapiens	122-125
20687958-0	2010	Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.	Fenretinide	36-47	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	0-5
20628055-0	2010	Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells.	Fenretinide	93-122	alkaline ceramidase 2	Homo sapiens	0-21
20628055-0	2010	Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells.	Fenretinide	93-122	alkaline ceramidase 2	Homo sapiens	23-28
20628055-1	2010	Increased generation of dihydrosphingosine (DHS), a bioactive sphingolipid, has been implicated in the cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells.	Fenretinide	142-171	haptoglobin-related protein	Homo sapiens	175-178
20583135-0	2010	Decreased expression of insulin-like growth factor binding protein-5 during N-(4-hydroxyphenyl)retinamide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells: regulation by CCAAT/enhancer-binding protein.	Fenretinide	76-105	insulin like growth factor binding protein 5	Homo sapiens	24-68
20583135-2	2010	We identified IGFBP5 by microarray analysis as a gene differentially regulated during N-(4-hydroxyphenyl)retinamide (4HPR)-induced neuronal differentiation of human retinal pigment epithelial (RPE) cells.	Fenretinide	86-115	insulin like growth factor binding protein 5	Homo sapiens	14-20
20583135-2	2010	We identified IGFBP5 by microarray analysis as a gene differentially regulated during N-(4-hydroxyphenyl)retinamide (4HPR)-induced neuronal differentiation of human retinal pigment epithelial (RPE) cells.	Fenretinide	117-121	insulin like growth factor binding protein 5	Homo sapiens	14-20
20520630-4	2010	Short hairpin RNA interference of XIAP was used to analyze the effect of XIAP expression on ER stress-induced apoptosis in response to fenretinide or bortezomib in vitro.	Fenretinide	135-146	X-linked inhibitor of apoptosis	Homo sapiens	73-77
20520630-7	2010	The correlation of XIAP expression with disease stage, as well as data showing that XIAP knockdown significantly increases fenretinide and bortezomib-induced apoptosis of metastatic melanoma cells, suggests that XIAP may prove to be an effective therapeutic target for melanoma therapy.	Fenretinide	123-134	X-linked inhibitor of apoptosis	Homo sapiens	84-88
20520630-7	2010	The correlation of XIAP expression with disease stage, as well as data showing that XIAP knockdown significantly increases fenretinide and bortezomib-induced apoptosis of metastatic melanoma cells, suggests that XIAP may prove to be an effective therapeutic target for melanoma therapy.	Fenretinide	123-134	X-linked inhibitor of apoptosis	Homo sapiens	84-88
20546536-4	2010	Down-regulation of GRP78 by small-interfering RNA increased fenretinide- or bortezomib-induced apoptosis.	Fenretinide	60-71	heat shock protein family A (Hsp70) member 5	Homo sapiens	19-24
20546536-5	2010	Treatment of cells with a GRP78-specific subtilase toxin produced a synergistic enhancement with fenretinide or bortezomib.	Fenretinide	97-108	heat shock protein family A (Hsp70) member 5	Homo sapiens	26-31
20546536-5	2010	Treatment of cells with a GRP78-specific subtilase toxin produced a synergistic enhancement with fenretinide or bortezomib.	Fenretinide	97-108	proprotein convertase subtilisin/kexin type 5	Homo sapiens	41-50
20687958-9	2010	CONCLUSIONS: Overall, our results reveal a novel cooperative role of Brg-1 and Sp1 in mediating the constitutive and fenretinide-induced expression of SPARC, and provide new insights for the understanding of the anti-cancer effects of fenretinide.	Fenretinide	117-128	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	69-74
20687958-9	2010	CONCLUSIONS: Overall, our results reveal a novel cooperative role of Brg-1 and Sp1 in mediating the constitutive and fenretinide-induced expression of SPARC, and provide new insights for the understanding of the anti-cancer effects of fenretinide.	Fenretinide	117-128	secreted protein acidic and cysteine rich	Homo sapiens	151-156
20687958-9	2010	CONCLUSIONS: Overall, our results reveal a novel cooperative role of Brg-1 and Sp1 in mediating the constitutive and fenretinide-induced expression of SPARC, and provide new insights for the understanding of the anti-cancer effects of fenretinide.	Fenretinide	235-246	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	69-74
20687958-9	2010	CONCLUSIONS: Overall, our results reveal a novel cooperative role of Brg-1 and Sp1 in mediating the constitutive and fenretinide-induced expression of SPARC, and provide new insights for the understanding of the anti-cancer effects of fenretinide.	Fenretinide	235-246	secreted protein acidic and cysteine rich	Homo sapiens	151-156
20687958-0	2010	Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1.	Fenretinide	36-47	secreted protein acidic and cysteine rich	Homo sapiens	70-75
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	15-26	haptoglobin-related protein	Homo sapiens	61-64
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	15-26	secreted protein acidic and cysteine rich	Homo sapiens	189-194
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	15-26	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	216-221
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	28-57	haptoglobin-related protein	Homo sapiens	61-64
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	28-57	secreted protein acidic and cysteine rich	Homo sapiens	189-194
20687958-7	2010	Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner.	Fenretinide	28-57	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	Homo sapiens	216-221
20687958-8	2010	Finally, our results demonstrated that fenretinide-induced expression of SPARC contributes significantly to a decreased invasion of mammary carcinoma cells.	Fenretinide	39-50	secreted protein acidic and cysteine rich	Homo sapiens	73-78
20537156-6	2010	4HPR was able to decrease AKT phosphorylation also when powerfully upregulated by IGF-1 and, consequently, to impair IGF-1-stimulated cell motility.	Fenretinide	0-4	insulin like growth factor 1	Homo sapiens	117-122
20034809-1	2010	Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent.	Fenretinide	35-65	haptoglobin-related protein	Homo sapiens	68-71
20034809-1	2010	Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent.	Fenretinide	73-84	haptoglobin-related protein	Homo sapiens	68-71
20537156-6	2010	4HPR was able to decrease AKT phosphorylation also when powerfully upregulated by IGF-1 and, consequently, to impair IGF-1-stimulated cell motility.	Fenretinide	0-4	AKT serine/threonine kinase 1	Homo sapiens	26-29
20537156-6	2010	4HPR was able to decrease AKT phosphorylation also when powerfully upregulated by IGF-1 and, consequently, to impair IGF-1-stimulated cell motility.	Fenretinide	0-4	insulin like growth factor 1	Homo sapiens	82-87
20399851-6	2010	In premalignant prostate epithelial cells and malignant cutaneous keratinocytes the suppression of DHODH activity by the chemical inhibitor teriflunomide or the reduction in DHODH protein expression by RNA interference markedly reduced 4HPR-induced ROS generation and apoptosis.	Fenretinide	236-240	dihydroorotate dehydrogenase (quinone)	Homo sapiens	99-104
20399851-6	2010	In premalignant prostate epithelial cells and malignant cutaneous keratinocytes the suppression of DHODH activity by the chemical inhibitor teriflunomide or the reduction in DHODH protein expression by RNA interference markedly reduced 4HPR-induced ROS generation and apoptosis.	Fenretinide	236-240	dihydroorotate dehydrogenase (quinone)	Homo sapiens	174-179
20537156-7	2010	Conversely, the expression of constitutively active AKT (myr-AKT) overcame the effects of 4HPR and beta-catenin-silencing on cell migration.	Fenretinide	90-94	AKT serine/threonine kinase 1	Homo sapiens	52-55
20537156-7	2010	Conversely, the expression of constitutively active AKT (myr-AKT) overcame the effects of 4HPR and beta-catenin-silencing on cell migration.	Fenretinide	90-94	AKT serine/threonine kinase 1	Homo sapiens	61-64
20537156-9	2010	CONCLUSION: These data point to 4HPR as a negative regulator of AKT phosphorylation, effectively targeting the beta-catenin pathway and inducing a relatively benign phenotype in prostate cancer cells, limiting neoangiogenesis and cell invasion.	Fenretinide	32-36	AKT serine/threonine kinase 1	Homo sapiens	64-67
20537156-9	2010	CONCLUSION: These data point to 4HPR as a negative regulator of AKT phosphorylation, effectively targeting the beta-catenin pathway and inducing a relatively benign phenotype in prostate cancer cells, limiting neoangiogenesis and cell invasion.	Fenretinide	32-36	catenin beta 1	Homo sapiens	111-123
19912993-0	2010	Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells.	Fenretinide	58-69	nuclear receptor subfamily 4 group A member 1	Homo sapiens	44-49
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	76-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	76-87	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	144-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	17-22
19912993-4	2010	The induction of Nur77 and the cytoplasmic distribution of Nur77 induced by fenretinide were positively correlated with the apoptotic effect of fenretinide in HCC cells.	Fenretinide	144-155	nuclear receptor subfamily 4 group A member 1	Homo sapiens	59-64
19912993-6	2010	The intracellular location of Nur77 was also associated with the differential capability of fenretinide-induced ROS generation in these two cell lines.	Fenretinide	92-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19912993-7	2010	In addition, the knockdown of Nur77 expression by siRNA greatly reduced fenretinide-induced apoptosis and cleaved caspase 3 in Huh-7 cells.	Fenretinide	72-83	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
19912993-8	2010	Therefore, our findings demonstrate that fenretinide-induced apoptosis of HCC cells is Nur77 dependent and that the intracellular localization of Nur77 dictates the sensitivity of the HCC cells to fenretinide-induced apoptosis.	Fenretinide	41-52	nuclear receptor subfamily 4 group A member 1	Homo sapiens	87-92
19912993-8	2010	Therefore, our findings demonstrate that fenretinide-induced apoptosis of HCC cells is Nur77 dependent and that the intracellular localization of Nur77 dictates the sensitivity of the HCC cells to fenretinide-induced apoptosis.	Fenretinide	197-208	nuclear receptor subfamily 4 group A member 1	Homo sapiens	146-151
20022965-3	2010	The aim of this study was to test the hypothesis that the early events of ER stress signaling and response pathways induced by fenretinide and bortezomib are mediated by the eukaryotic initiation factor 2alpha (eIF2alpha)-ATF4 signaling pathway.	Fenretinide	127-138	eukaryotic translation initiation factor 2A	Homo sapiens	211-220
20203181-8	2010	In addition, in vitro studies demonstrated that fenretinide reduced TNF-alpha (tumor necrosis factor-alpha) expression by reactive microglia.	Fenretinide	48-59	tumor necrosis factor	Mus musculus	68-77
20203181-8	2010	In addition, in vitro studies demonstrated that fenretinide reduced TNF-alpha (tumor necrosis factor-alpha) expression by reactive microglia.	Fenretinide	48-59	tumor necrosis factor	Mus musculus	79-106
20022965-3	2010	The aim of this study was to test the hypothesis that the early events of ER stress signaling and response pathways induced by fenretinide and bortezomib are mediated by the eukaryotic initiation factor 2alpha (eIF2alpha)-ATF4 signaling pathway.	Fenretinide	127-138	activating transcription factor 4	Homo sapiens	222-226
20022965-4	2010	Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34.	Fenretinide	56-67	eukaryotic translation initiation factor 2A	Homo sapiens	122-131
20022965-4	2010	Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34.	Fenretinide	56-67	eukaryotic translation initiation factor 2A	Homo sapiens	199-208
20022965-4	2010	Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34.	Fenretinide	56-67	activating transcription factor 4	Homo sapiens	210-214
20022965-4	2010	Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34.	Fenretinide	56-67	activating transcription factor 3	Homo sapiens	216-220
20022965-4	2010	Treatment of neuroblastoma and melanoma cell lines with fenretinide, bortezomib, or thapsigargin resulted in induction of eIF2alpha signaling, characterized by increased expression of phosphorylated eIF2alpha, ATF4, ATF3, and GADD34.	Fenretinide	56-67	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	226-232
20022965-7	2010	Although PERK-dependent phosphorylation of eIF2alpha enhanced ATF4 protein levels during ER stress, cell death in response to fenretinide, bortezomib, or thapsigargin was not abrogated by inhibition of eIF2alpha phosphorylation through PERK knockdown or overexpression of wild-type eIF2alpha.	Fenretinide	126-137	eukaryotic translation initiation factor 2A	Homo sapiens	43-52
20844597-0	2010	Role for PKC delta in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.	Fenretinide	22-33	protein kinase C delta	Homo sapiens	9-18
20022965-9	2010	These results demonstrate that ATF4 mediates ER stress-induced cell death of neuroectodermal tumor cells in response to fenretinide or bortezomib.	Fenretinide	120-131	activating transcription factor 4	Homo sapiens	31-35
20844597-2	2010	In the current paper, the role of PKC delta was examined in fenretinide-induced apoptosis in lymphoid leukemia cells.	Fenretinide	60-71	protein kinase C delta	Homo sapiens	34-43
20844597-8	2010	Now we have found that fenretinide-induced MCL-1 degradation may involve PKC delta as cleavage of the kinase correlated with loss of MCL-1 even in cells when JNK was not activated.	Fenretinide	23-34	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	43-48
20844597-8	2010	Now we have found that fenretinide-induced MCL-1 degradation may involve PKC delta as cleavage of the kinase correlated with loss of MCL-1 even in cells when JNK was not activated.	Fenretinide	23-34	protein kinase C delta	Homo sapiens	73-82
20844597-5	2010	The antioxidant Vitamin C prevented fenretinide-induced PKC delta cleavage and protected cells from fenretinide.	Fenretinide	36-47	protein kinase C delta	Homo sapiens	56-65
20844597-8	2010	Now we have found that fenretinide-induced MCL-1 degradation may involve PKC delta as cleavage of the kinase correlated with loss of MCL-1 even in cells when JNK was not activated.	Fenretinide	23-34	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	133-138
20844597-6	2010	Suppression of PKC delta expression by shRNA sensitized cells to fenretinide-induced apoptosis possibly by a mechanism involving ROS production.	Fenretinide	65-76	protein kinase C delta	Homo sapiens	15-24
20844597-8	2010	Now we have found that fenretinide-induced MCL-1 degradation may involve PKC delta as cleavage of the kinase correlated with loss of MCL-1 even in cells when JNK was not activated.	Fenretinide	23-34	mitogen-activated protein kinase 8	Homo sapiens	158-161
20844597-9	2010	These results suggest that PKC delta may play a complex role in fenretinide-induced apoptosis and may be targeted in antileukemia strategies that utilize fenretinide.	Fenretinide	64-75	protein kinase C delta	Homo sapiens	27-36
20844597-9	2010	These results suggest that PKC delta may play a complex role in fenretinide-induced apoptosis and may be targeted in antileukemia strategies that utilize fenretinide.	Fenretinide	154-165	protein kinase C delta	Homo sapiens	27-36
20844597-7	2010	A previous study demonstrated that fenretinide promotes degradation of antiapoptotic MCL-1 in ALL cells via JNK.	Fenretinide	35-46	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	85-90
20844597-7	2010	A previous study demonstrated that fenretinide promotes degradation of antiapoptotic MCL-1 in ALL cells via JNK.	Fenretinide	35-46	mitogen-activated protein kinase 8	Homo sapiens	108-111
19621427-3	2009	We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.	Fenretinide	121-132	haptoglobin-related protein	Homo sapiens	147-150
19826103-0	2009	Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.	Fenretinide	10-21	insulin	Homo sapiens	72-79
19826103-1	2009	The synthetic retinoid Fenretinide (FEN) increases insulin sensitivity in obese rodents and is in early clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (46).	Fenretinide	23-34	insulin	Homo sapiens	51-58
19826103-1	2009	The synthetic retinoid Fenretinide (FEN) increases insulin sensitivity in obese rodents and is in early clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (46).	Fenretinide	23-34	insulin	Homo sapiens	137-144
19826103-1	2009	The synthetic retinoid Fenretinide (FEN) increases insulin sensitivity in obese rodents and is in early clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (46).	Fenretinide	36-39	insulin	Homo sapiens	51-58
19826103-1	2009	The synthetic retinoid Fenretinide (FEN) increases insulin sensitivity in obese rodents and is in early clinical trials for treatment of insulin resistance in obese humans with hepatic steatosis (46).	Fenretinide	36-39	insulin	Homo sapiens	137-144
19996280-1	2009	The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines.	Fenretinide	80-91	haptoglobin-related protein	Homo sapiens	58-61
19996280-1	2009	The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines.	Fenretinide	80-91	haptoglobin-related protein	Homo sapiens	95-98
19996280-1	2009	The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines.	Fenretinide	80-91	haptoglobin-related protein	Homo sapiens	95-98
19844581-0	2009	Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.	Fenretinide	100-111	heat shock transcription factor 1	Homo sapiens	83-87
19446953-2	2009	Here we show that 4HPR induces apoptosis through increased level of ROS and activation of caspase-8, 9 and 3, and inhibits growth of several MM cell lines in a dose-dependent manner.	Fenretinide	18-22	caspase 8	Homo sapiens	90-108
19844581-0	2009	Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells.	Fenretinide	100-111	NFE2 like bZIP transcription factor 2	Homo sapiens	92-96
19482004-4	2009	To enable the search for nonretinoid molecules with fenretinide-like activities we developed a HTS-compatible homogeneous TR-FRET assay monitoring the displacement of retinoic acid derivatives from RBP4 in high-density 384-well and 1536-well microtiter plate formats.	Fenretinide	52-63	retinol binding protein 4, plasma	Mus musculus	198-202
19482004-2	2009	The retinoic acid derivative fenretinide (N-(4-hydroxyphenyl) retinamide; HPR) exerts therapeutic effects in mouse models of obesity, diabetes, and Stargardt"s disease by targeting RBP4.	Fenretinide	29-40	retinol binding protein 4, plasma	Mus musculus	181-185
19482004-2	2009	The retinoic acid derivative fenretinide (N-(4-hydroxyphenyl) retinamide; HPR) exerts therapeutic effects in mouse models of obesity, diabetes, and Stargardt"s disease by targeting RBP4.	Fenretinide	42-72	retinol binding protein 4, plasma	Mus musculus	181-185
19482076-1	2009	N-(4-hydroxyphenyl) retinamide (4-HPR), as a synthetic retinoid, has been shown to inhibit carcinogenesis in a variety of cancers.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
19482004-3	2009	Fenretinide competes with retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary secretion of RBP4 and systemic depletion of retinol.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	40-44
19482004-3	2009	Fenretinide competes with retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary secretion of RBP4 and systemic depletion of retinol.	Fenretinide	0-11	transthyretin	Mus musculus	63-81
19482004-3	2009	Fenretinide competes with retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary secretion of RBP4 and systemic depletion of retinol.	Fenretinide	0-11	transthyretin	Mus musculus	83-86
19482004-3	2009	Fenretinide competes with retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary secretion of RBP4 and systemic depletion of retinol.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	63-67
19421858-2	2009	The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) inhibits prostate cancer development in vivo, and triggers reactive oxygen species (ROS)-dependent prostate cancer cell apoptosis in vitro.	Fenretinide	23-52	haptoglobin-related protein	Homo sapiens	55-58
19041174-0	2009	Identification of ADP-ribosylation factor 4 as a suppressor of N-(4-hydroxyphenyl)retinamide-induced cell death.	Fenretinide	63-92	ADP ribosylation factor 4	Homo sapiens	18-43
19325135-0	2009	PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.	Fenretinide	18-29	mitogen-activated protein kinase 8	Homo sapiens	133-136
19325135-2	2009	We showed previously that 4HPR upregulates the proapoptotic gene placental bone morphogenetic protein (PLAB), which is a mediator of 4HPR-induced apoptosis in ovarian cancer cells.	Fenretinide	26-30	growth differentiation factor 15	Homo sapiens	65-101
19325135-2	2009	We showed previously that 4HPR upregulates the proapoptotic gene placental bone morphogenetic protein (PLAB), which is a mediator of 4HPR-induced apoptosis in ovarian cancer cells.	Fenretinide	133-137	growth differentiation factor 15	Homo sapiens	65-101
19325135-9	2009	These data indicate that 4HPR-induced PLAB upregulation occurs downstream of a signaling cascade involving ROS generation, ER stress induction and JNK activation and that these steps are mediators of 4HPR-induced apoptosis.	Fenretinide	25-29	mitogen-activated protein kinase 8	Homo sapiens	147-150
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Fenretinide	33-38	proliferating cell nuclear antigen	Rattus norvegicus	93-97
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Fenretinide	33-38	BCL2, apoptosis regulator	Rattus norvegicus	103-108
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Fenretinide	33-38	caspase 8	Rattus norvegicus	229-238
19285047-8	2009	Collectively, the combination of 4-HPR and PTX diminished the survival factors (e.g., rTERT, PCNA, and Bcl-2) to make glioblastoma cells highly prone to apoptosis with activation of cysteine proteases (e.g., calpain, cathepsins, caspase-8, caspase-3).	Fenretinide	33-38	caspase 3	Rattus norvegicus	240-249
19041174-2	2009	Yeast or U373MG cells that overexpressed ARF4 exhibited reduced reactive oxygen species (ROS) generation in response to Bax or N-(4-hydroxyphenyl)retinamide (4-HPR), respectively, which suggests that ROS play a role in the inhibition of cell death by ARF4.	Fenretinide	127-156	ADP ribosylation factor 4	Homo sapiens	41-45
19010927-0	2008	Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.	Fenretinide	10-21	insulin	Homo sapiens	48-55
19331667-0	2009	Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.	Fenretinide	0-11	caspase 8	Homo sapiens	20-29
19331667-2	2009	Patients are treated by maintenance CT. For some patients, an adjuvant retinoid therapy is proposed, such as the synthetic retinoid fenretinide (4-HPR), an apoptotic inducer.	Fenretinide	132-143	haptoglobin-related protein	Homo sapiens	147-150
19331667-6	2009	NB cell lines, i.e., IGR-N-91 and SH-EP, were treated with various doses of Fenretinide (4-HPR), then cytotoxicity was analyzed by MTS proliferation assay, apoptosis by the propidium staining method, gene or protein expressions by RT-PCR and immunoblotting and caspases activity by colorimetric protease assays.	Fenretinide	76-87	haptoglobin-related protein	Homo sapiens	91-94
18952041-3	2009	This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance.	Fenretinide	71-82	retinol binding protein 4	Homo sapiens	125-129
18952041-3	2009	This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance.	Fenretinide	71-82	retinol binding protein 4	Homo sapiens	182-186
18952041-3	2009	This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance.	Fenretinide	71-82	transthyretin	Homo sapiens	191-204
18952041-3	2009	This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance.	Fenretinide	71-82	transthyretin	Homo sapiens	206-209
18952041-3	2009	This can be accomplished by administration of small molecules, such as fenretinide, that compete with retinol for binding to RBP4 and disrupt the protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects RBP4 from renal clearance.	Fenretinide	71-82	retinol binding protein 4	Homo sapiens	182-186
18952041-5	2009	We present an allosteric model that describes the pharmacology of interaction among RBP4, TTR, retinol, and fenretinide, and we show data that support the model.	Fenretinide	108-119	retinol binding protein 4	Homo sapiens	84-88
18952041-5	2009	We present an allosteric model that describes the pharmacology of interaction among RBP4, TTR, retinol, and fenretinide, and we show data that support the model.	Fenretinide	108-119	transthyretin	Homo sapiens	90-93
18952041-6	2009	We show that retinol increases the affinity of RBP4 for TTR by a factor of 4 and determine the affinity constants of fenretinide and retinyl acetate.	Fenretinide	117-128	retinol binding protein 4	Homo sapiens	47-51
19213559-4	2009	In this manuscript we use as an example the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR), a molecule with confirmed clinical applications in breast cancer adjuvant therapy to prevent cancer recurrence and under evaluation in neuroblastoma and glioblastoma treatment.	Fenretinide	63-92	haptoglobin-related protein	Homo sapiens	95-98
18515328-3	2008	Here, we show that the natural retinoid 9-cis retinoic acid (9cRA) and the synthetic retinoid fenretinide (4-HPR) specifically inhibit the functional up-regulation of CCR7 on maturing human DCs, without affecting early steps of DC maturation.	Fenretinide	94-105	C-C motif chemokine receptor 7	Homo sapiens	167-171
18066548-1	2008	PURPOSE: Pharmacokinetic data on fenretinide (4-HPR) are scant, thus limiting the rational use of the drug.	Fenretinide	33-44	haptoglobin-related protein	Homo sapiens	48-51
18471963-1	2008	The role of NF-kappaB in the Ewing"s sarcoma family of tumours (ESFT) and their response to fenretinide has been investigated.	Fenretinide	92-103	nuclear factor kappa B subunit 1	Homo sapiens	12-21
18515328-3	2008	Here, we show that the natural retinoid 9-cis retinoic acid (9cRA) and the synthetic retinoid fenretinide (4-HPR) specifically inhibit the functional up-regulation of CCR7 on maturing human DCs, without affecting early steps of DC maturation.	Fenretinide	94-105	haptoglobin-related protein	Homo sapiens	109-112
18549809-4	2008	4-HPR-induced mitochondrial translocation of Bax, release of mitochondrial cytochrome c, and activation of caspase-3 were markedly attenuated in U373MG cells that stably expressed COX6A1.	Fenretinide	0-5	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
18602901-1	2008	N-(4-Hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid that has shown biological activity against several malignant tumors and minimal side effects in humans.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
18549809-2	2008	The overexpression of COX6A1 significantly suppressed Bax- and N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis in yeast and human glioblastoma-derived U373MG cells, respectively.	Fenretinide	63-92	cytochrome c oxidase subunit 6A1	Homo sapiens	22-28
18549809-4	2008	4-HPR-induced mitochondrial translocation of Bax, release of mitochondrial cytochrome c, and activation of caspase-3 were markedly attenuated in U373MG cells that stably expressed COX6A1.	Fenretinide	0-5	cytochrome c, somatic	Homo sapiens	75-87
18549809-2	2008	The overexpression of COX6A1 significantly suppressed Bax- and N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis in yeast and human glioblastoma-derived U373MG cells, respectively.	Fenretinide	94-99	cytochrome c oxidase subunit 6A1	Homo sapiens	22-28
18549809-4	2008	4-HPR-induced mitochondrial translocation of Bax, release of mitochondrial cytochrome c, and activation of caspase-3 were markedly attenuated in U373MG cells that stably expressed COX6A1.	Fenretinide	0-5	caspase 3	Homo sapiens	107-116
18549809-4	2008	4-HPR-induced mitochondrial translocation of Bax, release of mitochondrial cytochrome c, and activation of caspase-3 were markedly attenuated in U373MG cells that stably expressed COX6A1.	Fenretinide	0-5	cytochrome c oxidase subunit 6A1	Homo sapiens	180-186
18387645-2	2008	JWA, a novel retinoic acid-inducible gene, is known to be involved in apoptosis induced by various agents, for example, 12-O-tetradecanoylphorbol 13-acetate, N-4-hydroxy-phenyl-retinamide and arsenic trioxide.	Fenretinide	158-187	ADP ribosylation factor like GTPase 6 interacting protein 5	Homo sapiens	0-3
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase kinase 1	Homo sapiens	32-38
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 3	Homo sapiens	118-124
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 9	Homo sapiens	129-133
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 9	Homo sapiens	134-137
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 1	Homo sapiens	118-121
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 9	Homo sapiens	245-249
18410500-5	2008	By blocking the upstream kinase MEK1/2 with specific inhibitor U0126 we abrogated the 4HPR-induced phosphorylation of ERK1/2 and SAPK/JNK, indicating that the neuronal differentiation occurs through a positive cross-talk between the ERK and the SAPK/JNK pathways.	Fenretinide	86-90	mitogen-activated protein kinase 9	Homo sapiens	250-253
18519704-0	2008	Involvement of Rac in fenretinide-induced apoptosis.	Fenretinide	22-33	AKT serine/threonine kinase 1	Homo sapiens	15-18
18519704-3	2008	We explored the possibility that ROS induction by 4HPR involves the small GTPase Ras-related C3 botulinum toxin substrate (Rac), a regulatory subunit of the NADPH oxidase complex.	Fenretinide	50-54	AKT serine/threonine kinase 1	Homo sapiens	123-126
18425327-1	2008	The efficacy and mechanism of action of fenretinide (4-HPR), a vitamin A analogue, was investigated in a panel of six neuroblastoma cell lines and multicellular tumor spheroids.	Fenretinide	40-51	haptoglobin-related protein	Homo sapiens	55-58
18259116-6	2008	In particular we found that fenretinide treatment resulted in the increase in Beclin 1 expression, the conversion of the soluble form of LC3 to the autophagic vesicle-associated form LC3-II and its shift from diffuse to punctate staining and finally the increase in lysosomes/autophagosomes.	Fenretinide	28-39	beclin 1	Homo sapiens	78-86
18259116-6	2008	In particular we found that fenretinide treatment resulted in the increase in Beclin 1 expression, the conversion of the soluble form of LC3 to the autophagic vesicle-associated form LC3-II and its shift from diffuse to punctate staining and finally the increase in lysosomes/autophagosomes.	Fenretinide	28-39	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	137-140
18259116-6	2008	In particular we found that fenretinide treatment resulted in the increase in Beclin 1 expression, the conversion of the soluble form of LC3 to the autophagic vesicle-associated form LC3-II and its shift from diffuse to punctate staining and finally the increase in lysosomes/autophagosomes.	Fenretinide	28-39	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	183-186
18259116-7	2008	By contrast, caspase-3 reconstituted MCF-7 cell line showed apoptotic cell death features in response to fenretinide treatment.	Fenretinide	105-116	caspase 3	Homo sapiens	13-22
18342855-0	2008	The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells.	Fenretinide	84-113	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	4-8
18342855-0	2008	The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells.	Fenretinide	84-113	eukaryotic translation initiation factor 2A	Homo sapiens	9-19
18342855-0	2008	The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells.	Fenretinide	115-119	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	4-8
18342855-0	2008	The PERK/eIF2 alpha signaling pathway of Unfolded Protein Response is essential for N-(4-hydroxyphenyl)retinamide (4HPR)-induced cytotoxicity in cancer cells.	Fenretinide	115-119	eukaryotic translation initiation factor 2A	Homo sapiens	9-19
18342855-1	2008	N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that has been tested in clinical trials as a cancer chemopreventive drug.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	32-35
17988958-0	2008	Fenretinide prevents the development of osteoporosis in Cftr-KO mice.	Fenretinide	0-11	cystic fibrosis transmembrane conductance regulator	Mus musculus	56-60
17988958-4	2008	In this study, we characterized the protective effect of fenretinide [N-(4-hydroxyphenyl) retinamide], a vitamin A derivative, on the early onset of osteoporosis in cystic fibrosis transmembrane conductance regulator knockout (Cftr-KO) mice.	Fenretinide	57-68	cystic fibrosis transmembrane conductance regulator	Mus musculus	165-216
17988958-4	2008	In this study, we characterized the protective effect of fenretinide [N-(4-hydroxyphenyl) retinamide], a vitamin A derivative, on the early onset of osteoporosis in cystic fibrosis transmembrane conductance regulator knockout (Cftr-KO) mice.	Fenretinide	57-68	cystic fibrosis transmembrane conductance regulator	Mus musculus	227-231
17988958-4	2008	In this study, we characterized the protective effect of fenretinide [N-(4-hydroxyphenyl) retinamide], a vitamin A derivative, on the early onset of osteoporosis in cystic fibrosis transmembrane conductance regulator knockout (Cftr-KO) mice.	Fenretinide	70-100	cystic fibrosis transmembrane conductance regulator	Mus musculus	165-216
17988958-4	2008	In this study, we characterized the protective effect of fenretinide [N-(4-hydroxyphenyl) retinamide], a vitamin A derivative, on the early onset of osteoporosis in cystic fibrosis transmembrane conductance regulator knockout (Cftr-KO) mice.	Fenretinide	70-100	cystic fibrosis transmembrane conductance regulator	Mus musculus	227-231
18398104-0	2008	Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.	Fenretinide	24-53	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	110-115
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	275-300	retinoic acid receptor alpha	Homo sapiens	115-118
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	275-300	retinoic acid receptor alpha	Homo sapiens	169-197
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	275-300	retinoic acid receptor alpha	Homo sapiens	199-208
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	302-307	retinoic acid receptor alpha	Homo sapiens	115-118
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	302-307	retinoic acid receptor alpha	Homo sapiens	169-197
18416830-2	2008	Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-alpha (RAR-alpha)-selective agonist, AM580 but not with the RAR-beta/gamma ligand, 4-hydroxyphenylretinamide (4-HPR).	Fenretinide	302-307	retinoic acid receptor alpha	Homo sapiens	199-208
18398104-3	2008	The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1.	Fenretinide	33-62	haptoglobin-related protein	Homo sapiens	66-69
18398104-3	2008	The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1.	Fenretinide	33-62	mitogen-activated protein kinase 8	Homo sapiens	159-171
18398104-3	2008	The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1.	Fenretinide	33-62	mitogen-activated protein kinase 8	Homo sapiens	173-176
18398104-3	2008	The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1.	Fenretinide	33-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	221-226
17700534-0	2008	The sensitivity of the Ewing"s sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.	Fenretinide	60-71	EWS RNA binding protein 1	Homo sapiens	107-110
18174255-2	2008	Others and we have previously demonstrated apoptosis-inducing capacity of N-(4-hydroxyphenyl)retinamide (4-HPR) in malignant glioma cells.	Fenretinide	74-103	haptoglobin-related protein	Homo sapiens	107-110
18164543-0	2008	N-(4-Hydroxyphenyl)retinamide induced differentiation with repression of telomerase and cell cycle to increase interferon-gamma sensitivity for apoptosis in human glioblastoma cells.	Fenretinide	0-29	interferon gamma	Homo sapiens	111-127
18164543-3	2008	N-(4-Hydroxyphenyl)retinamide (4-HPR) induced astrocytic differentiation and increased sensitivity to interferon-gamma (IFN-gamma) for apoptosis in human glioblastoma A172, LN18, and SNB19 cells.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
18164543-3	2008	N-(4-Hydroxyphenyl)retinamide (4-HPR) induced astrocytic differentiation and increased sensitivity to interferon-gamma (IFN-gamma) for apoptosis in human glioblastoma A172, LN18, and SNB19 cells.	Fenretinide	0-29	interferon gamma	Homo sapiens	102-118
18164543-3	2008	N-(4-Hydroxyphenyl)retinamide (4-HPR) induced astrocytic differentiation and increased sensitivity to interferon-gamma (IFN-gamma) for apoptosis in human glioblastoma A172, LN18, and SNB19 cells.	Fenretinide	0-29	interferon gamma	Homo sapiens	120-129
18248980-0	2008	4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells.	Fenretinide	0-25	haptoglobin-related protein	Homo sapiens	28-31
18248980-1	2008	Recent studies exhibit that 4-hydroxyphenylretinamide (4HPR) decreases aromatase activity in breast and placental cells.	Fenretinide	28-53	haptoglobin-related protein	Homo sapiens	56-59
17700534-0	2008	The sensitivity of the Ewing"s sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.	Fenretinide	60-71	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	111-115
17700534-0	2008	The sensitivity of the Ewing"s sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.	Fenretinide	60-71	mitogen-activated protein kinase 14	Homo sapiens	140-143
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	EWS RNA binding protein 1	Homo sapiens	179-182
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	183-187
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	209-213
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	209-213
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	78-89	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	EWS RNA binding protein 1	Homo sapiens	179-182
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	183-187
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	209-213
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	209-213
17700534-3	2008	Here, we demonstrate for the first time that the sensitivity of ESFT cells to fenretinide-induced cell death is decreased following downregulation of the oncogenic fusion protein EWS-Fli1; siRNA targeting EWS-Fli1 attenuated fenretinide-induced cell death in cell lines expressing EWS-Fli1, but not EWS-ERG.	Fenretinide	225-236	EWS RNA binding protein 1	Homo sapiens	205-208
17700534-4	2008	This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWS-Fli1-dependent modulation of p38(MAPK) activity.	Fenretinide	95-106	EWS RNA binding protein 1	Homo sapiens	133-136
17700534-4	2008	This decrease in cell death was independent of the level of ROS produced following exposure to fenretinide, but was effected through EWS-Fli1-dependent modulation of p38(MAPK) activity.	Fenretinide	95-106	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	137-141
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	mitogen-activated protein kinase 14	Homo sapiens	27-30
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	EWS RNA binding protein 1	Homo sapiens	63-66
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	67-71
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	cytochrome c, somatic	Homo sapiens	132-144
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	poly(ADP-ribose) polymerase 1	Homo sapiens	166-170
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	80-91	mitogen-activated protein kinase 14	Homo sapiens	217-220
17700534-5	2008	Furthermore, inhibition of p38(MAPK) activity and knockdown of EWS-Fli1 reduced fenretinide-induced mitochondrial permeabilization, cytochrome c release, caspase and PARP cleavage, consistent with the hypothesis that p38(MAPK) is critical for activation of the death cascade by fenretinide in ESFT cells.	Fenretinide	278-289	EWS RNA binding protein 1	Homo sapiens	63-66
17700534-6	2008	These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.	Fenretinide	60-71	EWS RNA binding protein 1	Homo sapiens	42-45
17700534-6	2008	These data demonstrate that expression of EWS-Fli1 enhances fenretinide-induced cell death in ESFT and that this is effected at least in part through modulation of p38(MAPK) activity.	Fenretinide	60-71	Fli-1 proto-oncogene, ETS transcription factor	Homo sapiens	46-50
17955489-1	2008	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR) is an aminophenol-containing synthetic retinoid derivative of all-trans-retinoic acid, which is a potent chemopreventive and antiproliferative agent against various cancers.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	46-49
17955489-1	2008	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR) is an aminophenol-containing synthetic retinoid derivative of all-trans-retinoic acid, which is a potent chemopreventive and antiproliferative agent against various cancers.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	46-49
17883277-1	2007	N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) has been shown to be active toward many tumors without appreciable side effects.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	46-49
17656682-6	2008	Since it has been previously reported that in vitro treatment with fenretinide induced ceramide in neuroblastoma cell lines, we decided to test this drug in vivo using our Cftr-knockout mice in an attempt to correct this newly identified defect in ceramide levels.	Fenretinide	67-78	cystic fibrosis transmembrane conductance regulator	Mus musculus	172-176
17656682-8	2008	We further assessed the biological effect of fenretinide on the ability of Cftr-knockout mice to combat lung infection with P. aeruginosa.	Fenretinide	45-56	cystic fibrosis transmembrane conductance regulator	Mus musculus	75-79
22275964-9	2008	Antithrombin-III showed a 4% borderline significant reduction in the fenretinide arm relative to placebo, irrespective of the HRT administration route (p = 0.055).	Fenretinide	69-80	serpin family C member 1	Homo sapiens	0-16
17577665-0	2008	Inhibitors of EGFR signaling retard cytotoxicity of fenretinide in rat gliosarcoma cells.	Fenretinide	52-63	epidermal growth factor receptor	Rattus norvegicus	14-18
18166136-0	2007	Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent.	Fenretinide	0-11	MIR7-3 host gene	Homo sapiens	33-38
18166136-0	2007	Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent.	Fenretinide	0-11	retinoic acid receptor beta	Homo sapiens	67-94
18166136-5	2007	Transactivation assay and chromatin immunoprecipitation (ChIP) were conducted to evaluate the activation of RXRalpha/RARbeta pathway by fenretinide.	Fenretinide	136-147	retinoid X receptor alpha	Homo sapiens	108-116
18166136-5	2007	Transactivation assay and chromatin immunoprecipitation (ChIP) were conducted to evaluate the activation of RXRalpha/RARbeta pathway by fenretinide.	Fenretinide	136-147	retinoic acid receptor beta	Homo sapiens	117-124
18166136-7	2007	RESULTS: Our data revealed that fenretinide effectively induces apoptosis in Huh-7 and Hep3B cells.	Fenretinide	32-43	MIR7-3 host gene	Homo sapiens	77-82
18166136-8	2007	Gene expression analysis of nuclear receptors revealed that the basal and inducibility of retinoic acid receptor beta (RARbeta) expression positively correlate with the susceptibility of HCC cells to fenretinide treatment.	Fenretinide	200-211	retinoic acid receptor beta	Homo sapiens	90-117
18166136-8	2007	Gene expression analysis of nuclear receptors revealed that the basal and inducibility of retinoic acid receptor beta (RARbeta) expression positively correlate with the susceptibility of HCC cells to fenretinide treatment.	Fenretinide	200-211	retinoic acid receptor beta	Homo sapiens	119-126
18166136-9	2007	Furthermore, fenretinide transactivates the RXRalpha/RARbeta-mediated pathway and directly increases the transcriptional activity of RARbeta.	Fenretinide	13-24	retinoid X receptor alpha	Homo sapiens	44-52
18166136-9	2007	Furthermore, fenretinide transactivates the RXRalpha/RARbeta-mediated pathway and directly increases the transcriptional activity of RARbeta.	Fenretinide	13-24	retinoic acid receptor beta	Homo sapiens	53-60
18166136-9	2007	Furthermore, fenretinide transactivates the RXRalpha/RARbeta-mediated pathway and directly increases the transcriptional activity of RARbeta.	Fenretinide	13-24	retinoic acid receptor beta	Homo sapiens	133-140
18166136-10	2007	Knockdown of RARbeta mRNA expression significantly impairs fenretinide-induced apoptosis in Huh-7 cells.	Fenretinide	59-70	retinoic acid receptor beta	Homo sapiens	13-20
18166136-10	2007	Knockdown of RARbeta mRNA expression significantly impairs fenretinide-induced apoptosis in Huh-7 cells.	Fenretinide	59-70	MIR7-3 host gene	Homo sapiens	92-97
18166136-11	2007	CONCLUSION: Our findings reveal that endogenous expression of retinoids receptor RARbeta gene determines the susceptibility of HCC cells to fenretinide-induced apoptosis.	Fenretinide	140-151	retinoic acid receptor beta	Homo sapiens	81-88
18166136-12	2007	Our results also demonstrate fenretinide directly activates RARbeta and induces apoptosis in Huh-7 cells in a RARbeta-dependent manner.	Fenretinide	29-40	retinoic acid receptor beta	Homo sapiens	60-67
18166136-12	2007	Our results also demonstrate fenretinide directly activates RARbeta and induces apoptosis in Huh-7 cells in a RARbeta-dependent manner.	Fenretinide	29-40	MIR7-3 host gene	Homo sapiens	93-98
18166136-12	2007	Our results also demonstrate fenretinide directly activates RARbeta and induces apoptosis in Huh-7 cells in a RARbeta-dependent manner.	Fenretinide	29-40	retinoic acid receptor beta	Homo sapiens	110-117
17883277-1	2007	N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) has been shown to be active toward many tumors without appreciable side effects.	Fenretinide	31-42	haptoglobin-related protein	Homo sapiens	46-49
17213814-1	2007	Fenretinide (4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
17283068-11	2007	Additionally, we found that treatment of SMS-KCNR cells with fenretinide inhibited desaturase activity in a dose-dependent manner.	Fenretinide	61-72	Desaturase 1	Drosophila melanogaster	83-93
17471234-7	2007	E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxyphenylretinamide (4-HPR).	Fenretinide	182-209	E2F transcription factor 1 L homeolog	Xenopus laevis	0-5
17471234-7	2007	E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxyphenylretinamide (4-HPR).	Fenretinide	182-209	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	56-59
17471234-7	2007	E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxyphenylretinamide (4-HPR).	Fenretinide	211-216	E2F transcription factor 1 L homeolog	Xenopus laevis	0-5
17471234-7	2007	E2F-1 suppresses extracellular signal-regulated kinase (ERK) phosphorylation through PAC1 and causes cancer cell death by apoptosis following treatment with a chemotherapeutic agent N-4-hydroxyphenylretinamide (4-HPR).	Fenretinide	211-216	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	56-59
17273769-0	2007	Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.	Fenretinide	0-11	TNF receptor superfamily member 10b	Homo sapiens	25-28
17404501-4	2007	Different experimental approaches have indicated that 4HPR induces ER stress response: electron microscopy, which showed extensive ER dilation; splicing of the X-box binding protein 1 (XBP-1), a marker of unfolded protein response (UPR) activation; and quantitative real-time PCR and immunoblotting, which revealed the upregulation of several ER-stress associated mRNAs and proteins, including the chaperone heat shock protein HSPA1A.	Fenretinide	54-58	X-box binding protein 1	Homo sapiens	160-183
17404501-4	2007	Different experimental approaches have indicated that 4HPR induces ER stress response: electron microscopy, which showed extensive ER dilation; splicing of the X-box binding protein 1 (XBP-1), a marker of unfolded protein response (UPR) activation; and quantitative real-time PCR and immunoblotting, which revealed the upregulation of several ER-stress associated mRNAs and proteins, including the chaperone heat shock protein HSPA1A.	Fenretinide	54-58	X-box binding protein 1	Homo sapiens	185-190
17404501-4	2007	Different experimental approaches have indicated that 4HPR induces ER stress response: electron microscopy, which showed extensive ER dilation; splicing of the X-box binding protein 1 (XBP-1), a marker of unfolded protein response (UPR) activation; and quantitative real-time PCR and immunoblotting, which revealed the upregulation of several ER-stress associated mRNAs and proteins, including the chaperone heat shock protein HSPA1A.	Fenretinide	54-58	heat shock protein family A (Hsp70) member 1A	Homo sapiens	427-433
17404501-6	2007	Furthermore, siRNA-mediated silencing and chemical inhibition of HSPA1A, which exerts either pro- or anti-apoptotic effects, decreased 4HPR-induced apoptosis.	Fenretinide	135-139	heat shock protein family A (Hsp70) member 1A	Homo sapiens	65-71
17404501-7	2007	These results demonstrate that 4HPR induces ER stress and uncovered a pro-apoptotic role for HSPA1A in 4HPR-induced apoptosis.	Fenretinide	31-35	heat shock protein family A (Hsp70) member 1A	Homo sapiens	93-99
17216584-0	2007	Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours.	Fenretinide	32-43	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	8-12
17216584-1	2007	Fenretinide-induced apoptosis of neuroectodermal tumour cells is mediated through generation of reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, mitochondrial cytochrome c release and caspase activation.	Fenretinide	0-11	cytochrome c, somatic	Homo sapiens	176-188
17216584-3	2007	Noxa expression was induced by fenretinide in neuroblastoma and melanoma cells, including those with mutated p53, and this induction was abolished by antioxidants.	Fenretinide	31-42	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	0-4
17216584-4	2007	Knockdown of p53 by RNA interference (RNAi) demonstrated upregulation of Noxa protein levels in response to fenretinide was p53-independent, although evidence suggested that Noxa may be transcriptionally regulated by p53.	Fenretinide	108-119	tumor protein p53	Homo sapiens	13-16
17216584-4	2007	Knockdown of p53 by RNA interference (RNAi) demonstrated upregulation of Noxa protein levels in response to fenretinide was p53-independent, although evidence suggested that Noxa may be transcriptionally regulated by p53.	Fenretinide	108-119	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	73-77
17216584-4	2007	Knockdown of p53 by RNA interference (RNAi) demonstrated upregulation of Noxa protein levels in response to fenretinide was p53-independent, although evidence suggested that Noxa may be transcriptionally regulated by p53.	Fenretinide	108-119	tumor protein p53	Homo sapiens	124-127
17216584-4	2007	Knockdown of p53 by RNA interference (RNAi) demonstrated upregulation of Noxa protein levels in response to fenretinide was p53-independent, although evidence suggested that Noxa may be transcriptionally regulated by p53.	Fenretinide	108-119	tumor protein p53	Homo sapiens	124-127
17216584-8	2007	RNAi-mediated down-regulation of Noxa inhibited apoptosis in response to fenretinide or thapsigargin, whereas apoptosis induced by cisplatin or temozolomide was unaffected.	Fenretinide	73-84	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	33-37
17436572-4	2007	In this report we present data to show that fenretinide (a synthetic retinoid) potentiates the apoptotic effects of parthenolide (a drug that inhibits the activation of NF-kappa B) and BAY 11-7085 (an inhibitor of I-kappa B-alpha kinase).	Fenretinide	44-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	169-179
17436572-4	2007	In this report we present data to show that fenretinide (a synthetic retinoid) potentiates the apoptotic effects of parthenolide (a drug that inhibits the activation of NF-kappa B) and BAY 11-7085 (an inhibitor of I-kappa B-alpha kinase).	Fenretinide	44-55	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	214-229
17436572-5	2007	This potentiation of apoptosis by fenretinide is seen in the p53-deficient, deoxyadenosine-resistant L1210 cells, but not in the parental L1210 cells that express a mutant p53.	Fenretinide	34-45	transformation related protein 53, pseudogene	Mus musculus	61-64
17436572-5	2007	This potentiation of apoptosis by fenretinide is seen in the p53-deficient, deoxyadenosine-resistant L1210 cells, but not in the parental L1210 cells that express a mutant p53.	Fenretinide	34-45	transformation related protein 53, pseudogene	Mus musculus	172-175
17436572-7	2007	These data strongly suggest that fenretinide activates or inhibits some step or pathway that interacts with the inhibition of NF-kappa B activation required for the apoptotic response.	Fenretinide	33-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	126-136
17146731-5	2007	The apparent permeability coefficient (P(app)) of fenretinide across Caco-2 monolayers in the presence of bovine serum albumin (BSA) in the receiver was determined.	Fenretinide	50-61	albumin	Homo sapiens	113-126
17454142-1	2007	We have previously reported that, in leukemia cells, the cytotoxicity of the anticancer agent N-(4-hydroxyphenyl)retinamide (4-HPR) is mediated by mitochondria-derived reactive oxygen species (ROS) and cardiolipin peroxidation.	Fenretinide	94-123	haptoglobin-related protein	Homo sapiens	127-130
17353921-4	2007	The retinoid analogue fenretinide [N-(4-hydroxyphenyl) retinamide] is a new cancer preventive and chemotherapeutic drug, that induces apoptosis of some cancer cell types via oxidative stress, accompanied by induction of an ER stress-related transcription factor, GADD153.	Fenretinide	22-33	DNA damage inducible transcript 3	Homo sapiens	263-270
17353921-4	2007	The retinoid analogue fenretinide [N-(4-hydroxyphenyl) retinamide] is a new cancer preventive and chemotherapeutic drug, that induces apoptosis of some cancer cell types via oxidative stress, accompanied by induction of an ER stress-related transcription factor, GADD153.	Fenretinide	35-65	DNA damage inducible transcript 3	Homo sapiens	263-270
17353921-6	2007	The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in neuroectodermal tumour cells by fenretinide.	Fenretinide	115-126	DnaJ heat shock protein family (Hsp40) member C10	Homo sapiens	20-25
17353921-6	2007	The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in neuroectodermal tumour cells by fenretinide.	Fenretinide	115-126	protein disulfide isomerase family A member 3	Homo sapiens	27-32
17353921-6	2007	The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in neuroectodermal tumour cells by fenretinide.	Fenretinide	115-126	heat shock protein family A (Hsp70) member 5	Homo sapiens	34-39
17353921-6	2007	The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in neuroectodermal tumour cells by fenretinide.	Fenretinide	115-126	calreticulin	Homo sapiens	41-53
17353921-6	2007	The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in neuroectodermal tumour cells by fenretinide.	Fenretinide	115-126	calnexin	Homo sapiens	58-66
17353921-7	2007	In contrast to the apoptosis-inducing chemotherapeutic drugs vincristine and temozolomide, fenretinide induced the phosphorylation of eIF2alpha, expression of ATF4 and splicing of XBP-1 mRNA, events that define ER stress.	Fenretinide	91-102	eukaryotic translation initiation factor 2A	Homo sapiens	134-143
17353921-7	2007	In contrast to the apoptosis-inducing chemotherapeutic drugs vincristine and temozolomide, fenretinide induced the phosphorylation of eIF2alpha, expression of ATF4 and splicing of XBP-1 mRNA, events that define ER stress.	Fenretinide	91-102	activating transcription factor 4	Homo sapiens	159-163
17353921-7	2007	In contrast to the apoptosis-inducing chemotherapeutic drugs vincristine and temozolomide, fenretinide induced the phosphorylation of eIF2alpha, expression of ATF4 and splicing of XBP-1 mRNA, events that define ER stress.	Fenretinide	91-102	X-box binding protein 1	Homo sapiens	180-185
17353921-10	2007	Knockdown of ERp57 or ERdj5 by RNA interference in these cells increased the apoptotic response to fenretinide.	Fenretinide	99-110	protein disulfide isomerase family A member 3	Homo sapiens	13-18
17353921-10	2007	Knockdown of ERp57 or ERdj5 by RNA interference in these cells increased the apoptotic response to fenretinide.	Fenretinide	99-110	DnaJ heat shock protein family (Hsp40) member C10	Homo sapiens	22-27
17216584-9	2007	These data demonstrate the importance of Noxa induction in determining the apoptotic response to fenretinide and emphasise the role of Noxa in p53-independent apoptosis.	Fenretinide	97-108	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	41-45
17273769-4	2007	In this study, we report that fenretinide induces death receptor 5 (DR5)/TRAIL-R2 up-regulation via the induction of the transcription factor CHOP in colon cancer cell lines.	Fenretinide	30-41	TNF receptor superfamily member 10b	Homo sapiens	73-81
17273769-4	2007	In this study, we report that fenretinide induces death receptor 5 (DR5)/TRAIL-R2 up-regulation via the induction of the transcription factor CHOP in colon cancer cell lines.	Fenretinide	30-41	DNA damage inducible transcript 3	Homo sapiens	142-146
17273769-5	2007	Fenretinide induced DR5 expression at protein and mRNA levels.	Fenretinide	0-11	TNF receptor superfamily member 10b	Homo sapiens	20-23
17273769-6	2007	Furthermore, fenretinide increased DR5 promoter activity and the enhanced activity decreased by mutation of the CHOP binding site.	Fenretinide	13-24	TNF receptor superfamily member 10b	Homo sapiens	35-38
17273769-6	2007	Furthermore, fenretinide increased DR5 promoter activity and the enhanced activity decreased by mutation of the CHOP binding site.	Fenretinide	13-24	DNA damage inducible transcript 3	Homo sapiens	112-116
17273769-7	2007	CHOP was also up-regulated by fenretinide at the promoter level.	Fenretinide	30-41	DNA damage inducible transcript 3	Homo sapiens	0-4
17273769-10	2007	Fenretinide and TRAIL cooperatively activated caspase-3, -8, -10 and -9 and cleavage of Bid and PARP, and this activation was also blocked in the presence of DR5/Fc chimeric protein.	Fenretinide	0-11	caspase 3	Homo sapiens	46-71
17273769-10	2007	Fenretinide and TRAIL cooperatively activated caspase-3, -8, -10 and -9 and cleavage of Bid and PARP, and this activation was also blocked in the presence of DR5/Fc chimeric protein.	Fenretinide	0-11	BH3 interacting domain death agonist	Homo sapiens	88-91
17273769-10	2007	Fenretinide and TRAIL cooperatively activated caspase-3, -8, -10 and -9 and cleavage of Bid and PARP, and this activation was also blocked in the presence of DR5/Fc chimeric protein.	Fenretinide	0-11	collagen type XI alpha 2 chain	Homo sapiens	96-100
17273769-10	2007	Fenretinide and TRAIL cooperatively activated caspase-3, -8, -10 and -9 and cleavage of Bid and PARP, and this activation was also blocked in the presence of DR5/Fc chimeric protein.	Fenretinide	0-11	TNF receptor superfamily member 10b	Homo sapiens	158-161
17273769-11	2007	These results indicate that fenretinide-induced apoptosis is sensitized by TRAIL.	Fenretinide	28-39	TNF superfamily member 10	Homo sapiens	75-80
17273769-0	2007	Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.	Fenretinide	0-11	TNF receptor superfamily member 10b	Homo sapiens	29-37
17273769-0	2007	Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.	Fenretinide	0-11	DNA damage inducible transcript 3	Homo sapiens	95-99
17273769-0	2007	Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines.	Fenretinide	0-11	TNF superfamily member 10	Homo sapiens	29-34
17273769-3	2007	Oxidative stress induced by fenretinide has been shown to mediate apoptosis through a mitochondrial pathway by the induction of a transcription factor CCAAT/enhancer binding protein homologous protein (CHOP) and Bak.	Fenretinide	28-39	DNA damage inducible transcript 3	Homo sapiens	151-200
17273769-3	2007	Oxidative stress induced by fenretinide has been shown to mediate apoptosis through a mitochondrial pathway by the induction of a transcription factor CCAAT/enhancer binding protein homologous protein (CHOP) and Bak.	Fenretinide	28-39	DNA damage inducible transcript 3	Homo sapiens	202-206
17273769-4	2007	In this study, we report that fenretinide induces death receptor 5 (DR5)/TRAIL-R2 up-regulation via the induction of the transcription factor CHOP in colon cancer cell lines.	Fenretinide	30-41	TNF receptor superfamily member 10b	Homo sapiens	50-66
17273769-4	2007	In this study, we report that fenretinide induces death receptor 5 (DR5)/TRAIL-R2 up-regulation via the induction of the transcription factor CHOP in colon cancer cell lines.	Fenretinide	30-41	TNF receptor superfamily member 10b	Homo sapiens	68-71
17112722-0	2007	Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.	Fenretinide	67-96	haptoglobin-related protein	Homo sapiens	100-103
17112722-1	2007	Using solid phase-assisted synthesis and purification, a 49 member library of analogs of the mammary tumor chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been prepared.	Fenretinide	132-161	haptoglobin-related protein	Homo sapiens	165-168
17235241-4	2007	Annexin V was induced by nimesulide, 4-hydroxyphenylretinamide, and difluoromethylornithine in ultraviolet-B-treated radial growth-phase-like melanoma cells.	Fenretinide	37-62	annexin A5	Homo sapiens	0-9
16950796-5	2007	Among the synthetic agents, oltipraz and N-(4-hydroxyphenyl) retinamide (4-HPR) also increased MGMT expression, albeit to a lesser extent.	Fenretinide	41-71	haptoglobin-related protein	Homo sapiens	75-78
16950796-5	2007	Among the synthetic agents, oltipraz and N-(4-hydroxyphenyl) retinamide (4-HPR) also increased MGMT expression, albeit to a lesser extent.	Fenretinide	41-71	O-6-methylguanine-DNA methyltransferase	Homo sapiens	95-99
17159502-6	2007	Western blot analysis further showed down-regulation of procaspase-3, X-linked inhibitor of apoptosis protein and poly(ADP-ribose) polymerase cleavage in Bel-7402 cells treated with 15 mumol/l fenretinide for 48 h. Overexpression of p53 was observed in a time-dependent manner, along with a decrease in the Bcl-2/Bax ratio.	Fenretinide	193-204	caspase 3	Homo sapiens	56-68
17159502-6	2007	Western blot analysis further showed down-regulation of procaspase-3, X-linked inhibitor of apoptosis protein and poly(ADP-ribose) polymerase cleavage in Bel-7402 cells treated with 15 mumol/l fenretinide for 48 h. Overexpression of p53 was observed in a time-dependent manner, along with a decrease in the Bcl-2/Bax ratio.	Fenretinide	193-204	tumor protein p53	Homo sapiens	233-236
17159502-6	2007	Western blot analysis further showed down-regulation of procaspase-3, X-linked inhibitor of apoptosis protein and poly(ADP-ribose) polymerase cleavage in Bel-7402 cells treated with 15 mumol/l fenretinide for 48 h. Overexpression of p53 was observed in a time-dependent manner, along with a decrease in the Bcl-2/Bax ratio.	Fenretinide	193-204	BCL2 apoptosis regulator	Homo sapiens	307-312
17159502-6	2007	Western blot analysis further showed down-regulation of procaspase-3, X-linked inhibitor of apoptosis protein and poly(ADP-ribose) polymerase cleavage in Bel-7402 cells treated with 15 mumol/l fenretinide for 48 h. Overexpression of p53 was observed in a time-dependent manner, along with a decrease in the Bcl-2/Bax ratio.	Fenretinide	193-204	BCL2 associated X, apoptosis regulator	Homo sapiens	313-316
17237288-5	2007	We found that 4HPR causes lysosomal membrane permeabilization and cytosolic relocation of cathepsin D.	Fenretinide	14-18	cathepsin D	Homo sapiens	90-101
17044020-0	2006	Cell death induced by N-(4-hydroxyphenyl)retinamide in human epidermal keratinocytes is modulated by TGF-beta and diminishes during the progression of squamous cell carcinoma.	Fenretinide	22-51	transforming growth factor beta 1	Homo sapiens	101-109
17302189-8	2007	In one study, fenretinide (4-HPR) delayed development of ovarian cancer in women at increased risk of developing breast and ovarian cancer.	Fenretinide	14-25	haptoglobin-related protein	Homo sapiens	29-32
17044020-1	2006	It has been demonstrated that the chemopreventive agent N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptotic cell death, but recent data has suggested that late stage/recurrent tumours lose their response to 4-HPR-induced cell death by mechanisms that are unknown.	Fenretinide	56-85	haptoglobin-related protein	Homo sapiens	89-92
17044020-1	2006	It has been demonstrated that the chemopreventive agent N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptotic cell death, but recent data has suggested that late stage/recurrent tumours lose their response to 4-HPR-induced cell death by mechanisms that are unknown.	Fenretinide	56-85	haptoglobin-related protein	Homo sapiens	213-216
16972258-0	2006	N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153.	Fenretinide	0-29	heme oxygenase 1	Homo sapiens	193-209
17001693-11	2006	Fenretinide, a novel synthetic retinoic acid (RA) analog lowers RBP4 in glucose intolerant obese mice.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	64-68
16972258-0	2006	N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153.	Fenretinide	0-29	DNA damage inducible transcript 3	Homo sapiens	214-221
16972258-8	2006	Pyrrolidine dithiocarbamate (PDTC), a free-radical scavenger, inhibited 4HPR-induced ROS generation, the expression of its downstream mediator, Gadd153, and apoptosis in the pretreated cells.	Fenretinide	72-76	DNA damage inducible transcript 3	Homo sapiens	144-151
16979119-4	2006	As fenretinide is a ceramide up-regulating drug that inhibits the activation of the pro-inflammatory transcriptional factor, nuclear factor (NF)-kappaB, the impact of fenretinide on unstimulated and tumor necrosis factor (TNF)-alpha stimulated production of NF-kappaB-dependent interleukin (IL)-8 was studied in immortalized wild-type (non-CF; 9HTEo-) and mutant DeltaF508 CFTR (CF; CFTE29o-) tracheal epithelial cells.	Fenretinide	3-14	CF transmembrane conductance regulator	Homo sapiens	340-342
16979119-4	2006	As fenretinide is a ceramide up-regulating drug that inhibits the activation of the pro-inflammatory transcriptional factor, nuclear factor (NF)-kappaB, the impact of fenretinide on unstimulated and tumor necrosis factor (TNF)-alpha stimulated production of NF-kappaB-dependent interleukin (IL)-8 was studied in immortalized wild-type (non-CF; 9HTEo-) and mutant DeltaF508 CFTR (CF; CFTE29o-) tracheal epithelial cells.	Fenretinide	3-14	CF transmembrane conductance regulator	Homo sapiens	373-377
16979119-0	2006	Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.	Fenretinide	98-109	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
16979119-6	2006	Clinically relevant concentrations of fenretinide (1.25, 2.5 and 5 microM) inhibited TNF-alpha-induced IL-8 production of CF cells by up to 73% but had no effect or increased the IL-8 production in non-CF cells.	Fenretinide	38-49	tumor necrosis factor	Homo sapiens	85-94
16979119-0	2006	Inhibition of IL-8 release from CFTR-deficient lung epithelial cells following pre-treatment with fenretinide.	Fenretinide	98-109	CF transmembrane conductance regulator	Homo sapiens	32-36
16979119-4	2006	As fenretinide is a ceramide up-regulating drug that inhibits the activation of the pro-inflammatory transcriptional factor, nuclear factor (NF)-kappaB, the impact of fenretinide on unstimulated and tumor necrosis factor (TNF)-alpha stimulated production of NF-kappaB-dependent interleukin (IL)-8 was studied in immortalized wild-type (non-CF; 9HTEo-) and mutant DeltaF508 CFTR (CF; CFTE29o-) tracheal epithelial cells.	Fenretinide	3-14	tumor necrosis factor	Homo sapiens	199-232
16979119-6	2006	Clinically relevant concentrations of fenretinide (1.25, 2.5 and 5 microM) inhibited TNF-alpha-induced IL-8 production of CF cells by up to 73% but had no effect or increased the IL-8 production in non-CF cells.	Fenretinide	38-49	C-X-C motif chemokine ligand 8	Homo sapiens	103-107
16979119-7	2006	Although fenretinide treatment was associated with a higher intracellular ceramide content in the mutant DeltaF508 CFTR cells, the fenretinide-mediated decrease in IL-8 secretion was not consistently explained by changes in the intracellular content of this sphingolipid.	Fenretinide	9-20	CF transmembrane conductance regulator	Homo sapiens	115-119
16979119-7	2006	Although fenretinide treatment was associated with a higher intracellular ceramide content in the mutant DeltaF508 CFTR cells, the fenretinide-mediated decrease in IL-8 secretion was not consistently explained by changes in the intracellular content of this sphingolipid.	Fenretinide	131-142	C-X-C motif chemokine ligand 8	Homo sapiens	164-168
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	4-15	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	4-15	tumor necrosis factor	Homo sapiens	68-77
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	191-202	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
16979119-9	2006	The fenretinide mediated decrease in IL-8 release in CF cells under TNF-alpha stimulated conditions presents the possibility that the lung inflammation in CF could be attenuated via low dose fenretinide treatment.	Fenretinide	191-202	tumor necrosis factor	Homo sapiens	68-77
17018636-0	2006	Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.	Fenretinide	134-164	AKT serine/threonine kinase 1	Homo sapiens	33-36
17110918-0	2006	Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins.	Fenretinide	0-11	paired box 6	Homo sapiens	160-165
17110918-0	2006	Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins.	Fenretinide	0-11	tubulin beta 3 class III	Homo sapiens	167-183
17110918-0	2006	Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins.	Fenretinide	0-11	enolase 2	Homo sapiens	185-188
17110918-0	2006	Fenretinide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells is associated with the differential expression of Hsp70, 14-3-3, pax-6, tubulin beta-III, NSE, and bag-1 proteins.	Fenretinide	0-11	BAG cochaperone 1	Homo sapiens	194-199
17110918-6	2006	Fenretinide induced neuronal differentiation of ARPE-19 cells led to a decrease in pax-6 protein and an increase in tubulin beta-III protein expression after 5 days fenretinide treatment.	Fenretinide	0-11	paired box 6	Homo sapiens	83-88
17110918-6	2006	Fenretinide induced neuronal differentiation of ARPE-19 cells led to a decrease in pax-6 protein and an increase in tubulin beta-III protein expression after 5 days fenretinide treatment.	Fenretinide	0-11	tubulin beta 3 class III	Homo sapiens	116-132
17110918-8	2006	We also found a time-dependent increase in Hsp70 protein expression in ARPE-19 cells treated with fenretinide.	Fenretinide	98-109	heat shock protein family A (Hsp70) member 4	Homo sapiens	43-48
17110918-10	2006	CONCLUSIONS: The fenretinide-induced neuronal differentiation of ARPE-19 cells is associated with an increase in expression of the neuronal specific protein tubulin beta-III, and a decrease in expression of the progenitor cell marker pax-6.	Fenretinide	17-28	tubulin beta 3 class III	Homo sapiens	157-173
17110918-10	2006	CONCLUSIONS: The fenretinide-induced neuronal differentiation of ARPE-19 cells is associated with an increase in expression of the neuronal specific protein tubulin beta-III, and a decrease in expression of the progenitor cell marker pax-6.	Fenretinide	17-28	paired box 6	Homo sapiens	234-239
16850162-3	2006	Diverse signaling molecules including reactive oxygen species, ceramide, and ganglioside GD3 can mediate apoptosis induction by fenretinide in transformed, premalignant, and malignant cells.	Fenretinide	128-139	GRDX	Homo sapiens	89-92
17018636-8	2006	Furthermore, combinations of celecoxib and 4HPR suppressed the phosphorylation levels of serine/threonine kinase Akt and its substrate glycogen synthase kinase-3beta more effectively than the single agents did.	Fenretinide	43-47	AKT serine/threonine kinase 1	Homo sapiens	113-116
17018636-8	2006	Furthermore, combinations of celecoxib and 4HPR suppressed the phosphorylation levels of serine/threonine kinase Akt and its substrate glycogen synthase kinase-3beta more effectively than the single agents did.	Fenretinide	43-47	glycogen synthase kinase 3 beta	Homo sapiens	135-165
17018636-9	2006	Accordingly, overexpression of constitutively active Akt protected bronchial epithelial cells from undergoing apoptosis after incubation with both celecoxib and 4HPR.	Fenretinide	161-165	AKT serine/threonine kinase 1	Homo sapiens	53-56
17035399-1	2006	PURPOSE: To evaluate study feasibility, toxicity, drug concentrations, and activity of escalating doses of the synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] in ovarian cancer by measuring serum CA125 and cytomorphometric biomarkers in cancer cells collected from ascitic fluid before and after treatment.	Fenretinide	130-141	mucin 16, cell surface associated	Homo sapiens	219-224
16675469-1	2006	N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid is under clinical evaluation as a therapeutic agent in a variety of cancers.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
16520989-0	2006	Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells.	Fenretinide	17-28	haptoglobin-related protein	Homo sapiens	32-35
16520989-1	2006	PURPOSES: N-(4-Hydroxyphenyl)-retinamide (4-HPR, Fenretinide) is a synthetic retinoid with cytotoxicity in acute lymphoblastic leukemia (ALL) cell lines.	Fenretinide	10-40	haptoglobin-related protein	Homo sapiens	44-47
16520989-1	2006	PURPOSES: N-(4-Hydroxyphenyl)-retinamide (4-HPR, Fenretinide) is a synthetic retinoid with cytotoxicity in acute lymphoblastic leukemia (ALL) cell lines.	Fenretinide	49-60	haptoglobin-related protein	Homo sapiens	44-47
16837623-8	2006	Direct comparison of other inhibitors such as fenretinide and 13-cis-retinoic acid showed multiple advantages of Ret-NH2 and its amides, including a higher potency, specificity, and lower transcription activation.	Fenretinide	46-57	ret proto-oncogene	Mus musculus	113-116
16671099-1	2006	N-(4-Hydroxyphenyl)retinamide (4-HPR) is a nonclassical retinoid with cancer preventive effects in vivo and antiproliferative and apoptotic activities in vitro.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
16766039-7	2006	The miniaturised method was used to study the binding of three different ligands (4-HPR, arotinoid, warfarinyl palmitate) modelled to bind to betaLG.	Fenretinide	82-87	beta-lactoglobulin	Bos taurus	142-148
16407847-8	2006	PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR.	Fenretinide	89-93	mitogen-activated protein kinase kinase 1	Homo sapiens	12-18
16407847-8	2006	PD98059, an MEK1/2 inhibitor, also suppressed ERK1/2 activation and apoptosis induced by 4HPR.	Fenretinide	89-93	mitogen-activated protein kinase 3	Homo sapiens	46-52
16407847-2	2006	As ROS can activate MAP kinases and protein kinase C (PKC), we examined the role of such enzymes in 4HPR-induced apoptosis in HNSCC UMSCC22B cells.	Fenretinide	100-104	proline rich transmembrane protein 2	Homo sapiens	54-57
16407847-10	2006	These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Fenretinide	25-29	mitogen-activated protein kinase 8	Homo sapiens	162-165
16407847-5	2006	SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis.	Fenretinide	38-42	mitogen-activated protein kinase 8	Homo sapiens	12-15
16407847-5	2006	SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis.	Fenretinide	38-42	cytochrome c, somatic	Homo sapiens	74-86
16407847-10	2006	These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Fenretinide	25-29	mitogen-activated protein kinase 1	Homo sapiens	167-170
16407847-10	2006	These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Fenretinide	25-29	proline rich transmembrane protein 2	Homo sapiens	172-175
16407847-10	2006	These data indicate that 4HPR-induced apoptosis is triggered by ROS increase, leading to the activation of the mitogen-activated protein serine/threonine kinases JNK, p38, PKC and ERK, and subsequent apoptosis.	Fenretinide	25-29	mitogen-activated protein kinase 1	Homo sapiens	180-183
16127422-0	2005	Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells.	Fenretinide	47-76	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
16091745-0	2005	BBC3 mediates fenretinide-induced cell death in neuroblastoma.	Fenretinide	14-25	BCL2 binding component 3	Homo sapiens	0-4
16091745-1	2005	Fenretinide (4-HPR) is a synthetic retinoid whose apoptosis-inducing effects have been demonstrated in many tumor types.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	15-18
16403262-1	2005	The retinoid N-4-hydroxyphenyl retinamide (4-HPR also known as fenretinide), a synthetic derivative of all trans retinoic acid (ATRA), has shown as an efficient chemopreventive, chemotherapeutic agent and a potent inducer of apoptosis in various cancer cell types in vitro, including leukemic cells.	Fenretinide	13-41	haptoglobin-related protein	Homo sapiens	45-48
16403262-1	2005	The retinoid N-4-hydroxyphenyl retinamide (4-HPR also known as fenretinide), a synthetic derivative of all trans retinoic acid (ATRA), has shown as an efficient chemopreventive, chemotherapeutic agent and a potent inducer of apoptosis in various cancer cell types in vitro, including leukemic cells.	Fenretinide	63-74	haptoglobin-related protein	Homo sapiens	45-48
16540676-1	2006	4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a recently identified metabolite of fenretinide (4-HPR).	Fenretinide	89-100	haptoglobin-related protein	Homo sapiens	45-48
16540676-1	2006	4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a recently identified metabolite of fenretinide (4-HPR).	Fenretinide	89-100	haptoglobin-related protein	Homo sapiens	104-107
16302003-6	2006	Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines.	Fenretinide	94-123	haptoglobin-related protein	Homo sapiens	127-130
16302003-6	2006	Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines.	Fenretinide	94-123	cyclin D1	Homo sapiens	153-162
16375981-9	2006	This effect of fenretinide appears to be specific for virus as the endosomal accumulation of gp120, transferrin and horse-radish peroxidase was not increased.	Fenretinide	15-26	inhibitor of carbonic anhydrase	Equus caballus	100-111
16399227-1	2006	N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) a synthetic retinoid is in clinical trials for the treatment of several malignancies.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
16399227-1	2006	N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) a synthetic retinoid is in clinical trials for the treatment of several malignancies.	Fenretinide	39-50	haptoglobin-related protein	Homo sapiens	34-37
16399227-6	2006	Fenretinide-induced decrease in cell viability was in part due to activation of caspase-3 dependent cell death, which was further supported by the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1), a caspase-3 substrate.	Fenretinide	0-11	caspase 3	Homo sapiens	80-89
16399227-6	2006	Fenretinide-induced decrease in cell viability was in part due to activation of caspase-3 dependent cell death, which was further supported by the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1), a caspase-3 substrate.	Fenretinide	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	159-188
16399227-6	2006	Fenretinide-induced decrease in cell viability was in part due to activation of caspase-3 dependent cell death, which was further supported by the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1), a caspase-3 substrate.	Fenretinide	0-11	poly(ADP-ribose) polymerase 1	Homo sapiens	190-196
16399227-6	2006	Fenretinide-induced decrease in cell viability was in part due to activation of caspase-3 dependent cell death, which was further supported by the cleavage of poly(ADP-ribose) polymerase-1 (PARP-1), a caspase-3 substrate.	Fenretinide	0-11	caspase 3	Homo sapiens	201-210
16382122-5	2006	After a median follow-up of 40 months, there was a reduction of 13%, 2%, 20%, and 1% in IGF-I levels for patients on tamoxifen, fenretinide, tamoxifen plus fenretinide, and placebo, respectively.	Fenretinide	128-139	insulin like growth factor 1	Homo sapiens	88-93
16382122-5	2006	After a median follow-up of 40 months, there was a reduction of 13%, 2%, 20%, and 1% in IGF-I levels for patients on tamoxifen, fenretinide, tamoxifen plus fenretinide, and placebo, respectively.	Fenretinide	156-167	insulin like growth factor 1	Homo sapiens	88-93
17024972-0	2006	Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.	Fenretinide	46-75	haptoglobin-related protein	Homo sapiens	79-82
17024972-6	2006	This study examines the effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in combination with cholecalciferol (vitamin D3) on growth, and on the expression of vimentin, matrix metalloproteinase-2 (MMP-2), and retinoid and vitamin D receptor expression, using the non-tumorigenic, human prostate epithelial cell line RWPE-1.	Fenretinide	58-87	haptoglobin-related protein	Homo sapiens	91-94
16127422-6	2005	MCF-7/COX-2 cells were also resistant to the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) but not to its analog, all-trans retinoic acid.	Fenretinide	54-83	prostaglandin-endoperoxide synthase 2	Homo sapiens	6-11
16127422-6	2005	MCF-7/COX-2 cells were also resistant to the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) but not to its analog, all-trans retinoic acid.	Fenretinide	54-83	haptoglobin-related protein	Homo sapiens	87-90
16230421-0	2005	N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.	Fenretinide	0-29	nuclear factor kappa B subunit 1	Homo sapiens	161-182
16274795-1	2005	OBJECTIVE: To explore whether the mechanism of action of 4-hydroxyphenylretinamide (4-HPR, fenretidine), a synthetic retinoid, involves the functional activation of the nuclear hormone receptor class known as PPARs (peroxisome proliferator-activated receptors).	Fenretinide	57-82	haptoglobin-related protein	Homo sapiens	86-89
16230421-1	2005	N-(4-hydroxyphenyl) retinamide [4-HPR], a synthetic retinoid, has been shown to inhibit tumor cell growth, invasion, and metastasis by a mechanism that is not fully understood.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	34-37
15958647-0	2005	The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.	Fenretinide	164-193	bone morphogenetic protein 2	Homo sapiens	51-79
15907365-2	2005	In SH-SY5Y neuroblastoma cells, evidence suggests that acid sphingomyelinase activity is essential for the induction of ceramide and apoptosis in response to fenretinide.	Fenretinide	158-169	sphingomyelin phosphodiesterase 1	Homo sapiens	55-76
15907365-3	2005	Downstream of ceramide, apoptosis in response to fenretinide is mediated by increased glucosylceramide synthase activity resulting in increased levels of gangliosides GD3 and GD2 via GD3 synthase.	Fenretinide	49-60	UDP-glucose ceramide glucosyltransferase	Homo sapiens	86-111
15907365-3	2005	Downstream of ceramide, apoptosis in response to fenretinide is mediated by increased glucosylceramide synthase activity resulting in increased levels of gangliosides GD3 and GD2 via GD3 synthase.	Fenretinide	49-60	GRDX	Homo sapiens	167-170
15907365-3	2005	Downstream of ceramide, apoptosis in response to fenretinide is mediated by increased glucosylceramide synthase activity resulting in increased levels of gangliosides GD3 and GD2 via GD3 synthase.	Fenretinide	49-60	GRDX	Homo sapiens	183-186
16270382-11	2005	The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.	Fenretinide	18-23	cyclin-dependent kinase inhibitor 1B	Mus musculus	103-107
16270382-11	2005	The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.	Fenretinide	18-23	galactose-3-O-sulfotransferase 1	Mus musculus	132-160
16270382-11	2005	The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.	Fenretinide	18-23	galactose-3-O-sulfotransferase 1	Mus musculus	162-165
16270382-11	2005	The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.	Fenretinide	78-83	cyclin-dependent kinase inhibitor 1B	Mus musculus	99-102
16270382-11	2005	The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.	Fenretinide	78-83	cyclin-dependent kinase inhibitor 1B	Mus musculus	103-107
15700313-0	2005	Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.	Fenretinide	20-31	haptoglobin-related protein	Homo sapiens	35-38
16077929-1	2005	N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that has shown efficacy in cancer chemoprevention and therapy possibly due to its ability to induce growth inhibition and apoptosis in cancer cells.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	32-35
16077929-5	2005	Suppression of endogenous and 4HPR-induced levels of p67phox using small interfering RNA did not result in a change in ROS generation or apoptosis.	Fenretinide	30-34	neutrophil cytosolic factor 2	Homo sapiens	53-60
15894166-3	2005	We investigated the functional role of IB1/JIP-1 in LNCaP cells exposed to the proapoptotic agent N-(4-hydroxyphenyl)retinamide (4-HPR) which induced a reduction of IB1/JIP-1 content and a concomittant increase in JNK activity.	Fenretinide	98-127	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	39-42
15894166-3	2005	We investigated the functional role of IB1/JIP-1 in LNCaP cells exposed to the proapoptotic agent N-(4-hydroxyphenyl)retinamide (4-HPR) which induced a reduction of IB1/JIP-1 content and a concomittant increase in JNK activity.	Fenretinide	98-127	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	43-48
15894166-3	2005	We investigated the functional role of IB1/JIP-1 in LNCaP cells exposed to the proapoptotic agent N-(4-hydroxyphenyl)retinamide (4-HPR) which induced a reduction of IB1/JIP-1 content and a concomittant increase in JNK activity.	Fenretinide	98-127	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	165-168
15894166-3	2005	We investigated the functional role of IB1/JIP-1 in LNCaP cells exposed to the proapoptotic agent N-(4-hydroxyphenyl)retinamide (4-HPR) which induced a reduction of IB1/JIP-1 content and a concomittant increase in JNK activity.	Fenretinide	98-127	mitogen-activated protein kinase 8 interacting protein 1	Homo sapiens	169-174
15894166-3	2005	We investigated the functional role of IB1/JIP-1 in LNCaP cells exposed to the proapoptotic agent N-(4-hydroxyphenyl)retinamide (4-HPR) which induced a reduction of IB1/JIP-1 content and a concomittant increase in JNK activity.	Fenretinide	98-127	mitogen-activated protein kinase 8	Homo sapiens	214-217
15907982-2	2005	The synthetic retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR), has been used in the chemoprevention of ovarian cancer.	Fenretinide	24-54	haptoglobin-related protein	Homo sapiens	58-61
16123139-5	2005	In this article, we investigated the ability of retinoids, such as 9-cis retinoic acid, all-trans retinoic acid, and N-4-hydroxyphenylretinamide (4-HPR), to sensitize the ductal epithelial cells of virgin mammary glands to DNA damage responses.	Fenretinide	117-144	haptoglobin-related protein	Homo sapiens	148-151
16034410-8	2005	Fenretinide, a synthetic retinoid that increases urinary excretion of RBP4, normalizes serum RBP4 levels and improves insulin resistance and glucose intolerance in mice with obesity induced by a high-fat diet.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	70-74
16034410-8	2005	Fenretinide, a synthetic retinoid that increases urinary excretion of RBP4, normalizes serum RBP4 levels and improves insulin resistance and glucose intolerance in mice with obesity induced by a high-fat diet.	Fenretinide	0-11	retinol binding protein 4, plasma	Mus musculus	93-97
15958647-0	2005	The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.	Fenretinide	164-193	growth differentiation factor 15	Homo sapiens	84-116
15958647-7	2005	The inhibition of invasion induced by 4HPR was also associated with decreased activities of the metalloproteases matrix metalloproteinase-2 and CD13/APN.	Fenretinide	38-42	matrix metallopeptidase 2	Homo sapiens	113-139
15958647-7	2005	The inhibition of invasion induced by 4HPR was also associated with decreased activities of the metalloproteases matrix metalloproteinase-2 and CD13/APN.	Fenretinide	38-42	alanyl aminopeptidase, membrane	Homo sapiens	144-148
15958647-7	2005	The inhibition of invasion induced by 4HPR was also associated with decreased activities of the metalloproteases matrix metalloproteinase-2 and CD13/APN.	Fenretinide	38-42	alanyl aminopeptidase, membrane	Homo sapiens	149-152
15958647-10	2005	Blocking antibodies to bone morphogenetic protein-2 were able to reverse the suppressive effects of 4HPR in vitro and in vivo.	Fenretinide	100-104	bone morphogenetic protein 2	Homo sapiens	23-51
15865936-0	2005	Fenretinide: a p53-independent way to kill cancer cells.	Fenretinide	0-11	tumor protein p53	Homo sapiens	15-18
15917187-0	2005	ROS mediates 4HPR-induced posttranscriptional expression of the Gadd153 gene.	Fenretinide	13-17	DNA damage inducible transcript 3	Homo sapiens	64-71
15917187-1	2005	All-trans-N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that can induce apoptosis in many cancer cell lines.	Fenretinide	0-39	haptoglobin-related protein	Homo sapiens	42-45
15917187-4	2005	In 4HPR-treated cells, the elevation of Gadd153 protein level was prevented by vitamin C, which had no effect on the activation of the Gadd153 gene promoter.	Fenretinide	3-7	DNA damage inducible transcript 3	Homo sapiens	40-47
15917187-8	2005	The inhibition of 4HPR-induced expression of Gadd153 protein by vitamin C was independent of intracellular proteasome activity and vitamin C had no effect on the intracellular decay of Gadd153 protein.	Fenretinide	18-22	DNA damage inducible transcript 3	Homo sapiens	45-52
15865936-4	2005	Increased evidence suggests that the apoptotic pathway activated by fenretinide is p53-independent and this may represent a novel way to treat tumors resistant to DNA-damaging chemotherapeutic agents.	Fenretinide	68-79	tumor protein p53	Homo sapiens	83-86
15756035-1	2005	PURPOSE: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models.	Fenretinide	9-20	haptoglobin-related protein	Homo sapiens	24-27
16124896-1	2005	OBJECTIVE: To study the mechanism of the apoptosis induced by N-[4-hydroxyphenyl] retinamide (4-HPR) in bladder cancer cell line T24, and the involvement of DNA damage and repair.	Fenretinide	62-92	haptoglobin-related protein	Homo sapiens	96-99
16158929-1	2005	BACKGROUND: We have previously demonstrated that the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) induces the overproduction of reactive oxygen species (ROS) in human leukemia cells, which in turn triggers the intrinsic (mitochondrial) apoptotic pathway.	Fenretinide	72-102	haptoglobin-related protein	Homo sapiens	106-109
15695235-0	2005	N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.	Fenretinide	0-29	BRCA1 DNA repair associated	Homo sapiens	102-107
15695235-2	2005	The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have a clinical chemopreventive activity in patients with premenopausal breast cancer.	Fenretinide	23-52	haptoglobin-related protein	Homo sapiens	56-59
15909111-1	2005	Fenretinide induces apoptosis in SH-SY5Y neuroblastoma cells via a signaling pathway involving the production of reactive oxygen species (ROS), 12-lipoxygenase activity and the induction of the GADD153 transcription factor.	Fenretinide	0-11	DNA damage inducible transcript 3	Homo sapiens	194-201
15909111-4	2005	The aim of this study was to test the hypothesis that NF-kappa B activity mediates fenretinide-induced apoptosis in SH-SY5Y neuroblastoma cells.	Fenretinide	83-94	nuclear factor kappa B subunit 1	Homo sapiens	54-64
15909111-6	2005	In parental SH-SY5Y cells, fenretinide induced NF-kappa B activity and Ikappa Balpha phosphorylation.	Fenretinide	27-38	nuclear factor kappa B subunit 1	Homo sapiens	47-57
15909111-7	2005	These results suggest that NF-kappa B activity links fenretinide-induced ROS to the induction of apoptosis in SH-SH5Y cells, and may be a target for the future development of drugs for neuroblastoma therapy.	Fenretinide	53-64	nuclear factor kappa B subunit 1	Homo sapiens	27-37
15837770-0	2005	p38MAPK-Dependent sensitivity of Ewing"s sarcoma family of tumors to fenretinide-induced cell death.	Fenretinide	69-80	mitogen-activated protein kinase 14	Mus musculus	0-7
15837770-4	2005	The role of the stress-activated kinases p38(MAPK) and c-Jun NH(2)-terminal kinase in fenretinide-induced death was investigated by Western blot and inhibitor experiments.	Fenretinide	86-97	mitogen-activated protein kinase 14	Mus musculus	41-44
15837770-9	2005	p38(MAPK) was activated within 15 minutes of fenretinide treatment and was dependent on ROS accumulation.	Fenretinide	45-56	mitogen-activated protein kinase 14	Mus musculus	0-3
15837770-10	2005	Inhibition of p38(MAPK) activity partially rescued fenretinide-mediated cell death in ESFT but not in SH-SY5Y neuroblastoma cells.	Fenretinide	51-62	mitogen-activated protein kinase 14	Homo sapiens	14-17
15837770-12	2005	After 8 hours, fenretinide induced mitochondrial depolarization (Deltapsi(m)) and release of cytochrome c into the cytoplasm in a ROS- and p38(MAPK)-dependent manner.	Fenretinide	15-26	mitogen-activated protein kinase 14	Mus musculus	139-142
15837770-13	2005	CONCLUSIONS: These data show that the high sensitivity of ESFT cells to fenretinide is dependent in part on the rapid and sustained activation of p38(MAPK).	Fenretinide	72-83	mitogen-activated protein kinase 14	Mus musculus	146-149
15735044-6	2005	Fenretinide treatment also increased levels of the death receptor DR5 and caused mitochondrial membrane depolarization.	Fenretinide	0-11	TNF receptor superfamily member 10b	Homo sapiens	66-69
15735044-7	2005	The levels of the retinoid receptors, retinoic acid receptor alpha and retinoid X receptor gamma, were up-regulated in response to fenretinide, suggestive of ligand-induced receptor up-regulation.	Fenretinide	131-142	retinoic acid receptor alpha	Homo sapiens	38-66
15735044-7	2005	The levels of the retinoid receptors, retinoic acid receptor alpha and retinoid X receptor gamma, were up-regulated in response to fenretinide, suggestive of ligand-induced receptor up-regulation.	Fenretinide	131-142	retinoid X receptor gamma	Homo sapiens	71-96
15735044-8	2005	IGF-I-induced proliferation in the meningioma cells was abolished by fenretinide.	Fenretinide	69-80	insulin like growth factor 1	Homo sapiens	0-5
15735044-9	2005	We conclude that fenretinide induces apoptosis in all three histologic subtypes of meningioma and exerts diverse cellular effects, including DR5 up-regulation, modulation of retinoid receptor levels, and inhibition of IGF-I-induced proliferation.	Fenretinide	17-28	TNF receptor superfamily member 10b	Homo sapiens	141-144
15735044-9	2005	We conclude that fenretinide induces apoptosis in all three histologic subtypes of meningioma and exerts diverse cellular effects, including DR5 up-regulation, modulation of retinoid receptor levels, and inhibition of IGF-I-induced proliferation.	Fenretinide	17-28	insulin like growth factor 1	Homo sapiens	218-223
15498786-0	2005	Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis.	Fenretinide	16-45	methionine adenosyltransferase 1A	Rattus norvegicus	96-101
15498786-0	2005	Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-{kappa}B and Mat1A genes in the early stages of rat liver carcinogenesis.	Fenretinide	47-58	methionine adenosyltransferase 1A	Rattus norvegicus	96-101
15650234-2	2004	Fenretinide-induced cell death of neuroblastoma cells is caspase dependent and results in the release of cytochrome c from mitochondria independently of changes in permeability transition.	Fenretinide	0-11	cytochrome c, somatic	Homo sapiens	105-117
15862961-0	2005	Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production.	Fenretinide	69-99	haptoglobin-related protein	Homo sapiens	102-105
15816545-0	2005	Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells.	Fenretinide	10-21	haptoglobin-related protein	Homo sapiens	25-28
15816545-1	2005	BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid that has been reported to inhibit the growth of cancer cell lines in vitro.	Fenretinide	12-23	haptoglobin-related protein	Homo sapiens	27-30
15816545-8	2005	In OVCAR-5 cells treated with 1 mM fenretinide for 3 days, actin cytoskeleton stress fibers were disrupted and FAK tyrosine phosphorylation was elevated dose-dependently.	Fenretinide	35-46	protein tyrosine kinase 2	Homo sapiens	111-114
15816545-10	2005	CONCLUSION: Fenretinide has anti-tumor activity by acting on the actin cytoskeleton and by regulating FAK tyrosine phosphorylation.	Fenretinide	12-23	protein tyrosine kinase 2	Homo sapiens	102-105
15862961-2	2005	Recent studies on aromatase inhibition by the synthetic retinoid 4HPR, also known as fenretinide, and the PPARgamma agonist 15-dPGJ(2) have implicated a direct receptor-independent, redox-sensitive mechanism of action.	Fenretinide	85-96	haptoglobin-related protein	Homo sapiens	66-69
15650234-4	2004	Upstream events of fenretinide-induced signaling involve increased levels of ceramide as a result of increased sphingomyelinase activity, and the subsequent metabolism of ceramide to gangliosides via glucosylceramide synthase and GD3 synthase.	Fenretinide	19-30	UDP-glucose ceramide glucosyltransferase	Homo sapiens	200-225
15650242-5	2004	In addition, the apoptotic agent fenretinide (4HPR) and interferon-gamma (IFN-gamma) induce caspase-8 expression without modifying the methylation status of this gene.	Fenretinide	33-44	caspase 8	Homo sapiens	92-101
15650242-5	2004	In addition, the apoptotic agent fenretinide (4HPR) and interferon-gamma (IFN-gamma) induce caspase-8 expression without modifying the methylation status of this gene.	Fenretinide	46-50	caspase 8	Homo sapiens	92-101
15352033-5	2004	In the present study, fenretinide induced sustained-activation of both JNK and p38 MAPK in neuroblastoma cells.	Fenretinide	22-33	mitogen-activated protein kinase 8	Homo sapiens	71-74
15352033-0	2004	Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells.	Fenretinide	0-11	mitogen-activated protein kinase 8	Homo sapiens	44-47
15352033-5	2004	In the present study, fenretinide induced sustained-activation of both JNK and p38 MAPK in neuroblastoma cells.	Fenretinide	22-33	mitogen-activated protein kinase 14	Homo sapiens	79-82
15352033-0	2004	Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells.	Fenretinide	0-11	mitogen-activated protein kinase 14	Homo sapiens	48-51
15352033-6	2004	Pretreatment with the antioxidant L-ascorbic acid almost completely inhibited the accumulation of fenretinide-induced intracellular reactive oxygen species (ROS), activation of JNK and p38 MAPK and apoptosis.	Fenretinide	98-109	mitogen-activated protein kinase 8	Homo sapiens	177-180
15352033-6	2004	Pretreatment with the antioxidant L-ascorbic acid almost completely inhibited the accumulation of fenretinide-induced intracellular reactive oxygen species (ROS), activation of JNK and p38 MAPK and apoptosis.	Fenretinide	98-109	mitogen-activated protein kinase 14	Homo sapiens	185-188
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	52-63	mitogen-activated protein kinase 8	Homo sapiens	96-99
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	52-63	mitogen-activated protein kinase 14	Homo sapiens	104-107
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	52-63	mitogen-activated protein kinase 8	Homo sapiens	159-162
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	52-63	mitogen-activated protein kinase 14	Homo sapiens	167-170
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	200-211	mitogen-activated protein kinase 8	Homo sapiens	159-162
15352033-8	2004	Our study demonstrates that in neuroblastoma cells, fenretinide induces sustained-activation of JNK and p38 MAPK in an ROS-dependent manner and indicates that JNK and p38 MAPK signaling might mediate fenretinide-induced apoptosis.	Fenretinide	200-211	mitogen-activated protein kinase 14	Homo sapiens	167-170
15352033-9	2004	Our results also indicate that suppression of the fenretinide-induced ROS productive system and the downstream JNK and p38 MAPK signaling pathways causes neuroblastoma cells to become resistant to fenretinide.	Fenretinide	50-61	mitogen-activated protein kinase 14	Homo sapiens	119-122
15375546-7	2004	All-trans retinoic acid (atRA), 9-cis retinoic acid (9cRA), and 4-(hydroxyphenyl) retinamide (4-HPR) induced RARbeta2 protein expression exclusively in the benign MCF10A cells and the former two retinoids, mRNA expression in MCF10A and MCF10AT cells, but not in malignant, MCF10CA1a cells, suggesting that the loss of inducible RARbeta expression is associated with the progression and malignant transformation of MCF10A cells.	Fenretinide	64-92	haptoglobin-related protein	Homo sapiens	96-99
15375546-7	2004	All-trans retinoic acid (atRA), 9-cis retinoic acid (9cRA), and 4-(hydroxyphenyl) retinamide (4-HPR) induced RARbeta2 protein expression exclusively in the benign MCF10A cells and the former two retinoids, mRNA expression in MCF10A and MCF10AT cells, but not in malignant, MCF10CA1a cells, suggesting that the loss of inducible RARbeta expression is associated with the progression and malignant transformation of MCF10A cells.	Fenretinide	64-92	retinoic acid receptor beta	Homo sapiens	109-116
15289350-2	2004	We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse.	Fenretinide	83-113	haptoglobin-related protein	Homo sapiens	117-120
15448016-0	2004	Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.	Fenretinide	22-33	cytochrome P450 family 26 subfamily A member 1	Homo sapiens	152-172
15448016-1	2004	PURPOSE: The synthetic retinoid fenretinide (4-HPR) exhibits preventive and therapeutic activity against ovarian tumors.	Fenretinide	32-43	haptoglobin-related protein	Homo sapiens	47-50
15339967-7	2004	RESULTS: In neuroblastoma cells, ROS generation and apoptosis were associated with fenretinide-induced increased levels of ceramide, glucosylceramide synthase activity, GD3 synthase activity, and GD3.	Fenretinide	83-94	UDP-glucose ceramide glucosyltransferase	Homo sapiens	133-158
15339967-7	2004	RESULTS: In neuroblastoma cells, ROS generation and apoptosis were associated with fenretinide-induced increased levels of ceramide, glucosylceramide synthase activity, GD3 synthase activity, and GD3.	Fenretinide	83-94	GRDX	Homo sapiens	169-172
15339967-7	2004	RESULTS: In neuroblastoma cells, ROS generation and apoptosis were associated with fenretinide-induced increased levels of ceramide, glucosylceramide synthase activity, GD3 synthase activity, and GD3.	Fenretinide	83-94	GRDX	Homo sapiens	196-199
15339967-8	2004	Fenretinide also induced increased levels of GD2, a ganglioside derived from GD3.	Fenretinide	0-11	GRDX	Homo sapiens	77-80
15339967-12	2004	CONCLUSIONS: A novel pathway of fenretinide-induced apoptosis is mediated by acidic sphingomyelinase, glucosylceramide synthase, and GD3 synthase, which may represent targets for future drug development.	Fenretinide	32-43	UDP-glucose ceramide glucosyltransferase	Homo sapiens	102-127
15339967-12	2004	CONCLUSIONS: A novel pathway of fenretinide-induced apoptosis is mediated by acidic sphingomyelinase, glucosylceramide synthase, and GD3 synthase, which may represent targets for future drug development.	Fenretinide	32-43	GRDX	Homo sapiens	133-136
15289350-2	2004	We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse.	Fenretinide	122-133	haptoglobin-related protein	Homo sapiens	117-120
15240527-8	2004	Fenretinide decreased IGFBP-3 relative to placebo (P = 0.04).	Fenretinide	0-11	insulin like growth factor binding protein 3	Homo sapiens	22-29
15297165-1	2004	OBJECTIVE: This trial examined the use of 4-hydroxyphenyl-retinamide (4-HPR), demonstrated to be a potent inhibitor of carcinogenesis in vitro and in animal models, in patients with cervical intraepithelial neoplasia (CIN) grades 2 to 3.	Fenretinide	42-68	haptoglobin-related protein	Homo sapiens	72-75
14765134-0	2004	N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	33-36
15326375-0	2004	Inhibition of N-(4-hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3.	Fenretinide	14-43	galectin 3	Homo sapiens	88-98
15326375-6	2004	4HPR-induced apoptosis in these cells was associated with stimulation of reactive oxygen species generation, decreased levels of Bcl-2 protein, release of cytochrome c into the cytosol, increased caspase-3 activity, and poly(ADP-ribose) polymerase cleavage.	Fenretinide	0-4	BCL2 apoptosis regulator	Homo sapiens	129-134
15326375-6	2004	4HPR-induced apoptosis in these cells was associated with stimulation of reactive oxygen species generation, decreased levels of Bcl-2 protein, release of cytochrome c into the cytosol, increased caspase-3 activity, and poly(ADP-ribose) polymerase cleavage.	Fenretinide	0-4	cytochrome c, somatic	Homo sapiens	155-167
15326375-6	2004	4HPR-induced apoptosis in these cells was associated with stimulation of reactive oxygen species generation, decreased levels of Bcl-2 protein, release of cytochrome c into the cytosol, increased caspase-3 activity, and poly(ADP-ribose) polymerase cleavage.	Fenretinide	0-4	caspase 3	Homo sapiens	196-205
14765134-0	2004	N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.	Fenretinide	0-30	TNF superfamily member 10	Homo sapiens	47-52
15326375-8	2004	The demonstration that galectin-3 suppresses 4HPR-induced apoptosis in human breast carcinoma cells suggests that the increased expression of galectin-3 during cancer progression may be associated with 4HPR resistance.	Fenretinide	45-49	galectin 3	Homo sapiens	23-33
15326375-8	2004	The demonstration that galectin-3 suppresses 4HPR-induced apoptosis in human breast carcinoma cells suggests that the increased expression of galectin-3 during cancer progression may be associated with 4HPR resistance.	Fenretinide	45-49	galectin 3	Homo sapiens	142-152
15326375-8	2004	The demonstration that galectin-3 suppresses 4HPR-induced apoptosis in human breast carcinoma cells suggests that the increased expression of galectin-3 during cancer progression may be associated with 4HPR resistance.	Fenretinide	202-206	galectin 3	Homo sapiens	23-33
15326375-8	2004	The demonstration that galectin-3 suppresses 4HPR-induced apoptosis in human breast carcinoma cells suggests that the increased expression of galectin-3 during cancer progression may be associated with 4HPR resistance.	Fenretinide	202-206	galectin 3	Homo sapiens	142-152
15133197-1	2004	Retinoic acid and its amide derivative, N-(4-hydroxyphenyl)retinamide (4-HPR), have been proposed as chemopreventative and chemotherapeutic agents.	Fenretinide	40-69	haptoglobin-related protein	Homo sapiens	73-76
14765134-2	2004	Subtoxic concentrations of the semisynthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) enhanced TRAIL-mediated apoptosis in ovarian cancer cell lines but not in immortalized nontumorigenic ovarian epithelial cells.	Fenretinide	54-83	TNF superfamily member 10	Homo sapiens	100-105
14765134-2	2004	Subtoxic concentrations of the semisynthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) enhanced TRAIL-mediated apoptosis in ovarian cancer cell lines but not in immortalized nontumorigenic ovarian epithelial cells.	Fenretinide	85-89	TNF superfamily member 10	Homo sapiens	100-105
14647238-0	2004	Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells.	Fenretinide	24-35	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-20
15291358-1	2004	N-(4-hydroxyphenyl) retinamide (Fenretinide, 4-HPR) inhibits cell growth by inducing apoptosis in numerous tumor cell types including all-trans-retinoic acid (ATRA)-resistant tumor cells.	Fenretinide	0-30	haptoglobin-related protein	Homo sapiens	47-50
15291358-1	2004	N-(4-hydroxyphenyl) retinamide (Fenretinide, 4-HPR) inhibits cell growth by inducing apoptosis in numerous tumor cell types including all-trans-retinoic acid (ATRA)-resistant tumor cells.	Fenretinide	32-43	haptoglobin-related protein	Homo sapiens	47-50
15013522-5	2004	Several anticancer agents, including the cytotoxic retinoid, fenretinide (4-HPR), have been shown to act, at least in part, by increasing tumor cell ceramide via de novo synthesis.	Fenretinide	61-72	haptoglobin-related protein	Homo sapiens	76-79
14647238-1	2004	Fenretinide (HPR), a synthetic retinoid that exhibits lower toxicity than other retinoids, has shown preventive and therapeutic activity against ovarian tumors.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	13-16
14767528-4	2004	Like RA, 4-hydroxyphenyl retinamide (4-HPR) and 4-APRE, 4-BPRE was an active ligand for all three subtypes of RAR, but not for RXR, as determined by transcription assays in COS-1 cells.	Fenretinide	9-35	haptoglobin-related protein	Homo sapiens	39-42
14735468-1	2004	Fenretinide, 4-(N-hydroxyphenyl) retinamide (4-HPR), has demonstrated anticancer activity associated with a favorable toxicity profile and is now being investigated in several clinical trials.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	47-50
14973114-2	2004	We show that HER2/neu uses Akt to induce cyclooxygenase-2 (COX-2) expression and that inhibition of Akt or COX-2 increases 4-HPR-induced apoptosis and nitric oxide production.	Fenretinide	123-128	erb-b2 receptor tyrosine kinase 2	Homo sapiens	13-21
14973114-2	2004	We show that HER2/neu uses Akt to induce cyclooxygenase-2 (COX-2) expression and that inhibition of Akt or COX-2 increases 4-HPR-induced apoptosis and nitric oxide production.	Fenretinide	123-128	AKT serine/threonine kinase 1	Homo sapiens	100-103
14973114-0	2004	Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.	Fenretinide	55-85	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
14973114-0	2004	Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.	Fenretinide	55-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	34-38
14973114-2	2004	We show that HER2/neu uses Akt to induce cyclooxygenase-2 (COX-2) expression and that inhibition of Akt or COX-2 increases 4-HPR-induced apoptosis and nitric oxide production.	Fenretinide	123-128	prostaglandin-endoperoxide synthase 2	Homo sapiens	107-112
14973114-0	2004	Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.	Fenretinide	55-85	erb-b2 receptor tyrosine kinase 2	Homo sapiens	39-42
14645667-2	2003	The stress-inducible transcription factor known as growth and DNA damage (GADD)-inducible transcription factor 153 is induced in response to fenretinide and in other cell types modulates apoptosis via pro- and antiapoptotic members of the BCL2 family.	Fenretinide	141-152	BCL2 apoptosis regulator	Homo sapiens	239-243
14973114-1	2004	We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production.	Fenretinide	76-105	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-25
14973114-1	2004	We reported that HER2/neu reduces the sensitivity of breast cancer cells to N-(4-hydroxyphenyl)retinamide (4-HPR) by suppressing nitric oxide production.	Fenretinide	107-112	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-25
14680805-3	2003	Treatment of the antisense BAG-1-transfected cells with the anti-cancer drugs staurosporine, paclitaxel, all-trans retinoic acid (ATRA), and N-(4-hydroxyphenyl) retinamide (4-HPR) resulted in significantly enhanced apoptosis and reduced cell viability relative to vector-transfected cells.	Fenretinide	141-171	BAG cochaperone 1	Homo sapiens	27-32
14645674-0	2003	Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.	Fenretinide	35-46	caspase 8	Homo sapiens	22-31
14645674-4	2003	Transient transfection of cDNA-encoding cytokine response modifier A (CrmA), a caspase-8 inhibitor, diminished fenretinide-induced death in OV177 cells.	Fenretinide	111-122	caspase 8	Homo sapiens	79-88
14645667-3	2003	Because BCL2-family proteins are important in apoptosis induced by chemotherapeutic drugs, GADD153 may be a key mediator of synergy between fenretinide and chemotherapeutic drugs.	Fenretinide	140-151	BCL2 apoptosis regulator	Homo sapiens	8-12
14645674-6	2003	Further analysis demonstrated that inhibition of Fas ligand, tumor necrosis factor-alpha, or TRAIL signaling with blocking reagents did not affect fenretinide-induced apoptosis, raising the possibility that fenretinide activates caspase-8 in a death receptor-independent manner.	Fenretinide	207-218	caspase 8	Homo sapiens	229-238
14645667-3	2003	Because BCL2-family proteins are important in apoptosis induced by chemotherapeutic drugs, GADD153 may be a key mediator of synergy between fenretinide and chemotherapeutic drugs.	Fenretinide	140-151	DNA damage inducible transcript 3	Homo sapiens	91-98
14645674-9	2003	Similarly, fenretinide treatment increased ceramide levels equally in cells that do (OV177) and do not (OV202) rely on caspase-8 to initiate apoptosis.	Fenretinide	11-22	caspase 8	Homo sapiens	119-128
14645667-5	2003	Increased expression of GADD153 raised the background level of apoptosis and increased apoptosis induced by fenretinide or the chemotherapeutic drugs cisplatin and etoposide.	Fenretinide	108-119	DNA damage inducible transcript 3	Homo sapiens	24-31
14645667-7	2003	Conversely, expression of antisense-GADD153 virtually abolished the induction of apoptosis in response to fenretinide but overall had no significant effect on apoptosis induced by chemotherapeutic drugs.	Fenretinide	106-117	DNA damage inducible transcript 3	Homo sapiens	36-43
14645667-8	2003	The effect of antisense-GADD153 on synergy between chemotherapeutic drugs and fenretinide varied with the drug used: there was no effect on synergy between fenretinide and cisplatin, but the combination of fenretinide with etoposide became antagonistic.	Fenretinide	78-89	DNA damage inducible transcript 3	Homo sapiens	24-31
14645667-9	2003	These results suggest that mechanisms mediating synergy between fenretinide and chemotherapeutic drugs lie upstream of GADD153.	Fenretinide	64-75	DNA damage inducible transcript 3	Homo sapiens	119-126
14724932-7	2003	Although the mechanism of 4-HPR effects was not very clear, over expression of CST, which was inhibited by 4-HPR in our previous study, could diminish the apoptosis--inducing effect by 4-HPR.	Fenretinide	26-31	cortistatin	Mus musculus	79-82
14592467-1	2003	The retinamide, N-(4-hydroxyphenyl)retinamide (4-HPR), has shown promising anti-tumor activity, but it is unclear whether this compound is hydrolyzed to all-trans retinoic acid (atRA) and if so, whether this plays any role in its chemotherapeutic activity.	Fenretinide	16-45	haptoglobin-related protein	Homo sapiens	49-52
14555987-0	2003	HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.	Fenretinide	42-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	0-8
14649406-1	2003	Effects of two natural (retinol and retinoic acid, RA) and one synthetic N-(4-hydroxyphenyl) retinamide (4-HPR) retinoids on proliferation and expression of urokinase-plasminogen activator (u-PA) by bovine mammary epithelial cells were examined.	Fenretinide	73-103	plasminogen activator, urokinase	Bos taurus	157-188
14649406-1	2003	Effects of two natural (retinol and retinoic acid, RA) and one synthetic N-(4-hydroxyphenyl) retinamide (4-HPR) retinoids on proliferation and expression of urokinase-plasminogen activator (u-PA) by bovine mammary epithelial cells were examined.	Fenretinide	73-103	plasminogen activator, urokinase	Bos taurus	190-194
14649406-1	2003	Effects of two natural (retinol and retinoic acid, RA) and one synthetic N-(4-hydroxyphenyl) retinamide (4-HPR) retinoids on proliferation and expression of urokinase-plasminogen activator (u-PA) by bovine mammary epithelial cells were examined.	Fenretinide	105-110	plasminogen activator, urokinase	Bos taurus	157-188
14581342-0	2003	Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.	Fenretinide	162-173	insulin like growth factor 1	Homo sapiens	29-57
14581342-6	2003	Fenretinide induced reductions of IGF-I, IGFBP-3, and IGF-I:IGFBP-3 of 8% (95% CI, 2-12%; P = 0.004), 3% (95% CI, 1-5%; P = 0.002), and 5% (95% CI, 0-10%; P = 0.050), respectively.	Fenretinide	0-11	insulin like growth factor 1	Homo sapiens	34-39
14581342-6	2003	Fenretinide induced reductions of IGF-I, IGFBP-3, and IGF-I:IGFBP-3 of 8% (95% CI, 2-12%; P = 0.004), 3% (95% CI, 1-5%; P = 0.002), and 5% (95% CI, 0-10%; P = 0.050), respectively.	Fenretinide	0-11	insulin like growth factor binding protein 3	Homo sapiens	41-48
14581342-6	2003	Fenretinide induced reductions of IGF-I, IGFBP-3, and IGF-I:IGFBP-3 of 8% (95% CI, 2-12%; P = 0.004), 3% (95% CI, 1-5%; P = 0.002), and 5% (95% CI, 0-10%; P = 0.050), respectively.	Fenretinide	0-11	insulin like growth factor 1	Homo sapiens	54-59
14581342-6	2003	Fenretinide induced reductions of IGF-I, IGFBP-3, and IGF-I:IGFBP-3 of 8% (95% CI, 2-12%; P = 0.004), 3% (95% CI, 1-5%; P = 0.002), and 5% (95% CI, 0-10%; P = 0.050), respectively.	Fenretinide	0-11	insulin like growth factor binding protein 3	Homo sapiens	60-67
14581342-9	2003	CONCLUSIONS: Fenretinide induced a moderate reduction of IGF-I, which marginally explains observed cancer risk reductions in women </=50 years of age.	Fenretinide	13-24	insulin like growth factor 1	Homo sapiens	57-62
14519946-1	2003	4-(N-Hydroxyphenyl)retinamide (also known as 4-HPR or fenretinide), a synthetic amide of all-trans retinoic acid (RA), has been implicated as a promising anticancer agent associated with reducing the toxicity related to RA.	Fenretinide	54-65	haptoglobin-related protein	Homo sapiens	47-50
14555987-0	2003	HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.	Fenretinide	42-71	haptoglobin-related protein	Homo sapiens	75-78
14555987-1	2003	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	46-49
14555987-1	2003	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells.	Fenretinide	64-75	haptoglobin-related protein	Homo sapiens	46-49
13679861-0	2003	The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 family.	Fenretinide	26-55	BCL2 apoptosis regulator	Homo sapiens	137-142
13679861-1	2003	N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction.	Fenretinide	38-49	haptoglobin-related protein	Homo sapiens	33-36
14604280-0	2003	N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
14604280-1	2003	The role of reactive oxygen species (ROS) in the cytotoxicity of N-(4-hydroxyphenyl)retinamide (4-HPR) was studied with use of the B-precursor lymphoblastic leukemia cell line YCUB-2.	Fenretinide	65-94	haptoglobin-related protein	Homo sapiens	98-101
13679861-1	2003	N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
12939601-3	2003	Previously, we observed that a synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) effectively impaired cell growth and survival (induction of growth arrest and apoptosis) in human hepatoma cells, which was accompanied by over expression of GADD153.	Fenretinide	50-79	DNA damage inducible transcript 3	Homo sapiens	245-252
12939601-3	2003	Previously, we observed that a synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) effectively impaired cell growth and survival (induction of growth arrest and apoptosis) in human hepatoma cells, which was accompanied by over expression of GADD153.	Fenretinide	81-85	DNA damage inducible transcript 3	Homo sapiens	245-252
12873973-2	2003	GCS inhibition, by both antisense and the specific inhibitor (D-threo)-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), results in a drastic decrease of apoptosis induced by the p53-independent chemotherapeutic agent N-(4-hydroxyphenyl)retinamide in neuroepithelioma cells.	Fenretinide	225-254	UDP-glucose ceramide glucosyltransferase	Homo sapiens	0-3
12880976-0	2003	Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma.	Fenretinide	57-68	DNA damage inducible transcript 3	Homo sapiens	13-20
12880976-0	2003	Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma.	Fenretinide	57-68	BCL2 antagonist/killer 1	Homo sapiens	25-28
12880976-2	2003	The stress-induced transcription factor GADD153 and the Bcl2-related protein Bak are upregulated in response to fenretinide.	Fenretinide	112-123	DNA damage inducible transcript 3	Homo sapiens	40-47
12880976-2	2003	The stress-induced transcription factor GADD153 and the Bcl2-related protein Bak are upregulated in response to fenretinide.	Fenretinide	112-123	BCL2 antagonist/killer 1	Homo sapiens	77-80
12880976-5	2003	Neither GADD153 or Bak were induced by chemotherapeutic agents but over expression of GADD153 results in increased sensitivity to fenretinide-induced apoptosis.	Fenretinide	130-141	DNA damage inducible transcript 3	Homo sapiens	86-93
12880976-6	2003	Therefore, fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterised by the reactive oxygen species-dependent induction of GADD153 and Bak.	Fenretinide	11-22	retinoic acid receptor alpha	Homo sapiens	45-48
12880976-6	2003	Therefore, fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterised by the reactive oxygen species-dependent induction of GADD153 and Bak.	Fenretinide	11-22	retinoic acid receptor alpha	Homo sapiens	98-101
12880976-6	2003	Therefore, fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterised by the reactive oxygen species-dependent induction of GADD153 and Bak.	Fenretinide	11-22	DNA damage inducible transcript 3	Homo sapiens	193-200
12880976-6	2003	Therefore, fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterised by the reactive oxygen species-dependent induction of GADD153 and Bak.	Fenretinide	11-22	BCL2 antagonist/killer 1	Homo sapiens	205-208
12880980-1	2003	Retinoids are derivatives of vitamin A that include all trans-retinoic acid (ATRA), 13-cis-retinoic acid, (13-cis-RA), and fenretinide (4-HPR).	Fenretinide	123-134	haptoglobin-related protein	Homo sapiens	138-141
12843642-1	2003	Retinoic acid (RA), a potent inducer of cell differentiation, and N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), a potent inducer of apoptosis, are well known as anticancer agents that are administered orally to patients for leukemia, breast and prostate cancer, respectively.	Fenretinide	66-95	haptoglobin-related protein	Homo sapiens	99-102
12843642-1	2003	Retinoic acid (RA), a potent inducer of cell differentiation, and N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), a potent inducer of apoptosis, are well known as anticancer agents that are administered orally to patients for leukemia, breast and prostate cancer, respectively.	Fenretinide	104-115	haptoglobin-related protein	Homo sapiens	99-102
12815470-0	2003	Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation.	Fenretinide	0-11	cytochrome c, somatic	Homo sapiens	20-32
12815470-0	2003	Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation.	Fenretinide	0-11	caspase 9	Homo sapiens	42-51
12736045-6	2003	RESULTS: LNCaP cells were five times more sensitive to N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid, compared with PC-3 cells.	Fenretinide	55-84	haptoglobin-related protein	Homo sapiens	88-91
12855611-1	2003	PURPOSE: The synthetic retinoid N-(4-hydroxyphenyl)retinamide [4-HPR (or fenretinide)] has preclinical and clinical preventive activity in breast carcinogenesis.	Fenretinide	32-61	haptoglobin-related protein	Homo sapiens	65-68
12855611-1	2003	PURPOSE: The synthetic retinoid N-(4-hydroxyphenyl)retinamide [4-HPR (or fenretinide)] has preclinical and clinical preventive activity in breast carcinogenesis.	Fenretinide	73-84	haptoglobin-related protein	Homo sapiens	65-68
12792755-0	2003	Induction of apoptosis by fenretinide in tumor cell lines correlates with DLX2, DLX3 and DLX4 gene expression.	Fenretinide	26-37	distal-less homeobox 2	Homo sapiens	74-78
12792755-0	2003	Induction of apoptosis by fenretinide in tumor cell lines correlates with DLX2, DLX3 and DLX4 gene expression.	Fenretinide	26-37	distal-less homeobox 3	Homo sapiens	80-84
12792755-0	2003	Induction of apoptosis by fenretinide in tumor cell lines correlates with DLX2, DLX3 and DLX4 gene expression.	Fenretinide	26-37	distal-less homeobox 4	Homo sapiens	89-93
12796365-1	2003	PURPOSE: Fenretinide (4HPR), a synthetic retinoid, induces apoptosis in neuroblastoma cells.	Fenretinide	9-20	haptoglobin-related protein	Homo sapiens	23-26
12738746-0	2003	Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide.	Fenretinide	59-70	cyclin D1	Homo sapiens	0-9
12738746-1	2003	PURPOSE: Fenretinide has shown promise in the chemoprevention of breast cancer, a tumor type in which the oncogene cyclin D1 is overexpressed frequently.	Fenretinide	9-20	cyclin D1	Homo sapiens	115-124
12738746-2	2003	We aimed at determining the effect of cyclin D1 level on the response to fenretinide treatment.	Fenretinide	73-84	cyclin D1	Homo sapiens	38-47
12738746-4	2003	RESULTS: We show here that cells overexpressing cyclin D1 are significantly more sensitive to fenretinide than genetically matched cells that express low levels of cyclin D1, and that fenretinide prevents tumor formation arising from cyclin D1-overexpressing cells.	Fenretinide	94-105	cyclin D1	Homo sapiens	48-57
12738746-4	2003	RESULTS: We show here that cells overexpressing cyclin D1 are significantly more sensitive to fenretinide than genetically matched cells that express low levels of cyclin D1, and that fenretinide prevents tumor formation arising from cyclin D1-overexpressing cells.	Fenretinide	184-195	cyclin D1	Homo sapiens	48-57
12738746-4	2003	RESULTS: We show here that cells overexpressing cyclin D1 are significantly more sensitive to fenretinide than genetically matched cells that express low levels of cyclin D1, and that fenretinide prevents tumor formation arising from cyclin D1-overexpressing cells.	Fenretinide	184-195	cyclin D1	Homo sapiens	164-173
12738746-4	2003	RESULTS: We show here that cells overexpressing cyclin D1 are significantly more sensitive to fenretinide than genetically matched cells that express low levels of cyclin D1, and that fenretinide prevents tumor formation arising from cyclin D1-overexpressing cells.	Fenretinide	184-195	cyclin D1	Homo sapiens	164-173
12738746-5	2003	Furthermore, we show that fenretinide is also able to promote the regression of cyclin D1-positive tumors.	Fenretinide	26-37	cyclin D1	Homo sapiens	80-89
12738746-6	2003	We also show that cells expressing a mutant of cyclin D1 that cannot bind to cdk4 are also more sensitive to fenretinide.	Fenretinide	109-120	cyclin D1	Homo sapiens	47-56
12738746-7	2003	CONCLUSIONS: These results suggest that fenretinide may be particularly useful in the treatment of cyclin D1-positive breast cancers, and that the interaction between cyclin D1 and fenretinide is independent of cyclin D1 binding to cdk4.	Fenretinide	40-51	cyclin D1	Homo sapiens	99-108
12619033-2	2003	We investigated the influence of androgen stimulation with testosterone on N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis in the androgen-sensitive prostate cancer cell line LNCaP.	Fenretinide	75-104	haptoglobin-related protein	Homo sapiens	108-111
12619033-0	2003	Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis.	Fenretinide	63-92	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-20
12537979-0	2003	N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).	Fenretinide	32-43	haptoglobin-related protein	Homo sapiens	47-50
12537979-2	2003	N-(4-Hydroxyphenyl)-all-trans-retinamide (fenretinide, 4-HPR) is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid leukemia.	Fenretinide	0-40	haptoglobin-related protein	Homo sapiens	57-60
12537979-2	2003	N-(4-Hydroxyphenyl)-all-trans-retinamide (fenretinide, 4-HPR) is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid leukemia.	Fenretinide	42-53	haptoglobin-related protein	Homo sapiens	57-60
12540501-1	2003	OBJECTIVES: To assess, in women participating in a breast cancer prevention trialon fenretinide (4-HPR), the relationship of drug and retinol levels with the risk of second breast malignancy, taking into account age and menopausal status.	Fenretinide	84-95	haptoglobin-related protein	Homo sapiens	99-102
12388538-2	2002	Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)).	Fenretinide	104-115	haptoglobin-related protein	Homo sapiens	150-153
12517593-2	2003	A promising oral retinoid, 4-hydroxyphenylretinamide (4-HPR) induced apoptosis through non-retinoic acid-mediated pathways and is being studied in National Cancer Institute phase II trials in several organ sites.	Fenretinide	27-52	haptoglobin-related protein	Homo sapiens	56-59
12388538-2	2002	Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)).	Fenretinide	117-146	haptoglobin-related protein	Homo sapiens	150-153
12234979-0	2002	GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma.	Fenretinide	36-47	DNA damage inducible transcript 3	Homo sapiens	0-7
12417027-1	2002	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a synthetic amide of all-trans-retinoic acid (RA), which inhibits cell growth, induces apoptosis, and is an antioxidant, and cancer chemopreventive and antiproliferative agent.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	46-49
12417027-1	2002	Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a synthetic amide of all-trans-retinoic acid (RA), which inhibits cell growth, induces apoptosis, and is an antioxidant, and cancer chemopreventive and antiproliferative agent.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	46-49
12410564-0	2002	Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells.	Fenretinide	80-109	nuclear factor kappa B subunit 1	Homo sapiens	54-76
12138118-0	2002	GADD153-mediated anticancer effects of N-(4-hydroxyphenyl)retinamide on human hepatoma cells.	Fenretinide	39-68	DNA damage inducible transcript 3	Homo sapiens	0-7
12138118-9	2002	N-Acetyl-l-cysteine or GADD153 antisense significantly protected the cells from 4HPR-induced apoptosis, accompanying by the inhibition of GADD153 overexpression.	Fenretinide	80-84	DNA damage inducible transcript 3	Homo sapiens	23-30
12138118-9	2002	N-Acetyl-l-cysteine or GADD153 antisense significantly protected the cells from 4HPR-induced apoptosis, accompanying by the inhibition of GADD153 overexpression.	Fenretinide	80-84	DNA damage inducible transcript 3	Homo sapiens	138-145
12353227-0	2002	Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxyphenyl)retinamide (4HPR).	Fenretinide	65-94	DNA damage inducible transcript 3	Homo sapiens	16-23
12353227-0	2002	Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxyphenyl)retinamide (4HPR).	Fenretinide	65-94	haptoglobin-related protein	Homo sapiens	97-100
12353227-9	2002	In the HeLa cells, both 4HPR and ATRA caused a 2- to 4-fold stimulation of the promoter activity of gadd153, but similar to the CNE3 cells, ATRA was incapable of upregulating the protein level of gadd153.	Fenretinide	24-28	DNA damage inducible transcript 3	Homo sapiens	100-107
12481423-1	2002	N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
12481423-1	2002	N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	120-123
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	160-171	retinoic acid receptor alpha	Homo sapiens	114-117
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	160-171	arachidonate 15-lipoxygenase	Homo sapiens	194-200
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	160-171	DNA damage inducible transcript 3	Homo sapiens	239-246
12234979-4	2002	Expression of the stress-induced transcription factor, GADD153, was up-regulated at both the protein and mRNA levels in response to fenretinide.	Fenretinide	132-143	DNA damage inducible transcript 3	Homo sapiens	55-62
12234979-5	2002	Overexpression of GADD153 increased apoptosis in the presence and absence of fenretinide, whereas reduced expression of GADD153 by expression of antisense DNA abrogated the response to fenretinide.	Fenretinide	77-88	DNA damage inducible transcript 3	Homo sapiens	18-25
12234979-5	2002	Overexpression of GADD153 increased apoptosis in the presence and absence of fenretinide, whereas reduced expression of GADD153 by expression of antisense DNA abrogated the response to fenretinide.	Fenretinide	185-196	DNA damage inducible transcript 3	Homo sapiens	120-127
12234979-6	2002	Although fenretinide is a partial retinoic acid receptor (RAR)-beta/gamma agonist, RARbeta/gamma antagonists did not block the induction of GADD153 by fenretinide; conversely, the induction of GADD153 was blocked by antioxidants.	Fenretinide	9-20	retinoic acid receptor alpha	Homo sapiens	34-56
12234979-6	2002	Although fenretinide is a partial retinoic acid receptor (RAR)-beta/gamma agonist, RARbeta/gamma antagonists did not block the induction of GADD153 by fenretinide; conversely, the induction of GADD153 was blocked by antioxidants.	Fenretinide	9-20	retinoic acid receptor beta	Homo sapiens	58-67
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	27-38	retinoic acid receptor alpha	Homo sapiens	61-64
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	27-38	retinoic acid receptor alpha	Homo sapiens	114-117
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	27-38	arachidonate 15-lipoxygenase	Homo sapiens	194-200
12234979-10	2002	These results suggest that fenretinide induces apoptosis via RAR-dependent and -independent pathways in which the RAR-independent pathway is characterized by a fenretinide-dependent increase in 12-LOX activity, leading to the induction of GADD153.	Fenretinide	27-38	DNA damage inducible transcript 3	Homo sapiens	239-246
11986953-1	2002	The retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR), mediates p53-independent cytotoxicity and can increase reactive oxygen species and ceramide in solid tumor cell lines.	Fenretinide	14-43	tumor protein p53	Homo sapiens	62-65
12595744-4	2002	At 1.3 micro M concentration (a clinically pharmacologically achievable dose), 4HPR increased ATRA sensitivity synergistically in HER2/NEU-overexpressing BT-474, MDA-MB-453, and MCF-7/Her2 breast cancer cells.	Fenretinide	79-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	184-188
12124800-1	2002	The synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] has demonstrated growth inhibition and induction of apoptosis of various malignant cells, including lung cancer cell lines.	Fenretinide	23-34	haptoglobin-related protein	Homo sapiens	69-72
12124800-1	2002	The synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] has demonstrated growth inhibition and induction of apoptosis of various malignant cells, including lung cancer cell lines.	Fenretinide	36-65	haptoglobin-related protein	Homo sapiens	69-72
12079295-11	2002	Furthermore, a possible protective effect of fenretinide in BRCA-mutated women was suggested.	Fenretinide	45-56	BRCA1 DNA repair associated	Homo sapiens	60-64
12072549-0	2002	Re: Effects of N-(4-hydroxy-phenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers.	Fenretinide	15-45	telomerase reverse transcriptase	Homo sapiens	49-54
11979432-4	2002	Therefore, we analyzed the expression of OVCA1 and OVCA2 in cells in response to treatment with all-trans retinoic acid (RA) and N-(4-hydroxyphenyl)retinamide (4HPR), or under conditions of low serum and confluence, to determine further the roles of OVCA1 and OVCA2 in cell growth, apoptosis and differentiation.	Fenretinide	129-158	diphthamide biosynthesis 1	Homo sapiens	41-46
11979432-4	2002	Therefore, we analyzed the expression of OVCA1 and OVCA2 in cells in response to treatment with all-trans retinoic acid (RA) and N-(4-hydroxyphenyl)retinamide (4HPR), or under conditions of low serum and confluence, to determine further the roles of OVCA1 and OVCA2 in cell growth, apoptosis and differentiation.	Fenretinide	129-158	OVCA2 serine hydrolase domain containing	Homo sapiens	51-56
11979432-6	2002	In addition, we observed that OVCA2 protein is proteolytically degraded in response to RA and 4HPR treatment in a time- and dose-dependent manner in the promyelocytic leukemia cell line HL60.	Fenretinide	94-98	OVCA2 serine hydrolase domain containing	Homo sapiens	30-35
12161154-1	2002	Retinoic acid analogues such as N-(4-hydroxyphenyl)retinamide (4-HPR) are effective chemopreventatives and chemotherapeutics for numerous types of cancer.	Fenretinide	32-61	haptoglobin-related protein	Homo sapiens	65-68
12595744-0	2002	N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells.	Fenretinide	0-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	99-103
12595744-0	2002	N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells.	Fenretinide	0-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	104-107
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	0-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	0-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-121
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	0-30	epidermal growth factor receptor	Homo sapiens	145-177
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	0-30	epidermal growth factor receptor	Homo sapiens	179-183
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	32-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	113-117
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	32-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	118-121
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	32-36	epidermal growth factor receptor	Homo sapiens	145-177
12595744-2	2002	N-(4-hydroxyphenyl)-retinamide (4HPR), a synthetic analogue of ATRA, has been shown to repress the expression of HER2/neu and its family member, epidermal growth factor receptor (EGFR).	Fenretinide	32-36	epidermal growth factor receptor	Homo sapiens	179-183
12595744-4	2002	At 1.3 micro M concentration (a clinically pharmacologically achievable dose), 4HPR increased ATRA sensitivity synergistically in HER2/NEU-overexpressing BT-474, MDA-MB-453, and MCF-7/Her2 breast cancer cells.	Fenretinide	79-83	erb-b2 receptor tyrosine kinase 2	Homo sapiens	130-134
12175543-0	2002	N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
12175543-0	2002	N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines.	Fenretinide	0-29	growth arrest and DNA damage inducible alpha	Homo sapiens	48-54
12175543-1	2002	We previously demonstrated that N-(4-hydroxyphenyl)retinamide (4-HPR) and gamma-irradiation, when used in combination, had a synergistic effect in inducing apoptosis in bladder cancer cells, suggesting that 4-HPR may increase radiosensitivity in bladder cancer cells.	Fenretinide	32-61	haptoglobin-related protein	Homo sapiens	65-68
12175543-1	2002	We previously demonstrated that N-(4-hydroxyphenyl)retinamide (4-HPR) and gamma-irradiation, when used in combination, had a synergistic effect in inducing apoptosis in bladder cancer cells, suggesting that 4-HPR may increase radiosensitivity in bladder cancer cells.	Fenretinide	32-61	haptoglobin-related protein	Homo sapiens	209-212
11986953-1	2002	The retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR), mediates p53-independent cytotoxicity and can increase reactive oxygen species and ceramide in solid tumor cell lines.	Fenretinide	14-43	haptoglobin-related protein	Homo sapiens	47-50
11705848-2	2001	We tested N-(4-hydroxyphenyl)retinamide (4-HPR), a promising oral retinoid that has been shown to induce apoptosis through nonretinoic receptor acid-mediated pathways, for its toxicity and efficacy against CIN 2/3.	Fenretinide	10-39	haptoglobin-related protein	Homo sapiens	43-46
11698412-7	2002	Intriguingly, bongkrekic acid, a specific ANT inhibitor, enhanced 4HPR-induced deltapsi(m) disruption, which in turn decreased the level of CO III transcripts, which was accompanied by increases in the generation of reactive oxygen species and in apoptosis.	Fenretinide	66-70	solute carrier family 25 member 6	Homo sapiens	42-45
11698412-7	2002	Intriguingly, bongkrekic acid, a specific ANT inhibitor, enhanced 4HPR-induced deltapsi(m) disruption, which in turn decreased the level of CO III transcripts, which was accompanied by increases in the generation of reactive oxygen species and in apoptosis.	Fenretinide	66-70	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	140-146
11698412-8	2002	In contrast, atractyloside, an activator of ANT, inhibited those 4HPR-induced effects.	Fenretinide	65-69	solute carrier family 25 member 6	Homo sapiens	44-47
11921197-6	2002	The Italian trial of fenretinide (4-HPR) in women with stage I breast cancer randomized women to fenretinide or no intervention.	Fenretinide	21-32	haptoglobin-related protein	Homo sapiens	36-39
11921197-9	2002	It has been suggested that this effect may be related to insulin-like growth factor 1 (IGF-1), which has been shown to be modulated by fenretinide in premenopausal but not postmenopausal women.	Fenretinide	135-146	insulin like growth factor 1	Homo sapiens	57-85
11921197-9	2002	It has been suggested that this effect may be related to insulin-like growth factor 1 (IGF-1), which has been shown to be modulated by fenretinide in premenopausal but not postmenopausal women.	Fenretinide	135-146	insulin like growth factor 1	Homo sapiens	87-92
11732001-0	2001	Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells.	Fenretinide	31-60	caspase 8	Homo sapiens	14-23
12235869-0	2002	Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.	Fenretinide	59-88	estrogen receptor 1	Homo sapiens	121-138
12235869-0	2002	Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer.	Fenretinide	59-88	estrogen receptor 1	Homo sapiens	140-142
12235869-1	2002	We investigated the effects of combination therapy with N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) on estrogen receptor (ER) negative breast cancer, for which no effective supplementary therapy has been established, using the human breast cancer cell line MDA-MB-231.	Fenretinide	56-85	estrogen receptor 1	Homo sapiens	117-134
12235869-1	2002	We investigated the effects of combination therapy with N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) on estrogen receptor (ER) negative breast cancer, for which no effective supplementary therapy has been established, using the human breast cancer cell line MDA-MB-231.	Fenretinide	56-85	estrogen receptor 1	Homo sapiens	136-138
11807954-1	2002	To explore the mechanisms underlying the pro-apoptotic effects of the synthetic retinoid N-4-(hydroxyphenyl)retinamide (4-HPR) on LNCaP human prostate cancer cells, we used the differential display-polymerase chain reaction (DD-PCR) technique to identify 4-HPR-responsive genes.	Fenretinide	89-118	haptoglobin-related protein	Homo sapiens	122-125
11807954-1	2002	To explore the mechanisms underlying the pro-apoptotic effects of the synthetic retinoid N-4-(hydroxyphenyl)retinamide (4-HPR) on LNCaP human prostate cancer cells, we used the differential display-polymerase chain reaction (DD-PCR) technique to identify 4-HPR-responsive genes.	Fenretinide	89-118	haptoglobin-related protein	Homo sapiens	257-260
11504771-0	2001	Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers.	Fenretinide	11-40	telomerase reverse transcriptase	Homo sapiens	44-49
11483862-0	2001	Mechanism of fenretinide (4-HPR)-induced cell death.	Fenretinide	13-24	haptoglobin-related protein	Homo sapiens	28-31
11483862-1	2001	4-HPR (fenretinide) is a synthetic analog of retinoic acid (RA) whose potential as a chemopreventative agent has gained support from in vitro and animal experiments and in limited clinical trials.	Fenretinide	7-18	haptoglobin-related protein	Homo sapiens	2-5
11483862-5	2001	Apoptosis in response to fenretinide primarily occurs by a receptor-independent mechanism, which is accompanied by increases in signaling molecules, e.g., ceramide, and cysteine-dependent aspartate-directed proteases, termed caspases, including execution caspase-3.	Fenretinide	25-36	caspase 3	Homo sapiens	255-264
11483862-6	2001	Both caspase-3 inhibitor DEVD-CHO and ceramide synthase inhibitor fumonisin B(1) (FB(1)) block fenretinide-induced apoptosis.	Fenretinide	95-106	caspase 3	Homo sapiens	5-14
11483862-7	2001	Increase in caspase-3 appears to result from fenretinide-elicited stabilization of procaspase-3 zymogen.	Fenretinide	45-56	caspase 3	Homo sapiens	12-21
11483862-7	2001	Increase in caspase-3 appears to result from fenretinide-elicited stabilization of procaspase-3 zymogen.	Fenretinide	45-56	caspase 3	Homo sapiens	83-95
11551492-0	2001	N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention.	Fenretinide	0-29	haptoglobin-related protein	Homo sapiens	33-36
11551492-3	2001	This study focuses on the ability of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide (4-HPR), to reverse changes associated with malignant transformation and tumor progression, towards a normal phenotype.	Fenretinide	61-91	haptoglobin-related protein	Homo sapiens	95-98
11745408-2	2001	The synthetic retinoid fenretinide (HPR) inhibits carcinogenesis in various animal models.	Fenretinide	23-34	haptoglobin-related protein	Homo sapiens	36-39
11588130-2	2001	Because the synthetic retinoid fenretinide showed a beneficial effect on second breast cancers in premenopausal women in a Phase III trial, we studied its long-term effects on IGF-I levels.	Fenretinide	31-42	insulin like growth factor 1	Homo sapiens	176-181
11588130-11	2001	Fenretinide induces a moderate decline of IGF-I levels in women < or = 50 years of age.	Fenretinide	0-11	insulin like growth factor 1	Homo sapiens	42-47
11504771-2	2001	To determine the role of telomerase in early lung carcinogenesis and as a potential biomarker in chemoprevention trials, we analyzed the expression of the human telomerase reverse transcriptase catalytic subunit (hTERT) in bronchial biopsy specimens from cigarette smokers who were enrolled in a randomized, double-blinded, placebo-controlled chemoprevention trial of N-(4-hydroxyphenyl)retinamide (4-HPR).	Fenretinide	368-397	telomerase reverse transcriptase	Homo sapiens	213-218
11489831-0	2001	Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.	Fenretinide	27-38	haptoglobin-related protein	Homo sapiens	42-45
11489831-4	2001	In this report, we evaluate the in vitro effects of N-(4-hydroxyphenyl) retinamide (4-HPR) with and without anti-CD20 antibodies in B-cell lymphoma lines.	Fenretinide	52-82	haptoglobin-related protein	Homo sapiens	86-89
11384104-1	2001	We investigated whether the efficacy of fenretinide (HPR) against ovarian tumours may be limited by induction of resistance.	Fenretinide	40-51	haptoglobin-related protein	Homo sapiens	53-56
11431347-1	2001	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	46-49
11431347-1	2001	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl.	Fenretinide	13-42	haptoglobin-related protein	Homo sapiens	186-189
11431347-1	2001	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl.	Fenretinide	51-62	haptoglobin-related protein	Homo sapiens	46-49
11431347-1	2001	The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl.	Fenretinide	51-62	haptoglobin-related protein	Homo sapiens	186-189
11412986-2	2001	The synthesis of a nonhydrolyzable, carbon-linked analogue (4-HBR) of the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) using Umpolung methods is described.	Fenretinide	83-112	haptoglobin-related protein	Homo sapiens	116-119
11497248-2	2001	In the present study, we determined the influence of high dietary concentrations of 4-hydroxyphenylretinamide (4-HPR) and 13-cis-retinoic acid (13-cis-RA) on RAR-beta mRNA expression in female mice.	Fenretinide	84-109	retinoic acid receptor, beta	Mus musculus	158-166
11497248-2	2001	In the present study, we determined the influence of high dietary concentrations of 4-hydroxyphenylretinamide (4-HPR) and 13-cis-retinoic acid (13-cis-RA) on RAR-beta mRNA expression in female mice.	Fenretinide	111-116	retinoic acid receptor, beta	Mus musculus	158-166
11295632-2	2001	A phase 2 chemoprevention trial of 4-hydroxyphenyl retinamide (4-HPR) versus placebo was conducted in men with a histologic diagnosis of early prostate cancer and scheduled to have radical prostatectomy.	Fenretinide	35-61	haptoglobin-related protein	Homo sapiens	65-68
11287445-3	2001	Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials.	Fenretinide	30-41	haptoglobin-related protein	Homo sapiens	82-85
11287445-3	2001	Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials.	Fenretinide	49-78	haptoglobin-related protein	Homo sapiens	82-85
11368409-3	2001	Suppression of pRB protein expression in HMECs by retroviral-mediated expression of the E7 protein of the human papillomavirus strain 16 (HPV-16) was associated with resistance to ATRA-mediated growth arrest but not to the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR or fenretinide).	Fenretinide	242-272	RB transcriptional corepressor 1	Homo sapiens	15-18
11166911-0	2001	The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines.	Fenretinide	13-24	prostaglandin-endoperoxide synthase 2	Homo sapiens	66-82
11166911-1	2001	Fenretinide [N-(4-Hydroxyphenyl)retinamide, 4-HPR] (10(-10)-10(-6) M) treatment of HT-29 human colon cancer cells for 24-72 h significantly inhibited their growth.	Fenretinide	0-11	haptoglobin-related protein	Homo sapiens	46-49
11368409-3	2001	Suppression of pRB protein expression in HMECs by retroviral-mediated expression of the E7 protein of the human papillomavirus strain 16 (HPV-16) was associated with resistance to ATRA-mediated growth arrest but not to the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR or fenretinide).	Fenretinide	283-294	RB transcriptional corepressor 1	Homo sapiens	15-18
11434448-9	2001	Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.	Fenretinide	96-107	insulin like growth factor 1	Homo sapiens	53-58
11176527-10	2001	All-trans-retinoic acid and 4HPR induced retinoic acid receptor beta expression in 1 bladder cancer cell line.	Fenretinide	28-32	retinoic acid receptor beta	Homo sapiens	41-68
11434448-9	2001	Ongoing studies on the validation of the circulating IGF-1 as a surrogate endpoint biomarker of fenretinide activity and on the effectiveness of the combination with low dose tamoxifen may provide further insight into the future clinical application of fenretinide.	Fenretinide	253-264	insulin like growth factor 1	Homo sapiens	53-58
11107142-1	2000	The RARbeta/gamma-selective retinoids fenretinide and CD437 induce caspase-dependent apoptosis but generate free radicals independently of caspases.	Fenretinide	38-49	retinoic acid receptor beta	Homo sapiens	4-11
11106681-1	2000	BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways.	Fenretinide	40-69	haptoglobin-related protein	Homo sapiens	73-76
11106681-1	2000	BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways.	Fenretinide	40-69	tumor protein p53	Homo sapiens	245-248
11106681-1	2000	BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways.	Fenretinide	40-69	tumor protein p53	Homo sapiens	264-268
11106681-1	2000	BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways.	Fenretinide	78-89	tumor protein p53	Homo sapiens	245-248
11106681-1	2000	BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways.	Fenretinide	78-89	tumor protein p53	Homo sapiens	264-268
11107126-7	2000	Both parental and RA-resistant lines showed 2-4 logs of cell kill in response to N-(4-hydroxyphenyl)retinamide (4- HPR, fenretinide).	Fenretinide	81-110	haptoglobin-related protein	Homo sapiens	115-118